Multi-peptide-based vaccines for personalized cancer therapy : Analytical fundamentals translated into clinical applications by Weinschenk, Toni
  
 
 
Multi-peptide-based Vaccines for 
Personalized Cancer Therapy 
– Analytical fundamentals translated into clinical applications 
 
 
 
Multi-Peptid-Impfstoffe zur individuellen 
Behandlung von Tumorpatienten 
– Von den analytischen Grundlagen zur klinischen Anwendung 
 
 
 
DISSERTATION 
 
der Fakultät für Chemie und Pharmazie 
der Eberhard-Karls-Universität Tübingen 
 
zur Erlangung des Grades eines Doktors 
der Naturwissenschaften 
 
 
2004 
 
 
vorgelegt von 
Toni Weinschenk
II   
 
 
    III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag der mündlichen Prüfung:  27.01.2004 
 
Dekan:     Prof. Dr. H. Probst 
1. Berichterstatter:    Prof. Dr. H.-G. Rammensee 
2. Berichterstatter:    PD Dr. S. Stevanović 
3. Berichterstatter:    Dr. phil. Dr. med. habil. F. Lottspeich 
IV   
 
 
PREFACE    V 
 
Preface 
The results of this thesis are presented in three parts: 
 
Part 1 introduces the concept for the identification of multi-peptide-based vaccines for 
personalized cancer therapy by integrating genome and proteome analysis. The results 
achieved during establishing the approach up to its clinical usage in personalized 
medicine are given. Genome-wide gene expression analysis by DNA-chip-technology is 
presented only in this part of the work, which is the central one of this thesis. 
 
The results presented in Part 2 provide new insight in antigen processing. The rules for 
the events making parts of antigens presented as short peptides on the cell surface are 
fundamental for peptide-based vaccines. Whereas Part 1 represents applied clinical 
investigations, Part 2 shows results related to basic research. 
 
Part 3 shows the inset of mass spectrometry in the field of proteome analysis as analytical 
basics for Part 1: Mass spectrometrical sequencing of peptides only present in limited 
amounts as well as protein identification by mass spectrometry. 
 
 
 
 
At the beginning of each chapter it is indicated which experiments were contributed by the 
author of this thesis. Some chapters are parts of publications. The authors of these 
publications are mentioned at the ends of these chapters. 
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Die Ergebnisse der vorliegenden Dissertation sind in drei Teile gegliedert: 
 
Teil 1 stellt das Konzept der Identifizierung von Multi-Peptid-Impfstoffen zur individuellen 
Behandlung von Tumorpatienten durch die Integration von Genom- und Proteomanalyse 
dar. Die Ergebnisse der Etablierungsphase bis hin zum klinischen Einsatz des Verfahrens 
in der personalisierten Medizin werden gezeigt. Die genomweite Genexpressionsanalyse 
durch DNA-Chip-Technologie wird ausschließlich in diesem Kapitel behandelt. Ergebnisse 
dieses Teils stehen im Zentrum der Dissertation. 
 
Teil 2 behandelt neue Erkenntnisse in der Antigenprozessierung. Die Regeln für den Weg 
vom Antigen zum präsentierten Peptid bilden das Fundament für Peptid-basierte 
Impfstoffe. Während also in Teil 1 eher angewandte, klinische Arbeiten im Vordergrund 
stehen, besteht Teil 2 aus Ergebnissen der Grundlagenforschung. 
 
Teil 3 zeigt den Einsatz der Massenspektrometrie in der Proteomanalyse als analytische 
Grundlage für Teil 1: Die massenspektrometrische Sequenzierung von Peptiden bei 
geringen Analytmengen sowie die Identifizierung von Proteinen über die 
Massenspektrometrie. 
 
 
 
 
Generell ist der Anteil des Autors dieser Dissertation an den Ergebnissen der einzelnen 
Kapitel jeweils zu Beginn der Kapitel beschrieben. Manche Kapitel sind Teil von 
Veröffentlichungen. Die Autoren der Veröffentlichungen sind an den jeweiligen 
Kapitelenden aufgeführt. 
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1 Introduction 
1.1 The immune system 
The adaptive immune system is a typical feature of vertebrates. It has developed 
during evolution to prevent higher organisms from severe damage by viruses, 
bacteria, fungi and other parasites. But also tumor cells can be destroyed. The 
different parts of the immune system arise from haematopoietic stem cells in the 
bone marrow. The lymphoid organs are called central – bone marrow and thymus 
– and peripheral – lymph nodes, lymphatic vessels and the spleen. Immune 
responses are mediated by specialized cells or proteins. Both have fast 
responding but rigid innate components and parts which are very flexible and able 
to perfectly adapt to the problem: the antigen. Moreover, the immune system does 
not forget anything. Encountering the same antigen for the second time, the 
immune system remembers how to handle the problem and solves it much faster. 
And it knows when to slow down again after the job is done. 
Despite of its huge diversity, theoretically based on ~1018 different T cell receptors 
and ~1014 B cell receptors, nevertheless, each receptor is highly specific. This 
specificity in combination with lessons learned during development prevents from 
self-destruction. As usual, there are failures also in this system, which attract 
interest from scientists as well as from suffering patients. But more often, the 
immune system saves lives and fascinates many immunologists. 
1.2 MHC-molecules and T cells 
T cells are very diverse in their phenotype, their function and in the target 
structures they recognize. Early in development, the progenitors differentiate in T 
cells expressing γδ-T cell receptors (γδ-TCR) or αβ-T cell receptors. γδ-T cells 
recognize non-peptidic antigens such as sphingolipids bound to non-classical 
MHC molecules like CD1 and, additionally, might have regulatory effects. αβ-T 
cells can be NK T cells, CD8+ T cells or CD4+ T cells. NK T cells express NK1.1, 
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CD4 or no coreceptor and show a limited TCR diversity. CD4 CD8 positive T cells 
are positively selected by self MHC molecules during their development in the 
thymus. A T cell expressing a T cell receptor which binds to an MHC class I 
molecule loses its CD4 expression and becomes CD8 positive. The opposite is 
true for T cells with appropriate receptors for MHC class II molecules. They 
become CD4 positive T cells. T cells with TCR binding to neither self MHC class I 
nor II molecules die. To prevent self-destruction, T cells recognizing self peptides, 
which are presented on healthy cells, are also removed during the following 
negative selection step. Some antigens are not expressed in the thymus but in 
other tissues or organs. Self-reactive T cells recognizing peptides from those 
antigens become anergic because they lack important additional signals during 
the first antigen encounter. Thus, T cells are able to distinguish between self and 
foreign or malignant. 
T cells which successfully passed all selection criteria circle through the body via 
the blood stream as so-called naïve T cells. When they encounter a professional 
antigen presenting cell (APC) such as dendritic cells, B cells or macrophages, they 
can be activated. Activation requires engagement of the TCR by a peptide/MHC 
complex plus delivery of a second signal from the APC. In the case of CD8 
positive T cells, the resulting armed effector cells now are able to kill specifically 
infected or malignant transformed target cells. Activated CD4 T cells differentiate 
into cells with a TH1 or TH2 phenotype, determined by the secreted cytokine 
profile. TH1 cells have a rather direct inflammatory effect due to secretion of IFN-γ 
and lead to cellular responses whereas TH2 cells support a humoral response. 
A further modulation of T cell response is achieved by the recently identified 
regulatory T cells (Treg). They are CD4 positive and constitutively express CD25. In 
the presence of Treg, T cell resonses are impaired for reasons which are not 
completely understood until now. 
Together with TCR, MHC molecules are in the centre of cellular immunity. MHC 
class I molecules – called human leukocyte antigen (HLA) in human – are 
membrane bound glycoproteins found on the surface of all nucleated cells. They 
are heterodimers built by a heavy α-chain which is non-covalently linked to β2-
microglobulin (β2m). The α-chain has a short cytoplasmic C-terminal part, a 
transmembrane domain and three extracellular immunoglobulin-like domains α1- 
α3. The two N-terminal domains α1 and α2 form a peptide binding groove – two 
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parallel α-helical domains on a β-sheeted floor – which is closed at both ends. 
This peptide binding groove harbours the presented peptide with a length of 8-10 
amino acids. Non-covalent hydrophobic and ionic interactions between the peptide 
and the α-chain mainly take place between so called pockets in the α1-domain and 
the anchor amino acids of the ligand and involve the N- and C-termini of the 
peptide. 
A remarkable feature of the major histocompatibility complex is its polymorphism. 
On the human chromosome 6, there are three gene loci for the MHC class I α-
chain: HLA-A, -B and –C. Each of these loci is highly polymorphic. Table  1.2.1 
shows the number of named HLA class I alleles known in April 2003. 
 
Table  1.2.1 Number of known HLA alleles* 
Gene locus Number of alleles 
HLA-A 275 
HLA-B 521 
HLA-C 134 
*data from the Anthony Nolan Trust, HLA informatics group (http://www.anthonynolan.com/HIG) 
 
Major differences between the alleles are found at the positions responsible for 
the peptide binding, namely the α1-helix. Every allele has its more or less unique 
set of two pockets. Each of them allows binding of only a restricted set of amino 
acids with common special chemical features at defined positions within the 
peptide sequence. All features a peptide should exploit for the capacity to bind to 
a given HLA-allele are called “peptide binding motif” of this allele [1]. The motif for 
HLA-A*24 [2], shown in Table  1.2.2, gives an example. 
 
Table  1.2.2 Peptide binding motif of HLA-A*24 
Position 1 2 3 4 5 6 7 8 9 
 
Anchor amino acids  Y       L 
  F       F 
         I 
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The three different gene loci together with codominant heterozygous gene 
expression result in the expression of up to six different HLA-alleles in an 
individual. This allows each individuum to present mostly more than only one 
peptide from hardly any protein in the context of different HLA-alleles and thus 
lowers the likelihood of immune evasion of pathogens. Moreover, looking at the 
whole population of a species, survival of some individuals is likely in the case of 
an epidemy.  
MHC class II molecules are found on professional antigen presenting cells and 
occasionally also on tumor cells. They are heterodimers built up by α- and β-
chains. These genes are also highly polymorphic. The overall structure is similar 
but in contrast to MHC class I molecules, the peptide binding groove is open at 
both ends. This allows binding of longer peptides with 10 to 15 amino acids. Due 
to the different antigen processing pathway, MHC class II-bound peptides are 
mainly derived from extracellular proteins, but also peptides from cytosolic 
proteins are frequently found. Another characteristic feature is the presentation of 
length variants from one protein covering the same core sequence, the N- and C-
termini are not that clearcut as in MHC class I-ligands.  
1.3 Antigen processing 
1.3.1 Processing of MHC class I epitopes 
MHC class I-bound peptides are derived from cytosolic proteins. Exo- and 
endoproteolytic events during the physiological protein turnover lead to the 
generation of peptides of different length. But, probably, even more important, 
misfolded proteins and premature chains released during translation feed the pool 
of epitope precursors [3-5]. They are called defective ribosomal products (DRiPs) 
and presumably contribute the most significant part of substrates for epitope 
production, allowing a cell to quickly display changes from inside to the outside. 
The proteasome, a large multienzyme complex with the shape of a barrel, is 
mainly responsible for the generation of the C-termini of T cell epitopes. In some 
cases it directly excices the epitope, in many cases it provides N-terminal 
elongated precursors, which are further trimmed by other proteases as already 
suggested in 1990 [6]. The 20S core proteasome with its three constitutive 
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proteolytic subunits (δ/Y, Z and X) can be converted into an immuno proteasome 
by IFNγ. In this proteasome species, δ/Y, Z and X are replaced by low molecular 
weight protein 2 (LMP2), MECL-1 and low molecular weight protein 7 (LMP7). On 
both sides of the barrel, the 20S proteasome to some extent is singly or doubly 
capped, either by the 19S regulatory particle or by the IFNγ-inducible activator 
PA28, both of which regulate substrate access to the core particle. For a long time 
it was assumed that substrates are channelled sequentially into the proteasome 
and cut in an exopeptidase-like way, but recently it has been shown that the 
proteasome can also act as an endoprotease [7]. 
Several cytosolic proteases besides the proteasome have been described being 
involved in trimming events: leucine aminopeptidase (LAP) [8], tripeptidyl-
peptidase II (TPPII) [9], bleomycin hydrolase (BH), and puromycin-sensitive 
aminopeptidase (PSH) [10]. 
Epitopes and their precursors enter the endoplasmatic reticulum via the 
transporter associated with antigen processing (TAP). To be transported by 
human TAP, peptides have to fullfill some requirements. Their length must be 
between 8 and 16 amino acids and the C-terminus has to be hydrophobic or basic 
[11, 12]. After some discussion in the last years about the relevance of trimming 
proteases in the ER [13-19], several publications in the last months could show 
the impact of an aminopeptidase called ERAAP1 present in the ER [20-22]. 
Several ER resident proteins (calreticulin, calnexin, tapasin, Erp57) provide help 
for the loading of empty MHC class I molecules with processed peptides matching 
the respective motifs. The complete complex of MHC class I α-chain, β2m and 
peptide is exported to the cell membrane by the classical secretion pathway. 
Recently, it was shown that peptides are rapidly degraded if not loaded on MHC 
molecules and that a large part is rescued from degradation by entering the 
nucleus, where peptides bind to chromatin [23]. 
 
1.3.2 Processing of MHC class II epitopes 
Peptides presented by MHC class II molecules are mainly derived from 
extracellular or membrane-bound proteins. They are taken up by phagocytosis, 
pinocytosis or receptor-mediated endocytosis, are degraded in vesicles fused to 
lysosomes and end up in the “so-called” MHC class II loading compartment MIIC. 
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Several different proteases mainly from the cathepsin family are involved in 
antigen processing. The MHC class II α- and β-chains are synthesized into the ER 
and transported in association with the trimeric invariant chain (Ii) to the MHC 
class II loading compartment. There, the class II-associated invariant-chain 
peptide (CLIP), a part of the invariant chain which occupies the peptide binding 
groove of the MHC class II-molecules, is replaced by the later presented peptides. 
This exchange is catalyzed and regulated by HLA-DM and HLA-DO [24, 25].  
 
1.3.3 Cross presentation 
Presentation of peptides from extracellular proteins on MHC class I-molecules is 
called cross presentation. This phenomenon was observed in several cases and 
breaks the general separation of the two processing pathways. It is necessary for 
the generation of CD8+ T cell-responses against viruses which do not infect 
professional antigen presenting cells. In this situation, the infected cells are not 
capable to provide the necessary costimulatory signals for T cell priming in 
addition to the TCR-MHC class I-interaction. And without cross presentation, the 
APCs would not present peptides from this virus on MHC class I. Still it is not clear 
how the peptides channel from the endocytotic pathway to the cytosol. But also for 
the generation of most naturally occurring CTL responses against tumor cells, 
cross presentation is a prerequisite, because most tumor cells do not have MHC 
class II molecules neither do they have costimulatory molecules. But necrotic 
tumor material can be taken up by surrounding stroma cells, which then cross 
present the digested tumor-derived proteins on MHC class I [26]. 
1.4 Immunotherapy in cancer 
1.4.1 Classes of tumor associated antigens 
Nearly all possibilities for tumor associated antigens one can think about have 
been found (Table  1.4.1).  
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Table  1.4.1 Classes of tumor antigens* 
  recognized by 
class examples T cells  antibodies 
    
point mutation of normal gene CDK4 [27] x  - 
frame shift mutation of normal gene TGFβRII [28] x  - 
anti sense transcript of normal gene RU2AS [29] x  - 
expressed intron of normal gene N-acetylglucosaminyltransferase V [30] x  - 
fusion protein caused by translocation BCR-ABL [31] x  - 
altered postranslational modifications tyrosinase [32] x   - 
cancer/embryonic antigen CEA [33, 34] x  x 
overexpressed antigens – protein Her2/neu, MUC1 [35, 36] x  x 
overexpressed antigens – non-protein gangliosid GD3 [37] -  x 
cancer testis antigen NY-ESO-1 [38] x  x 
 MAGE family [39] x  x 
oncogenes ras [40-42] x  x 
tumor suppressor genes p53 [43, 44] x  x 
differenciation antigen tyrosinase [45, 46] x  x 
 gp100 [47, 48] x  x 
viral proteins HPV [49, 50] x  x 
* adapted from Rammensee et al. [51] 
 
This is not a big surprise considering the estimated number of all changes in a 
tumor. However, there are major differences in the quality of the named classes. 
For vaccination purposes, antigens which play a central role in the transformation 
event itself such as the observed point mutation in CDK4 are favorable, because 
to escape the selection pressure of an immune response these genes cannot be 
easily avoided by the tumor. On the other hand, this criterium might be neglectible, 
if many targets are addressed at the same time. Another interesting point is the 
frequency of the antigen among many patients or even among several tumors. 
This topic is especially relevant for the question, how many percent of all patients 
fit to the vaccine. E.g. a mutated gene leading to a mutated epitope, which 
accidently arose in a single patient compared with the overexpression of p53, 
which is found in many tumor entities and in frequencies of more than 50% of all 
patients in some entities. For sure, antigens not exclusively expressed in the 
tumor when compared to other healthy tissues and cells are problematic because 
of existing tolerances towards these antigens. And vaccination against them might 
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induce autoimmunity. Many antigens – most of them in melanoma – have been 
identified yet, but still there is need for more. 
 
1.4.2 Vaccination trials 
Although W. C. Coley’s first pioneering attempt to fight cancer by immunotherapy 
in the 1890s is most likely uneffective, it was the beginning of a new area in the 
field of oncology. He injected Coley toxins – bacterial cultures – into cancer 
patients, believing the bacterial infection helps to stimulate the immune system, 
causing it to fight off cancer cells. This approach from ancient times is not too far 
away from some vaccines recently still used: tumors taken out of patients, mixed, 
loaded on dendritic cells – the best known adjuvant today – and reinjected again 
[52]. The number of different types of vaccines used in clinical trials until now is 
immense: irradiated allogenic [53] or autologous tumor cells [54], modified in 
several ways to become more immunogenic, hybrid cells made by fusion of tumor 
cells and professional antigen presenting cells [55], DNA coding for tumor 
rejection genes delivered by sophisticated methods such as viral transporters [56], 
heat shock proteins isolated from the autologous tumor [57], DCs transfected with 
total RNA [58] or with RNA coding for defined tumor antigens [59] or DCs loaded 
with MHC class I peptides [52], proteins alone [60] and, last but not least, 
peptides, peptides plus adjuvants such as GM-CSF [61], IL-2 [62], Montanide ISA-
51 [63], keyhole-limpet hemocyanin (KLH) [61], tumor associated [64] or artificial 
MHC class II ligands [65]. The many different vaccination protocols – injection 
sites, time schedule concerning the number of injections and the frequency, 
amount of vaccine used for injection – make comparisons between trials from 
different groups impossible. 
All vaccines made from autologous tumors have the advantage that the number of 
antigens is as high as the molecular changes within this tumor. In principle, this 
should lead to an immune response against many targets, thus the risk of immune 
evasion due to tumoral changes under the selection pressure of the immune 
response is minimized [66]. But these advantages are accompanied by some side 
effects. In some cases, the amount of the vaccine is related to the tumor size and, 
therefore, limited with respect to the number of possible repeated vaccinations. In 
general, these tumor derived vaccines are not defined on the molecular level, and 
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monitoring as well as the final immunological readout as a surrogate marker for 
the decision about the success of a vaccine depends on the knowledge about T 
cell epitopes. Furthermore, the relevant antigens in this category of vaccines are 
diluted in a large excess of irrelevant structures. E.g. gp96 isolated from the 
autologous tumor, where most of the bound peptides are probably self-peptides. 
Dendritic cells loaded with tumor lysates give another example. Here, the lysate 
mainly consists of housekeeping proteins and the same is true for DCs 
transfected with total RNA.  
Immunological responses against molecular defined vaccines such as peptides 
can be monitored with several sensitive up-to-date methods. They can be 
synthesized in machines in any amounts, allowing repeated vaccinations over 
years. But the big limitation so far is the small number of known T cell epitopes 
from tumor rejection antigens. This fact prevented studies with many epitopes at 
the same time, but now there is evidence from first trials designed in this way for 
superior clinical outcome the more peptides were included in the vaccine [67]. 
Thus, after the first use of a peptide derived from a tumor antigen in a vaccination 
trial in the mid 1990s [68], several studies showed clinical responses [52, 69-80] 
and even the correlation to immunological response could be shown [67]. 
 
1.4.3 Identification of T cell epitopes derived from tumor 
associated antigens 
1.4.3.1 The classical approach: Starting with T cells recognizing tumor cells 
The very first gene encoding an antigen recognized by CTL on a human tumor 
has been identified by expression cloning in 1991 [81]. Cytotoxic T cells were 
used to screen expression libraries prepared from the recognized tumor cell. The 
gene was called MAGE-1. The gene segment containing the epitope was further 
narrowed down to a 0.3 kb region by expressing fragments of MAGE-1 and 
analysis of the transfectants using again the specific CTL line. The last step to the 
epitope was done by “epitope mapping”, a frequently used method since these 
days. The primary sequence is represented by many adjacent small peptides of 
about 15 amino acids in length and each of the peptides is analyzed for its ability 
to mediated CTL response. When a 15-mer peptide is recognized, all possible 
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included nonamer peptides are tested again. Thus, the HLA-A*01-restricted 
epitope (EADPTGHSY) was identified [39]. 
Another approach also starting with T cells was carried out for the first time by the 
group of Slingluff Jr. [82]. Using the method described by Falk et al. [1], they 
isolated MHC-bound peptides from a melanoma cell line, which was recognized 
by melanoma-specific CTL lines from five different melanoma patients. After 
separation by HPLC, fractions were tested for their ability to reconstitute epitopes 
for two of the five CTLs after loading on T2 cells. Three peptides coeluting with the 
cytotoxic activity were sequenced by tandem mass spectrometry, and finally one 
of them, (YLEPGPVTA), has been shown to be recognized by all the five 
melanoma-specific CTLs. 
 
1.4.3.2 Reverse Immunology: T cell epitope prediction and verification – 
Combining computer algorithms with experimental approaches 
allows for rapid and accurate identification of T cell epitopes from 
defined antigens 
This chapter is published in the Journal of Immunological Methods by Markus 
Schirle, Toni Weinschenk and Stefan Stevanović  
 
Summary 
The identification of T cell epitopes from immunologically relevant antigens 
remains a critical step towards the development of vaccines and methods for the 
monitoring of T cell responses. This review presents an overview over strategies 
that employ computer algorithms for the selection of candidate peptides from 
defined proteins and subsequent verification of their in vivo relevance by 
experimental approaches. 
Several computer algorithms are currently being used for epitope prediction for 
various MHC class I and II molecules, based either on the analysis of natural MHC 
ligands or on the binding properties of synthetic peptides. Moreover, the analysis 
of proteasomal digests of peptides and whole proteins has led to the development 
of algorithms for the prediction of proteasomal cleavages. In order to verify the 
generation of the predicted peptides during antigen processing in vivo as well as 
their immunogenic potential, several experimental approaches have been pursued 
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in the recent past. Mass spectrometry-based bioanalytical approaches have been 
used to specifically detect predicted peptides among isolated natural ligands. 
Other strategies employ various methods for the stimulation of primary T cell 
responses against the predicted peptides and subsequent testing of the 
recognition pattern towards target cells that express the antigen.  
 
Introduction 
MHC molecules are highly polymorphic cell surface molecules that present 
peptidic ligands to cells of the T cell compartment of the immune system. MHC 
class I ligands have a typical length of 8-12 amino acids and are derived from 
endogenously expressed proteins that are degraded by cytosolic proteases, most 
notably the proteasome. The proteolytic fragments are transported into the 
endoplasmatic reticulum in an ATP-dependent fashion by the transporter 
associated with antigen processing (TAP), where they bind to newly synthesized 
empty MHC class I molecules. The MHC-peptide complex is subsequently 
transported to the cell surface and can be recognized by the T cell receptor (TCR) 
of CD8+ cytotoxic T cells (CTL). MHC class II ligands have a more variable length 
of 9-25 amino acids and are derived mainly from exogenous or transmembrane, 
but also from cytosolic proteins that are degraded by various proteases which 
originate from the lysosomal compartment. After binding to MHC class II-
molecules in the late endosomal/lysosomal compartment, the MHC-peptide 
complex is also transported to the cell surface, where it can be recognized by the 
TCR of CD4+ T cells. 
Recognition of a peptide derived from a disease-associated protein, e g. a viral or 
a tumor-specific protein, in presence of a costimulatory signal leads to T cell 
activation and triggers a T cell-mediated immune response. Therefore, the 
question which peptide fragments of immunologically relevant antigens are 
available in context of a certain MHC-molecule for recognition by T cells is crucial 
for the development of peptide-based or other defined antigen-based vaccines. 
Moreover, tools for monitoring specific T cell responses such as MHC-peptide 
tetramers, intracellular cytokine staining or ELISPOT assay depend on the 
identification of the relevant T cell epitope.  
A major breakthrough for the identification of T cell epitopes was the discovery 
that ligands of a certain MHC-molecule carry chemically related amino acids in 
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certain positions of their primary sequence, which allows the definition of a 
“peptide motif” for every MHC allele [1]. This information was rapidly used to 
predict potential epitopes from protein sequences [83, 84] and was the start signal 
for the so called “reverse immunology” approach [85], which has since then 
become the most successful strategy for the identification of T cell epitopes. 
The first step of such studies is usually the computer-based prediction of potential 
MHC ligands from a protein of interest which is followed by experiments to verify 
the natural processing of the predicted peptides and their recognition by T cells. 
The classical and most straightforward approach relies on the stimulation of 
primary T cell responses against the predicted peptides in vitro or in (transgenic) 
animals and subsequent testing of the recognition pattern of the generated T cells 
towards target cells that endogenously express the antigen. Alternatively, patient-
derived T cells, which might have been already primed in vivo, are used. This 
“pure” reverse immunology-approach has been used extensively in the recent past 
for the identification of CTL and to a lesser extent helper T cell epitopes from a 
wide variety of immunologically relevant proteins. However, a major drawback of 
this labor- and resource-intensive approach is the high failure rate, even if the 
peptide in question binds well to the MHC molecule and the generated T cells 
recognize target cells loaded with the synthetic peptide. The reason for this is 
either that the peptide is not produced by the processing machinery of the cell, or 
the T cells raised by primary peptide stimulation in vitro are of low affinity, or a 
combination of both.  
In consequence, various groups have made attempts to decrease the number of 
candidate peptides by applying additional criteria to epitope prediction. For 
example, the increasing knowledge about specificities of other cellular 
components of the antigen processing machinery, most notably the proteasome 
and TAP, has made it possible to apply these specificities as additional filters to 
the selection of candidate peptides. Moreover, experimental selection criteria such 
as MHC–peptide binding assays and the bioanalytical verification of presentation 
of predicted MHC-ligands have been applied successfully. 
This review tries to give a comprehensive overview on available computer-based 
prediction algorithms and strategies that combine the predictive power of these 
theoretical approaches with experimental approaches for a reliable and rapid 
identification of T cell epitopes.  
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Since it was written from an immunologist’s point of view, this review focuses 
mostly on prediction programs that have already been applied to the identification 
of novel epitopes. Furthermore, it should be noted that there are tremendous 
differences between different prediction softwares in terms of availability. Some 
programs are easily accessible for free in the WWW, others are available from 
authors of the corresponding publications, still others are available on a 
commercial basis only.  
 
Computational predictions 
Epitope prediction 
The recognition of MHC-peptide complexes by the T cell receptor (TCR) is the first 
step in a series of cellular processes that lead to the initiation of T cell-mediated 
immunity. It is therefore not surprising, that as soon as the peptidic nature of MHC 
ligands was discovered, but even before the rules for the binding of peptides to 
MHC molecules were elucidated, first attempts for the predicition of T cell 
antigenic structures from protein sequences were published. These predictions 
were based solely on comparisons of precursor peptide sequences known to 
contain T cell epitopes. Suggested characteristics of T cell epitopes were 
predicted secondary structures (amphipathic helices) [86] or short primary 
sequence motifs [87, 88]. It was the discovery of allele-specific motifs shared by 
eluted natural MHC ligands [1], that finally allowed the exact prediction of peptides 
from a given protein sequence presented on MHC class I molecules [83, 84].  
For MHC class II ligands the elucidation of peptide motifs turned out to be more 
difficult due to the variable length of the ligands as well as the more degenerate 
anchor positions, which are sometimes not used at all. Several methods for the 
determination of MHC class II peptide motifs have been based on sequence 
information of natural ligands, including the alignment of natural ligands, pool 
sequence analysis, or substitution variants of known ligands [89-93]. In 1992, the 
first HLA-DR-motif based on binding assays using a phage peptide display library 
was published [94]. 
While in the beginning of the 1990s, the selection of candidate peptides was done 
manually or using simple pattern search programs by scanning protein sequences 
for main anchor positions only, the constant refinement of peptide motifs and 
knowledge about secondary anchor amino acids, disfavored amino acids and 
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other chemical interactions important for binding to the MHC molecule quickly led 
to the development of more complex computational predictions.  
Depending on the focus of research, the determination of peptide motifs has been 
approached from two sides: 
On the one hand, the binding properties of a certain MHC molecule have been 
analyzed by determining the binding of synthetic peptides from protein antigens 
using MHC-peptide binding assays [95-98]. The most refined descriptions of such 
“peptide binding motifs” have been achieved by using positional scanning with 
random synthetic peptide libraries [99-101].  
On the other hand, the analysis of natural ligands by individual ligand analysis as 
characterized by Edman degradation [1, 92, 102, 103] and tandem mass 
spectrometry [91] as well as Edman pool sequencing [1] leads to so-called 
“natural ligand motifs”, that give information about the natural peptide repertoire 
presented by a certain MHC molecule. These motifs are therefore not only a result 
of the binding properties of this MHC molecule, but reflect also – to a certain 
extent – features of the antigen processing machinery, e. g. cleavage specificities 
of the proteasome or sequence requirements for transport into the ER by TAP. 
Indeed, MHC binding motifs derived from random peptide libraries show 
significant differences, especially for the C-terminal amino acids, compared to 
motifs derived from natural ligands [104]. This raises the question of the in vivo 
relevance of motifs based on binding properties of synthetic peptides.  
 
Epitope prediction: MHC class I 
Historically, MHC class I epitope prediction had a headstart over its MHC class II 
counterpart. The reasons for this include the defined length of MHC class I ligands 
of mostly 9 amino acids and the more clearcut rules of MHC class I motifs, that in 
turn have been more clearly characterized. Currently there are two predictive 
algorithms available in the world wide web, that allow unrestricted predictions free 
of charge: “BIMAS”, developed by K. C. Parker et al. [97] (http://www-
bimas.dcrt.nih.gov/molbio/hla_bind/) and “SYFPEITHI”, developed by our group 
[105] (http://www.syfpeithi.de). SYFPEITHI uses motif matrices deduced from 
refined motifs based on the pool sequencing and single peptide analysis 
exclusively of natural ligands. Potential binders for various human, mouse and rat 
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MHC class I molecules are ranked according to the presence of primary and 
secondary anchor amino acids as well as favored and disfavored amino acids.  
BIMAS ranks potential HLA-binders according to predicted half-time dissociation 
of MHC-peptide complexes. While the motif matrix for HLA-A*02 is based solely 
on binding studies, other matrices have been deduced from reported motifs, 
regardless of the method used for their identification. This might explain the highly 
similar results that were obtained with both algorithms in a recent study that 
identified HLA-B*07-presented epitopes from the tumor-associated antigen (TAA) 
carcinoembryonic antigen (CEA) [106], since for HLA-B*07 the reported motifs are 
based on natural ligands. Both algorithms have been used successfully during the 
last years for identification of CTL epitopes from a wide range of antigens, for 
example from the human TAAs telomerase (BIMAS) [107] and TRP2 
(SYFPEITHI) [108].  
Other prediction programs that have been applied to the identification of MHC 
class I-presented epitopes are distributed on disk (e. g., “MOTIFS” [109]), part of 
commercial websites (e. g., “EPIMATRIX” [110] 
(http://www.brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html)) or are 
currently not publicly available [111].  
The motif-based algorithms so far described are still relatively simple programs 
that consider every amino acid position in a peptide individually. For every 
position, a coefficient is assigned to each amino acid and the overall score or 
binding value of the peptide are determined by addition or multiplication of amino 
acid coefficients. Besides, there are several reports employing artificial neural 
networks (ANN) [112-115] or the polynomial method [114]. These approaches 
open up the possibility to consider amino acid preferences that depend on the 
properties of amino acids in other positions of the peptide.  
Still another approach is based on structural information from crystallographically 
solved peptide-MHC complexes [116, 117]. 
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Table  1.4.2 Comparison of MHC class I prediction programs 
Sequence Source HLA program used reference SYFPEITHI BIMAS PAPROC* 
 (position) molecule for identification  rank/score rank/value 
 
ILAKFLHWL Human TERT A*0201 BIMAS [107] 1/30 1/ 1745.714 No 
 (540-548) 
KVLEYVIKV Human MAGE-A1 A*0201 SYFPEITHI [118] 3/26 1/743.189 Yes 
 (278-286) 
ILHNGAYSL Human Her-2/neu A*0201 Sette et al. [119] 3/27 16/36.316 Yes 
 (435-443) 
HLSTAFARV Human G250 A*0201 MOTIFS [120] 19/22 38/4.493 No 
 (254-262) 
 
* prediction of proteasomal generation of C-terminus by human proteasome wild type III 
Comparison of MHC class I predictions. Epitopes identified using different epitope prediction programs were recalculated 
using programs that are available free of charge on interactive websites: the epitope prediction programs BIMAS and 
SYFPEITHI and a program for prediction of proteasomal cleavage sites PAPROC. 
 
Table  1.4.2 demonstrates the similarities and differences of some of the currently 
used MHC class I prediction programs. It shows selected CTL epitopes that were 
identified using four different computer programs and also lists the corresponding 
results from SYFPEITHI, BIMAS and a prediction algorithm for proteasomal 
cleavages, PAPROC (see below), i. e. programs that are available at interactive 
websites at no cost. However, it should be noted that some studies do not give the 
results of the original prediction procedure, such as ranks or values, but only lists 
of peptides, that were selected after performing additional tests.  
  
Epitope prediction: MHC class II 
The main obstacle for the prediction of MHC class II-ligands has been the varying 
degree of degeneration of motifs. While some alleles, e. g. HLA-DRB1*0405 show 
a strong preference for certain related amino acids in the anchor positions that is 
comparable to MHC class I motifs (in this case D, E in P9) [105], other alleles 
make the definition of primary anchor amino acids virtually impossible (e. g. for 
HLA-DRB1*0401 all amino acids except G, P, F, W have been assigned anchor 
amino acids in P9) [105]. To date, the focus has been on predictions of HLA-DR 
ligands, with only one report on predictions of HLA-DQ-restricted epitopes [121]. 
The first matrix-based prediction algorithms for HLA-DRB1*0401 were based on 
the results of side chain scanning experiments using simplified, polyalanine-based 
peptide libraries [98, 122]. The work by Hammer and colleagues resulted in the 
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commercial program TEPITOPE, which focuses on promiscuous HLA-DR binding 
peptides, but also allows allele-specific predictions. It has been used in several 
studies, for example in the identification of an HLA-DR11-presented epitope from 
MAGE-A3 [123].  
Another matrix-based HLA-DRB1*0401-prediction algorithm, also based on 
binding studies using synthetic peptides [124] has been used for the retrospective 
calculation of an epitope from human gp100 [125] that had been identified before 
[126]. This program is available for free on request from the Surgery Branch of the 
NCI. 
Still another customized computer algorithm also based on published HLA-DR 
binding motifs has been used for the identification of HLA-DR-presented 
promiscuous T cell epitopes from Plasmodium falciparum [127].  
The first program for prediction of MHC class II based on natural ligands of two 
HLA-DR13 alleles was the PAP program [128]. This program, which can be 
obtained for free from the author, uses corrected amino acid yields from Edman 
pool sequencing directly as coefficients in motif matrices. One of the following 
publications also reports for the first time predictions for HLA-DQ2 and –DQ8 and 
the identification of a novel HLA-DQ2-presented epitope from gliadin, the antigen 
of celiac disease [121].  
Currently, SYFPEITHI is the only the interactive website offering unrestricted MHC 
class II predictions free of charge. As for MHC class I, the available predictions for 
HLA-DR and several mouse MHC class II alleles are based on motif matrices 
deduced from natural ligands by single ligand analysis and Edman pool 
sequencing.  
For HLA-DRB1*0401, predictions by artificial neural networks have already been 
applied successfully to the identification of helper T cell epitopes. Zarour and 
colleagues have used an ANN, based on the work by Honeyman, Brusic and 
colleagues [129, 130], for the identification of epitopes from the TAAs Melan-
A/MART-1 [131] and NY-ESO-1 [132]. These prediction programs are currently 
not publicly available. 
Finally, several publications have explored the possibilities of other more complex 
computational predictions. E. g., Mallios has described an iterative algorithm to 
align and optimize an MHC class II-binding matrix based on sequences of known 
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class II ligands alone or in combination with suggested motifs [133]. Up to now, 
none of these predictions have been applied to the identification of T cell epitopes. 
Table  1.4.3 shows examples of helper T cell epitopes, that were identified by four 
different computer programs and also lists the corresponding results from 
SYFPEITHI and the HLA-DRB1*0401 prediction program from the NCI. However, 
in contrast to MHC class I, comparisons of MHC class II predictions can be even 
more difficult for several reasons. 
Table  1.4.3 Helper T cell epitopes identified by prediction 
Epitope sequence Source HLA reference program used SYFPEITHI NCI 
 (position) molecule  for identification rank/score rank/value 
 
WNRQLYPEWTEAQRLD Human gp100 DRB1*0401 [125] NCI 2/26 1/0.0195 
 (44-59) 
RNGYRALMDKSLHVGTQCALTRR Human MART-1 DRB1*0401 [132] ANN 1/22 -/- 
 (51-73) 
TSYVKVLHHMVKISG Human DRB1*1101 [123] TEPITOPE 8/22** n. a.  
 MAGE-A3 
 (281-295) 
 
putative core sequences are underlined; **best ranked peptides 284-298 (score 28) and 280-294 (score 24) also contain 
other putative core sequences; n. a. not available 
Comparison of MHC class II predictions. Epitopes identified using different epitope prediction programs were recalculated 
using programs that are available free of charge either on an interactive website (SYFPEITHI) or by email (NCI). 
 
First, due to the variable length of MHC class II ligands, the identified epitopes 
may harbor more than one putative core sequence. Furthermore, some studies 
focus on promiscuous MHC class II-binding peptides, while others use allele-
specific predictions. 
 
Predictions of antigen processing 
Much of the work combining computational predictions and applied immunology 
has focused on MHC-peptide binding only. However, the increasing knowledge 
about specificities of other cellular components involved in antigen processing, 
such as the proteasome and TAP, has been used to create comparable prediction 
algorithms with the future prospect of fusing them to epitope prediction programs.  
The proteasome is a cytosolic multisubunit protease that is, among other 
functions, involved in the generation of peptide ligands for MHC class I molecules 
and responsible for the generation of the correct C-terminus of CTL epitopes [134, 
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135]. The proteolytically active core complex (20S proteasome) can associate with 
the 19S cap complex to form the 26S proteasome, which is responsible for the 
degradation of ubiquitin-marked proteins. The three different active sites show 
different proteolytic specificities, cleaving after large, hydrophobic amino acids, 
basic amino acids and acidic amino acids, respectively. Upon exposure of cells to 
interferon γ (IFNγ), the catalytically active subunits are replaced by three IFNγ-
inducible subunits. This results in a shift in the overall cleavage specificity of this 
immunoproteasome towards hydrophobic amino acids, while cleavages after 
acidic amino acids are disfavored. This corresponds to the fact that almost all 
reported peptide motifs of vertebrate MHC molecules demand hydrophobic or 
basic C-terminal anchor amino acids.  
An experimental approach was chosen by Kessler at al., for the identification of 
HLA-A*0201-presented CTL epitopes from the TAA PRAME by an extended 
reverse immunology strategy that incorporates proteasomal digest analysis [136]. 
Predicted HLA-A*0201-binding peptides were tested in binding and stability 
assays, followed by analysis of in vitro proteasome-mediated digestions of 27mer 
precursor peptides encompassing candidate epitopes. For only 4 out of 19 high 
affinity binders efficient generation of the correct C-terminus was observed and all 
4 peptides were found to be efficient CTL epitopes.  
The first published prediction algorithm for cleavages by 20S proteasomes, 
“FRAGPREDICT”, is based on published peptide cleavage data [137] 
(http://www.mpiib-berlin.mpg.de/MAPPP/cleavage.html). The “PAPROC”-algorithm 
[138] (http://www.paproc.de), developed by our group, is based on an evolutionary 
algorithm trained on cleavage data of 20S proteasomal digests of a whole protein 
substrate (enolase [139]), and additional peptide digest data from the literature. 
While the currently available prediction programs are based only on semi-
quantitative data from human or yeast constitutive 20S proteasomal digests, more 
accurate predictions based on fully quantified protein digestion data as well as 
immunoproteasomal digestion data [140] are currently being developed. Another 
program, “NETCHOP” [141] (http://www.cbs.dtu.dk/services/NetChop/) is an ANN 
that was trained on data from the analysis of residues at the termini and flanking 
regions of known natural MHC class I ligands. All these programs for the 
prediction of proteasomal cleavages are available free of charge on interactive 
websites. 
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The overall goal of combining proteasomal prediction algorithms with epitope 
prediction is already possible using combinations of FRAGPREDICT and 
PAPROC with SYFPEITHI and BIMAS at the website of the Max-Planck-Institute 
for Infection Biology (www.mpiib-berlin.mpg.de/MAPPP/). It should be noted that 
this program also predicts C-terminally extended precursor peptides.  
 
An ANN-based device has also been reported for prediction of human TAP 
peptide-binding affinities using a polyalanine-based peptide library [142]. The 
program predicted a higher affinity to TAP for eluted natural ligands compared to 
randomly selected peptides with similar binding affinities to the same HLA 
molecule, indicating that such predictions might be – at least for some HLA-alleles 
– a valuable addition for epitope prediction tools. However, this would probably 
require a more profound investigation of peptide translocation by TAP, not only 
binding of peptides. The reported preferences of TAP for peptide translocations 
[12] have not yet led to a prediction program. 
 
Experimental verification of predicted epitopes 
Analysis of binding properties 
In most cases epitope prediction is followed by binding studies with synthetic 
peptides in order to reduce the number of potential candidate peptides by 
discarding non-binding peptides for the final analysis of recognition by peptide-
specific T cells. 
Binding of synthetic peptides to MHC molecules is mainly studied by assays 
based on competition [111, 143, 144], reconstitution of MHC-peptide complexes 
on the cell surface [145-147], or stabilization of MHC-peptide complexes on TAP-
deficient cells [148]. 
In competition assays, the studied peptides compete with a labeled reference 
peptide of intermediate affinity for binding to MHC molecules. Such assays are 
performed either using whole cells or purified MHC molecules in solution. In both 
cases the amount of labeled MHC-bound peptide is measured. While for MHC 
class II binding assays usually fluorescence dyes like fluorescein or 7-amino-4-
methylcoumarin-3-acetic acid (AMCA) are used for labeling the N-terminal amino 
acid of the MHC ligand, for MHC class I binding studies amino acid side chains 
have to be labeled by fluorescent dyes or by radioactive isoltopes such as 125I 
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without interfering with the more restricted binding properties of MHC class I 
molecules. Performing in-solution assays using purified MHC molecules, MHC-
peptide complexes have to be separated from unbound free peptide by gel 
filtration [111], spun columns [149] or high performance size exclusion 
chromatography (HPSEC) [144]. In addition, ELISA-based assays [150, 151] or 
the more sensitive time-resolved fluorimetry in an europium fluoroimmunoassay 
[152] have been used as the readout. Competition based binding assays result in 
IC50 values, which do not represent an absolute dissociation constant since they 
are dependent on the reference peptide. However, they allow a better comparison 
of binding affinities of different peptides than the results obtained by reconstitution 
or stabilization assays. Competition assays using purified MHC molecules employ 
soluble MHC molecules, which might have a slightly different structure compared 
to native molecules embedded in the cell membrane. Whole cell assays overcome 
these problems by using MHC molecules on the surface of intact cells. As an 
additional feature, mild acid treatment of the cells can be used to remove peptides 
from the MHC binding groove. Cells are then incubated with a fluorescence-
labeled reference peptide together with different concentrations of the peptides of 
interest [153]. The amount of bound reference peptide can be measured by FACS 
analysis. As peptide-depleted MHC molecules have a short half time and β2-
microglobulin dissociates rapidly, only membrane-anchored MHC-α-chains are left 
and thus this competition assay might also represent a reconstitution assay. 
In classical reconstitution assays, cells expressing the appropriate HLA alleles are 
stripped by incubation at pH 3.2 for a short time, then the peptide of interest and a 
conformation dependent monoclonal antibody are added. The difference in 
fluorescence intensity determined by FACS analysis between cells incubated with 
and without peptide after staining with fluorescence-labeled secondary antibody is 
used to determine peptide binding [147].  
The stabilization assay was first described by Stuber et al. in 1992 [148]. Cell lines 
with defective peptide loading mechanisms like the TAP-deficient murine cell line 
RMA-S [154] or the human cell lines T2 [155] or ST-EMO [156] display a low level 
of mostly empty MHC class I molecules on their surface, due to the rapid turnover 
of empty MHC molecules. Addition of exogenous binding peptide to the cells, 
however, leads to stabilization and accumulation of the MHC molecules, which 
can be determined by using monoclonal antibodies and FACS analysis. Due to its 
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simplicity, this assay can serve for screening large numbers of peptides. 
Moreover, transfection of any human cell with cDNA of the immediate early protein 
ICP47 of the Herpes simplex virus generates a TAP deficient phenotype and thus 
allows to expand the stabilization assay to virtually any HLA allele [157]. 
 
Analysis of presentation 
Since the first identification of a natural MHC class I-ligand by tandem mass 
spectrometry (MSMS), this technique has become the bioanalytical method of 
choice for high sensitivity sequencing of natural MHC ligands. This has lead to the 
development of approaches that combine epitope prediction and HPLC-MS and –
MS/MS for specific detection and identification of disease-associated MHC class I-
ligands. Brockman and colleagues used a simple main-anchor-based epitope 
prediction to identify masses of candidate H2-Kb-ligands from Trypanosoma cruzi 
[158]. The corresponding mass chromatograms showed in two cases significant 
peaks and subsequent HPLC-MS/MS analysis revealed indeed two naturally 
processed peptides. A variant is the “Predict, Calibrate, Detect” (PCD) -approach 
[159], that allows a more rapid and sensitive screening of tumor samples by 
calibrating the HPLC-MS-system with synthetic analogs of predicted potential 
HLA-A*02 ligands from tumor-associated proteins. HLA-A*02 ligands from TAAs 
p53, CEA and MAGE-A1 have been identified using PCD [118, 159]; the MAGE-
A1-derived peptide has been verified as a CTL epitope using an HLA-A*02 
transgenic mouse model [118]. 
These approaches do not substitute for testing peptide-specific recognition of 
tumor cells by CTL, but they allow a further focussing of these efforts to those 
peptides that are not only binding to the MHC molecule, but are actually 
processed and presented. 
 
Analysis of T cell recognition 
The final experimental verification of a predicted epitope is achieved by the 
identification of T cells, which specifically recognize the naturally processed 
epitope in an HLA-restricted fashion. One major source for T cells are peripheral 
blood mononuclear cells (PBMC) from patients or healthy donors, which either are 
already primed in vivo or which can be primed in vitro, respectively. In addition, 
immunization of various HLA class I and class II transgenic mice (reviewed in 
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[160] and [161]) can be used to generate specific T cells. T cell responses after 
stimulation can be measured by means of lytic activity, proliferation and cytokine 
production. Lytic activity of cytotoxic T lymphocytes has been analyzed since 1968 
using the 51Cr-release assay [162, 163], but this assay requires the cumbersome 
in vitro expansion of specific T cells from PBMCs. Nevertheless, it is still widely 
used. As an alternative, T cell proliferation has been investigated by radioactive 
3H-thymidine incorporation. To determine peptide specific T cell response, a 
sensitive proliferation assay was established in 1996. This assay avoids 
radioactivity and uses BrdU incorporation instead [164]. Comparison with the 51Cr-
release assay revealed a much higher sensitivity of the proliferation assay in this 
report. The first quantitative assay for IL-2 production by activated T cells 
described in 1978 is still used today [165]. This sensitive method is based upon an 
IL-2 dependent mouse T cell line, CTLL, as target cell population, which 
proliferates and incorporates 3H-thymidine in response to IL-2 in culture medium. 
After IL-2 and IFNγ specific antibodies have been available, enzyme-linked 
immunosorbent assays (ELISA) have been used to measure T cell responses 
[166-168]. Advantages of ELISA assays are their simple setup and the capacity to 
proceed with many samples in parallel. 
All methods discussed so far cannot detect cytokine production by T cells on a 
single cell level. The first application to address this question was the ELISPOT 
assay reported in 1988 for enumerating IFNγ-secreting lymphocytes [169, 170], 
originally developed for detection of single specific antibody-secreting cells [171]. 
In this assay activated T cells are plated in anti-IFNγ antibody coated wells; single 
IFNγ-secreting cells are detected as spots after staining trapped IFNγ with an 
insoluble dye generated by an enzyme coupled to the second anti-IFNγ antibody. 
Peptide-specific T cells can be assessed this way with higher sensitivity compared 
to the 51Cr-release assay [172], even without need for prior in vitro expansion, 
which may bias the result. ELISPOT has been used to measure TNFα secretion 
[173] or IFNγ secretion [174, 175] as markers for T cell activation. The tedious 
visual counting of spots was no longer necessary after introduction of a computer-
assisted image analysis system, which has made the data analysis convenient, 
objective and suitable for handling large sample pools [176]. 
Another way to assess cytokine production on a single cell level is achieved by 
intracellular cytokine staining and flow cytometry analysis. After stimulation in the 
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presence of monensin T cells are fixed by paraformaldehyde and permeabilized 
by saponin to allow antibodies to penetrate through the cell membrane, the cytosol 
and the membranes of the endoplasmatic reticulum and Golgi organelle. 
Monensin interrupts intracellular transport processes leading to an accumulation 
of the cytokine in the Golgi complex and thus an increase of the signal/noise ratio 
leads to a higher sensitivity [177, 178]. Intracellular cytokine staining allows high 
throughput of samples and multiparameter characterization of cytokine production 
as well as parallel detection of cell surface markers on a single cell basis without 
the need for prolonged in vitro culture and cloning. However, the sensitivity is 
limited by the fluorescence-activated cell-sorting analysis. 
Visualization of antigen-specific T cells is possible by staining T cell receptors with 
MHC/peptide tetrameric complexes [179-182]. These tetramers are made by in 
vitro folding MHC heavy chain in the presence of β2-microglobulin and a specific 
peptide ligand. The heavy chain is engineered in a way that the purified MHC-
peptide complex can be biotinylated and than tetramerized via fluorochrome dye-
coupled avidin. Tetramerization enhances the affinity of the αβTCRs to soluble 
peptide-loaded MHC molecules. By this method, a quantitation of T cells 
displaying TCRs specific for the analyzed peptide is possible, but nothing can be 
said about functionality of these T cells. The tetramer approach is well established 
for MHC class I molecules, but detection of antigen-specific CD4+ T cells with 
soluble MHC class II tetramers is about to begin [183-189]. Application of MHC 
class I tetramers in the field of virus immunology is reviewed by Doherty and 
Christensen [190]. 
Probably the most sensitive method to detect T cell responses is quantitation of 
induced cytokine mRNA after activation by quantitative real time RT-PCR. This 
quantitative method is based on the 5` nuclease assay in which during PCR the 
5`→ 3` endonuclease activity of the Taq DNA polymerase cleaves a hybridized 
sequence-specific fluorogenic internal oligonucleotide probe. Relative increase in 
fluorescence emission from the reporter dye is detected online in an analytical 
thermal cycler [191]. This assay has been used to quantify cytokine mRNA 
expression (IL-2, IL-4, IL-10, TNFα, IFNγ) in previously frozen whole blood 
samples [192]. More recently, this very sensitive and highly reproducible method 
was adapted by normalizing copy numbers of cytokine mRNAs to CD8 mRNA 
copy numbers in order to analyze specific T cell responses in fresh PBMCs 
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without any further stimulation [193, 194]. This way it was possible to monitor the 
specific T cell response after peptide vaccination in melanoma patients. Though 
this is no single cell assay, it is very sensitive, highly reproducible and allows high 
sample throughput.  
 
Outlook 
While computational predictions have already become a familiar tool for many 
immunologists searching for T cell epitopes from immunologically relevant 
proteins, there is the constant need of using new data to update and extend the 
available programs. Reliable epitope prediction is still only available for a limited 
number of organisms and alleles because no or not enough information is 
available about the corresponding peptide specificities. However, several studies 
have shown both for MHC class I and II, that the knowledge, which amino acids 
occupy those positions of the MHC polypeptide chain that are responsible for the 
interaction with peptide ligands, may in some cases allow the prediction of peptide 
specificities for MHC molecules with yet unknown motifs [195, 196].  
Furthermore, the predictions for other components of the antigen processing such 
as proteasomal cleavage specificities are still in their infancy, with programs that 
are based on quantified cleavage data from immuno- and constitutive 
proteasomes being not yet publicly available. On the other hand, the development 
of prediction programs for MHC class II that are able to take antigen processing 
into consideration are still in the distant future. 
Since the increasing usage of screening techniques such as DNA microarrays 
[197] and SEREX (Serological analysis of recombinant cDNA expression libraries) 
[198] provide a rapidly growing pool of candidate protein antigens, interactive 
combinations of computational epitope predictions with these approaches, such 
as the recently described combination of DNA microarray analysis and TEPITOPE 
[196], are expected to provide a rapidly growing number of epitopes to be used in 
immunotherapy of a wide range of diseases.  
However, while the described strategies combining computational prediction and 
experimental methods are likely to provide a rapidly increasing number of T cell 
epitopes as potential tools for therapeutic and diagnostic purposes, the identified 
epitopes still have to pass the ultimate test: they have to prove to be useful in the 
in vivo situation. 
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1.4.3.3 Exploring the MHC-Ligandome 
Parts of this chapter are parts of a publication in Immunological Reviews by Hans-
Georg Rammensee, Toni Weinschenk, Cecile Gouttefangeas, and Stefan 
Stevanović. 
 
Ideal would be the identification of all presented MHC ligands of a given tumor. In 
principle this aim was tackled in this thesis. It is shown here that identification of 
 1.4 INTRODUCTION   31 
 
 
more than 100 peptides is feasible, but still this is probably less than 10 % of the 
complete MHC-ligandome [199]. But as the big majority of all MHC-bound 
peptides are derived from self antigens and thus are not useful for 
immunotherapy, immediately the question about the selection of the appropriate 
antigens and peptides arises. 
 
Selection of tumor antigens for individual patients 
To get a selection of tumor antigens well suited to be targeted in a particular 
cancer patient, first an analysis of differences between this tumor and normal cells 
is necessary on the molecular level. The amount of starting material ranges 
between whole organs such as a kidney in the case of renal cell carcinoma on the 
one hand and small biopsies on the other hand. In the first case malignant and 
normal material is easily available for analysis, in the latter case amounts are 
limited and it can be difficult especially to get material from normal tissues. 
Moreover, accurate analysis requires homogenous tumor and normal cell 
populations, which sometimes only can be obtained after enrichment procedures. 
Enrichment can be achieved by several methods, e.g. laser capture 
microdissection, cell sorting by magnetic beads or fluorescence-assisted cell 
sorting, but cell numbers available for analysis are then further decreased. 
Expression analysis of single tumor cells by chip technology has been described 
[200]; however, a critical issue here is the fidelity of quantitative representation of 
the original individual mRNA species after PCR-based cDNA amplification. 
Large scale screening for differences between tumor and normal cells can be 
done on the level of DNA, protein, mRNA or MHC ligands. Array-based 
comparative genomic hybridization (array-CGH) [201] can be used for genome-
wide analysis of DNA copy-number changes, but to identify target genes 
appropriate for immunotherapy, they are of less interest compared to changes in 
gene expression. Another interesting feature detectable in principle on the DNA 
level are point mutations and frameshifts due to microsatellite instability [28, 202], 
but methods for rapid parallel large scale mutation analysis as needed for patient 
individual analysis are lacking. Commercially available is a microarray for analysis 
of mutations in the tumor suppressor gene p53, a gene frequently mutated in 
tumors, but parallel screening for the most frequently occuring mutations 
distributed among several genes is not possible. An array covering the hot spots 
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of these genes such as ras [203] would be acclaimed. The classical proteomics 
approach uses two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) for 
high-resolution protein separation followed by identification via mass 
spectrometry. Here, not only proteins overexpressed in the tumor versus the 
normal tissue are detectable, but additional TAA-classes are accessible, such as 
frameshift-derived antigens, antigens translated from the antisense strand, fusion-
derived antigens and antigens showing different posttranslational modifications 
(PTM) in the tumor. For the aim to immunize with peptides, MHC ligand-prediction 
can be performed on most of these TAA-classes, but differences due to PTM 
cannot easily be transferred to MHC ligands. 
Analysis based on electrophoresis is laborious, time-consuming, and of low 
sensitivity, despite still having the highest separation resolution. Thus, new 
simplified methods were developed: a method well suited to identify proteins only 
present in one of two samples, the surface-enhanced laser desorption/ionization 
(SELDI) technique [204, 205], and an approach to quantitative proteome analysis, 
using isotope-coded affinity tags (ICAT) [206, 207]. In the last years, development 
of protein based microarrays – arrays of antibodies, recombinant proteins or whole 
proteomes – made its contribution to tumor immunology [208-210]. 
For most cellular requirements, it is the proteins which do the job, suggesting the 
protein-level to be more relevant than the mRNA-level. But there is increasing 
evidence that the majority of MHC ligands are not derived from native proteins, but 
instead are processed from defective ribosomal products (DRiP) by proteasomal 
degradation [3-5, 211, 212]. This suggests that the number of peptides displayed 
by MHC molecules on the surface of a cell is closer related to the expression of 
the encoding mRNA species compared to the respective expression of the protein 
measured in the steady state. 
Comparative expression profiling of a tumor and the corresponding autologous 
normal tissue enabled by DNA microarray technology [197, 213] is an excellent 
method for identifying large numbers of candidate TAA from individual tumor 
samples [214-216]. Using chip technology, genome wide expression analysis of all 
genes is possible within few days, and customized arrays can be used for high 
throughput screenings [217]. One disadvantage is that some important TAA-
classes are not considered such as products of frameshift mutations, proteins 
translated from the antisense strand or fusion proteins. A big advantage is the 
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possibility to get expression levels for all known TAA in an individual patient on 
call. This means one could screen an MHC class I-ligand database (e.g. 
SYFPEITHI at http://www.syfpeithi.de) for all reported cancer-related epitopes 
restricted to the HLA alleles expressed by an individual patient, check the 
expression of the respective encoding genes in the very same patient and use the 
appropriate epitopes for vaccination on short notice. In addition, expression data 
for each gene in almost all normal human tissues and organs are available from 
already existing databases (see below) and databases that are in development. 
This is especially important for the choice as to which antigens are suitable for 
vaccination with respect to autoimmunity and T cell tolerance. 
Ideal would be a differential “MHC-ligandome” analysis of the tumor and the 
corresponding normal cells because in this setting also differences in antigen 
processing between tumor and normal tissues are detected. Epitopes might exist 
which only are presented on the tumor cells although the source protein is present 
in equal amounts in both cell types. As an example a HLA-B*40-restricted T cell 
epitope of MAGE-3 was only generated in tumor cells expressing the 
immunoproteasome [218]. There is increasing evidence that the peptide pool 
generated by the immunoproteasome differs from that produced by the standard 
proteasome [140, 219, 220], an interesting aspect in the context of tumors 
exposed to local release of IFN-γ. But differential MHC-ligandome analysis is hard 
to achieve because of the low amounts of individual peptides obtained after MHC 
immunoprecipitation and elution. Comparison can be performed by off-line mass 
spectrometrical analysis of corresponding fractions obtained after reverse-phase 
HPLC separation. A more sensitive approach is the comparison of liquid-capillary 
mass spectrometry (LC-MS) runs of peptide mixtures eluted from the tumor and 
from the normal cells, a method already reported ten years ago for comparative 
analysis of different cell lines [91]. For quantitative conclusions, the challenge in 
this case is how to normalize. 
 
Data-mining 
How to select peptides out of the pool eluted from an individual patient’s tumor for 
their suitability as vaccine components? Apart from the obvious considerations – 
overexpression in tumor, limited expression in other tissues – other criteria, such 
as known cancer association, involvement in the oncogenic process or 
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immunogenicity of the gene product, can be made. The analysis of existing 
databases should provide assistance: Serological identification of antigens by 
recombinant expression cloning (SEREX) [46, 221] gives a list of TAA recognized 
by antibodies. Some antigens identified by this method were shown to be 
recognized concomitantly by CD8+ T cells [38]. Despite the fact that there is no 
direct linkage between detection of antibodies in cancer patient’s sera against a 
particular TAA and the presence of CD8+ T cells recognizing the very same TAA, 
at least one could state that antigens identified by SEREX are immunogenic, in 
general. These antigens are suitable enough for the immune system to be 
recognized by antibodies and CD4+ T cells, so probably likewise by CTL. For 
these reasons, data-mining after MHC ligand analysis of an individual tumor 
should include comparison of the peptide-encoding source proteins with the 
SEREX database (http://www.licr.org/SEREX.html). 
Other useful tools are databases for gene expression. Compared to data sets 
obtained from the individual patient, they have only a small impact regarding the 
overexpression of genes, but they can help to decide if a gene is a TAA shared 
among several tumors or not. Moreover, they are important for limitation of risk 
concerning autoimmunity because more and more data about tissue distribution of 
a candidate gene will be available. Some examples for databases that allow 
unrestricted access are: SAGEmap (http://www.ncbi.nlm.nih.gov/SAGE) [222], a 
database compiled from data obtained by serial analysis of gene expression [223, 
224], allows to display virtual northern blots. Gene Expression Omnibus (GEO) 
[225] (http://www.ncbi.nlm.nih.gov/geo) is a public repository for high-throughput 
gene expression and genomic hybridization data derived from SAGE, hybridization 
on filter, microarray and high-density oligonucleotide array experiments. 
HugeIndex [226] is a database especially for data from normal human tissues 
(http://www.hugeindex.org). Certainly, in-house gene expression databases are 
preferable, because data sets are more coherent due to exactly identical sample 
preparations, but they are rather expensive to build up. One general drawback of 
expression databases lies in the diversity of platforms. Even within one technology 
platform such as high-density oligonucleotide arrays, data generated from new 
chips covering more genes and with another design are not comparable to data 
obtained from out-of-date chip generations. As an example, data from HugeIndex 
are based on Affymetrix GeneChip Hu6800 arrays, therefore only a small 
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number of genes is represented and comparison with data from recently released 
arrays is not possible. 
Further useful quick information, especially gene annotations, for the selection of 
peptides out of the pool eluted from an individual patient can be obtained from 
databases about gene ontology. A nice tool for this purpose is the Gene Ontology 
database (http://www.geneontology.org) [227] also linked to LokusLink 
(http://www.ncbi.nlm.nih.gov/LocusLink), a central platform for many informations 
about genes [228]. 
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1.6 Aims of this thesis 
Therapeutic tumor-immunotherapy in human beings in general as well as 
vaccination with peptides have been more or less established at the beginning of 
this thesis. Even personalized vaccines – vaccines especially adapted to the 
needs of every patient – have been studied in a variety of applications. On the one 
hand, personalization was achieved using processed autologous material from 
each patient. This autologous material was either whole tumor lysate, total RNA 
isolated from the tumor or gp96 isolated from autologous tumor cells. On the other 
hand, all studies using MHC class I-restricted peptides have been sort of 
personalized because almost all of them studied HLA-A*02-restricted peptides 
and it’s obvious that patients had to be selected according to their HLA-type. 
Expression of the respective antigen was not analyzed in most of the latter cases.  
 
Thus, the aim of this thesis was to establish an approach for the identification of 
personalized tumor vaccines consisting of MHC class I-bound peptides. This 
approach should take into account: 
• the expressed antigens in the tumor 
• the expressed HLA alleles 
• antigen processing in the tumor 
Further demands were: 
• many different targets should be addressed 
• peptides should be presented preferably on many HLA-alleles 
 
Several up-to-date technologies were used for this aim: 
• capillary LC-MS (already established in the laboratory) 
• oligonucleotide microarray expression profiling (established by the author of 
this thesis in the lab already in 2000) 
• real-time RT-PCR (established by the author of this thesis in the lab) 
• LCM (established by the author of this thesis in the lab) 
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Especially LC-MS was also applied to the second and related topic of this thesis, 
antigen processing. Here, the focus was set on processing enzymes beside the 
proteasome. During establishment and optimisation of the above mentioned 
technologies, some side projects, mainly protein identifications by tryptic in-gel 
digestions followed by mass spectrometric analysis (MALDI and ESI), were 
performed.
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2 Results, Part 1: Tumor Immunology 
2.1 Integrated functional genomics approach for the 
design of patient-individual antitumor vaccines 
This chapter is published in Cancer Research. The author of this thesis performed 
all experiments shown in this chapter with the exception of Figure  2.1.3, Figure 
 2.1.4, and Figure  2.1.5. Figure  2.1.3 resulted from the work of Oliver Schoor, 
Markus Schirle did the LC-MS run shown in Figure  2.1.4 and Steffen Walter did 
the tetramer stainings in Figure  2.1.5. 
 
2.1.1 Summary 
Our aim is to identify as many candidates as possible for tumor-associated T cell 
epitopes in individual patients. First, we performed expression profiling of tumor 
and normal tissue to identify genes exclusively expressed or overexpressed in the 
tumor sample. Then, using mass spectrometry, we characterized up to 77 
different MHC ligands from the same tumor sample. Several of the MHC ligands 
were derived from overexpressed gene products, one from a proto-oncogene, and 
another from a frameshift mutation. At least one was identified as an actual T cell 
epitope. Thus, we could show that by combining these two analytic tools, it is 
possible to propose several candidates for peptide-based immunotherapy. We 
envision the use of this novel integrated functional genomics approach for the 
design of antitumor vaccines tailored to suit the needs of each patient. 
 
2.1.2 Introduction 
Treatment of cancer by T cell-based immunotherapy can induce antigen-specific T 
cell responses in vivo and lead to clinical benefit, as shown in several clinical trials 
[1-6]. Induction of a defined specific CD8+ CTL response directed against the 
tumor is dependent on identification of MHC class I-ligands derived from TAA. 
66   2.1. TUMOR IMMUNOLOGY 
 
 
TAA can be exclusively present in malignant cells, such as the products of 
mutated genes. Another important class of TAA are tissue-specific structures such 
as the cancer-testis antigens and a third class of TAA are proteins overexpressed 
in tumors. Classically, the identification of tumor-associated T cell epitopes 
involved patient-derived T cells and either a gene expression approach [7] or MS-
assisted sequencing of the recognized peptides [8]. A more recent approach is 
“reverse immunology”, which uses the prediction of MHC class I-ligands from a 
selected TAA followed by their verification as T cell epitopes [9]. Major drawbacks 
of T cell-based strategies are the time-consuming culture techniques, and, more 
importantly, their limitation by the frequency of pre-existing T cells. Recently, we 
developed a T cell-independent approach, combining epitope prediction and 
screening for the predicted peptides in complex peptide mixtures eluted from 
tumors by highly sensitive capillary LC-MS [10]. 
Comparative expression profiling of a tumor and the corresponding autologous 
normal tissue enabled by DNA microarray technology [11, 12] is an excellent 
method for identifying large numbers of candidate TAA from individual tumor 
samples [13-15]. HLA-presented peptides from overexpressed or selectively 
expressed proteins should provide targets for specific CTL recognition of tumors. 
The feasibility of combining expression analysis with epitope prediction for a 
successful vaccine design has been demonstrated in a mouse model [16]. 
However, epitope prediction even for only a few target genes results in a vast 
number of candidate peptides, the majority of which are actually not presented by 
MHC molecules. Ideal would be a combination of epitope prediction with 
biochemical verification. 
Here we describe an integrated functional genomics approach that provides the 
basis for making an individual selection of peptides that can be used for peptide-
based multi-epitope immunotherapy tailored to suit the needs of each patient 
(Figure  2.1.1). 
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Figure  2.1.1 Integrated functional genomics approach for an optimized identification of 
tumor-associated epitopes. 
MHC class I-ligands presented on solid tumors are identified by MS. Expression data for the source 
proteins are immediately available from microarrays. T cell reactivity against new potential tumor-
associated epitopes before and after vaccination can be monitored by MHC-tetramer technique and 
a quantitative real-time PCR-based T cell assay. SYFPEITHI (http://www.syfpeithi.de) and PAPROC 
(http://www.paproc.de) allow epitope and proteasomal cleavage prediction for identified target 
genes, respectively. 
 
We analyzed samples from surgically removed malignant and normal tissue and 
blood from RCC patients in three different ways. 
First, we performed gene expression profiling using high density oligonucleotide 
array-technology to identify genes selectively expressed or overexpressed in the 
malignant tissue. Second, we identified MHC class I-ligands from the malignant 
material by mass spectrometry. Newly identified MHC ligands encoded by 
selectively expressed or overexpressed genes as detected in step one should be 
suitable candidates for an individual, multi-epitope-based vaccine. Furthermore, all 
known ligands from TAA reported already can be included immediately in the 
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vaccine if they match the patient’s HLA type and if the TAA are expressed in the 
individual tumor. Third, peripheral CD8+ T cells of tumor patients and healthy 
individuals were tested for reactivity against several of the tumor-associated MHC 
class I-ligands by a qPCR-based T cell assay [17] and by MHC peptide-tetramers 
[18]. 
 
2.1.3 Materials and Methods 
2.1.3.1 Patient samples 
Patient samples were obtained from the Department of Urology, University of 
Tübingen. The local ethical committee approved this study and informed consent 
was obtained from the patients. Both patients had histologically confirmed RCC, 
clear cell subtype, and had not received preoperative therapy. RCC01 was staged 
pT3bNxMx (G2), RCC13 was pT2NxMx (G3). HLA-typing for patient RCC01 was 
HLA-A*02 A*68 B*18 B*44 and for patient RCC13 HLA-A*02 A*24 B*07 B*40. 
 
2.1.3.2 Isolation of MHC Class I-Bound Peptides 
Shock-frozen tumor samples were essentially processed as described [10]. 
Peptides were isolated according to standard protocols [19] using the mAb W6/32 
[20] specific for HLA class I or HLA-A*02-specific mAb BB7.2 [21]. 
 
2.1.3.3 Mass spectrometry. 
Peptides from tumor RCC01 were separated by reversed phase HPLC (SMART 
system, µRPC C2/C18 SC 2.1/10, Amersham Pharmacia Biotech, Freiburg, 
Germany) and fractions analyzed by nanoESI MS on a hybrid quadrupole 
orthogonal acceleration time of flight tandem mass spectrometer (Q-TOF, 
Micromass, Manchester, United Kingdom) as described [10]. Peptides from tumor 
RCC13 were identified by on-line capillary LC-MS as described [10] with minor 
modifications: Sample volumes of about 100 µl were loaded, desalted, and 
preconcentrated on a 300 µm * 5 mm C18 µ-Precolumn (LC Packings, San 
Francisco, CA). A syringe pump (PHD 2000, Harvard Apparatus, Inc., Holliston, 
MA), equipped with a gastight 100 µl syringe (1710 RNR, Hamilton, Bonaduz, 
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Switzerland), delivered solvent and sample at 2 µl/min. For peptide separation, the 
preconcentration column was switched in line with a 75 µm * 250 mm C-18 
column (LC Packings, San Francisco, CA). A binary gradient of 25%-60% B within 
70 min was performed, applying a 12 µl/min flow rate reduced to approximately 
300 nl/min with a pre-column split using a TEE-piece (ZT1C, Valco, Schenkon, 
Switzerland) and a 300 µm * 150 mm C-18 column as a backpressure device. A 
blank run was always included to ensure that the system was free of residual 
peptide. On-line fragmentation was performed as described [10]. Fragment 
spectra were analyzed manually and database searches (NCBInr, EST) were 
made using MASCOT1 [22]. 
 
2.1.3.4 Preparation of RNA 
Fragments of normal and malignant renal tissue were dissected, shock-frozen, 
ground by mortar and pestle under liquid nitrogen and homogenized with a rotary 
homogenizer (Heidolph Instruments, Schwabach, Germany) in TRIZOL (Life 
Technologies, Inc., Karlsruhe, Germany). Total RNA was prepared according to 
the manufacturer’s protocol followed by a clean-up with RNeasy (QIAGEN, Hilden, 
Germany). Total RNA from human tissues were obtained commercially (Human 
total RNA Master Panel II, Clontech, Heidelberg, Germany). 
 
2.1.3.5 High-Density Oligonucleotide Microarray Analysis 
Double-stranded DNA was synthesized from 40 µg of total RNA using SuperScript 
RTII (Life Technologies, Inc., Karlsruhe, Germany) and the primer (Eurogentec, 
Seraing, Belgium) as given by the Affymetrix manual. In vitro transcription using 
the BioArray™ High Yield™ RNA Transcript Labeling Kit (ENZO Diagnostics, Inc., 
Farmingdale, NY), fragmentation, hybridization on Affymetrix HuGeneFL 
GeneChips (Affymetrix, Santa Clara, CA), and staining with streptavidin-
phycoerythrin and biotinylated anti-streptavidin antibody (Molecular Probes, 
Leiden, The Netherlands) followed the manufacturer’s protocols (Affymetrix). The 
Affymetrix GeneArray Scanner was used and data were analyzed with the 
Microarray Analysis Suite 4.0 software. After scaling, exclusive expression was 
                                            
1 Internet address: http://www.matrixscience.com 
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determined by the absolute call algorithms. Only genes showing an increase 
according to the difference call algorithm were considered to be upregulated by 
the factor as given by the fold change, calculated from average difference 
changes. 
 
2.1.3.6 Real-time RT-PCR 
The cDNA generated for microarray analysis was used for qPCR analysis. Tissue 
expression of adipophilin and keratin 18 was analyzed using single-stranded 
cDNA synthesized from 1 µg total RNA by SuperScript RTII (Life Technologies, 
Inc., Karlsruhe, Germany) and a random hexamer primer. Each gene was run in 
duplicates (40 cycles, 95°C x 15 s, 60°C x 1 min) using SYBRGreen chemistry on 
the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, 
Weiterstadt, Germany). Samples were independently analyzed 2 to 3 times. 
Primers (MWG-Biotech, Ebersberg, Germany) were selected to flank an intron 
and PCR efficiencies were tested for all primer pairs and found to be close to 1. 
Primer sequences (forward; reverse) were for ADFP: 5´-CACTGT 
GCTGAGCAATTTGAG-3´; 5´-TTGGCTTGATCTTGGATGTTC-3´. KIAA0367: 5´-
AATGCCTCAGTAGTTTGTTCCC-3´; 5´-TTTATTCTGAGCAATCCAATGC-3´. 
LGALS2: 5´-AAGATCACAGGCAGCATCG-3´; 5´-GACAATGGTGGATTCGCTG-
3´. CCND1: 5´-CACGATTTCATTGAACACTTCC-3´; 5´-TGAACTTCACATCTGTG 
GCAC-3´. MET: 5´-ACATTGAAATGCACAGTTGGTC-3´; 5´-ACAGGATCCACAT 
AGGAGAATG-3´. ETS1: 5´-AAAGTGCCAACTTCCCCTG-3´; 5´-GGAAATCCGA 
CTTTCTTCCC-3´. KRT18: 5´-GAGCCTGGAGACCGAGAAC-3´; 5´-TTGCGAAG 
ATCTGAGCCC-3´. LMP2: 5´-TGGGATAGAACTGGAGGAACC-3´; 5´-CATATAC 
CTGACCTCCTTCACG-3´. LMP7: 5´-CTATCTGCGAAATGGAGAACG-3´; 5´-CCT 
TCTTATCCCAGCCACAG-3´. 18S rRNA: 5´-CGGCTACCACATCCAAGGAA-3´; 
5´-GCTGGAATTACCGCGGCT-3´. PCR products were analyzed on 3% agarose 
gels for purity and sequence-verified after cloning into pCR4-TOPO vector using 
the TOPO TA Cloning Kit (Invitrogen, Groningen, The Netherlands). Data analysis 
involved the delta CT method for relative quantification. 
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2.1.3.7 Laser Capture Microdissection 
Embedded frozen-tissue specimens were cut at 6 µm thickness and transferred in 
70% ethanol for less than 15 min. Slides were incubated 90 s in Mayer’s 
hematoxylin (Merck, Darmstadt, Germany), rinsed in water, incubated 1 min in 
70% ethanol, 1 min in 95% ethanol, 30 s in 1% alcoholic eosin Y (Sigma, Munich, 
Germany), 2 x 2 min in 95% ethanol, 2 x 2 min in 100% ethanol and finally 2 x 5 
min in xylene. After air-drying for 15 min, slides were stored under dry conditions. 
Nonmalignant epithelial tubular cells and carcinoma cells were isolated by LCM 
using the PixCell II LCM System (Arcturus Engineering, Harpenden, United 
Kingdom). Total RNA was extracted in 400 µl TRIZOL. 
 
2.1.3.8 PBMC, Tetramer Production and Flow Cytometry 
Buffy coats from HD were provided by the Bloodbank, Tübingen. HD1 and HD2 
were serologically typed as CMV-positive, HD4 and HD6 as CMV-negative. PBMC 
were isolated by gradient centrifugation (FicoLite H, Wertheim-Bettingen, 
Germany) and frozen. HLA-A*0201 tetrameric complexes were produced as 
previously described [18, 23], with minor modifications. The HLA-A*02 binding 
peptides used for the refolding were (ALLNIKVKL) from keratin 18 and the epitope 
(NLVPMVATV) from pp65 HCMVA. Tetramers were assembled by mixing 
biotinylated monomers with streptavidin-PE or streptavidin-APC (Molecular 
Probes, Leiden, The Netherlands) at a 4:1 ratio. PBMC were thawed and 2-3 x 106 
cells were incubated 30 min at 4 °C with both tetramers (10 µg/ml for each 
monomer in PBS, 0.01% NaN3, 2 mM EDTA, 50% fetal calf serum; optimal 
concentration determined after titration experiments), then anti-CD4-FITC 
(Coulter-Immunotech, Hamburg, Germany) and anti-CD8-PerCP (Becton 
Dickinson, Heidelberg, Germany) mAbs were added for 20 min. After 3 washes, 
samples were fixed in FACS buffer, 1% formaldehyde. Four-color analysis was 
performed on a FACSCalibur cytometer (Becton Dickinson). Under these 
conditions, the average background of nonspecific staining with tetramers was 
found to be less than 0.01% on CD8+ cells. 
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2.1.4 Results 
2.1.4.1 Candidates for Target Antigens in Individual Cancer Patients are 
Revealed by Expression Profiling 
We analyzed the expression of approximately 7000 genes in tumors and 
corresponding normal tissues of two RCC. Between 400 and 500 genes were 
found to be overexpressed or selectively expressed in the tumors. In RCC01, we 
found 268 overexpressed and 129 exclusively detected genes (partially shown in 
Table  2.1.1). Most of the overexpressed genes might be cancer-related, i.e. they 
are either oncogenes, tumor suppressor genes or genes already described as 
overexpressed in cancer, such as cyclin D1 (CCND1, increased by factor 4.9, data 
not shown) [24], carbonic anhydrase IX (CA9) [25], cerebroside sulfotransferase 
(CST) [26], and parathyroid hormone-like hormone [27] (Table  2.1.1). The cancer-
associated adipose differentiation-related protein (ADFP), or adipophilin, showed 
the second highest degree of overexpression. We compared the list of 
overexpressed genes with the SEREX database1 [28] and found KIAA0367 to be 
included (clone ID NGO-St-87). Both tumors showed increased expression levels 
of IFN-γ-inducible genes: TAP1, MHC class I heavy chain, and the 
immunoproteasomal subunits LMP2 and LMP7 (not shown). 
                                            
1 Internet address: http://www.licr.org/SEREX.html 
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Table  2.1.1 Genes overexpressed in RCC01 (partial list)a 
 
  SEREX cancer Fold 
Gene Nameb Acc. No. databasec relatedd Changee 
 
CST (cerebroside sulfotransferase) D88667 - + EEf 
VEGF (vascular endothelial growth factor) M27281 - + EE 
INHBB (inhibin) M31682 - + EE 
LGALS2 (galectin 2) M87860 - - EE 
FOLR1 (folate receptor 1)  U20391 - + EE 
CA9 (carbonic anhydrase IX) X66839 - + EE 
EGFR (epidermal growth factor receptor) X00588 - + EE 
ANG (angiogenin) M11567 - + EE 
TYMS (thymidylate synthetase)  D00596 - + EE 
BTN3A2 (butyrophilin, subfamily 3, member A2)  U90546 - - EE 
TGFA (TGFα)  X70340 - + EE 
MMP1 (matrix metalloproteinase 1) X54925 - + EE 
PLD1 (phospholipase D1) U38545 - + EE 
ABP1 (amiloride binding protein 1)  U11862 - - 34.6 
ADFP (adipose differentiation-related protein)  X97324 - + 29.1 
GSTA2 (glutathione S-transferase A2) M16594 - - 23.3 
HSF4 (heat shock transcription factor 4)  D87673 - - 19.6 
ASM3A (acid sphingomyelinase-like phosphodiesterase) Y08136 - - 17.6 
ESM1 (endothelial cell-specific molecule 1)  X89426 - + 14.9 
ASPA (aspartoacylase) S67156 - - 12.8 
CP (ceruloplasmin) M13699 - + 12.4 
PTHLH (parathyroid hormone-like hormone) M24349 - + 11.6 
KIAA0367 AB002365 + - 11.3 
ENPP2 (autotaxin) L35594 - + 10.7 
P4HA1 (proline 4-hydroxylase) M24486 - - 9.6 
SHMT1 (serine hydroxymethyltransferase 1) L23928 - + 9.4 
a to constrain the size of Table  2.1.1, genes overexpressed more than 9.0 fold are shown and ranked by fold change; in 
addition arbitrarily selected genes exclusively expressed in the tumor are shown;  
b gene symbols and names refer to GeneCards (http://bioinformatics.weizmann.ac.il/cards); whenever possible symbols 
approved by the HUGO Gene Nomenclature Committee were used. 
c http://www.licr.org/SEREX.html. 
d oncogenes, tumor suppressor genes or genes overexpressed in cancer. 
e expression in tumor relative to corresponding normal tissue. 
f exclusively expressed in tumor, not in normal tissue. 
 
To verify data obtained by microarray analysis, we analyzed the expression of 
selected genes – genes from which ligands were identified (see below) and which 
are interesting because of either reported overexpression or tumor-association – 
by qPCR (Figure  2.1.2 A).  
 
74   2.1. TUMOR IMMUNOLOGY 
 
 
 
Figure  2.1.2 Expression analysis by quantitative RT-PCR for selected genes. 
Expression was analyzed by qPCR using the same cDNA as generated for microarray analysis or 
cDNA generated from laser-capture microdissected (LCM) pure cell populations. Copy numbers are 
relative to 18S rRNA and normalized to the normal tissue of each patient, which is set at 1 (  
RCC01 tumor,  RCC01 normal tissue,  RCC13 tumor,  RCC13 normal tissue). A, Expression 
of potential target genes. Symbols for gene names are adipophilin (ADFP), galectin 2 (LGALS2), 
cyclin D1 (CCND1), met proto-oncogene/hepatocyte growth factor receptor (MET), ets-1 (ETS1), 
and keratin 18 (KRT18). B, Expression of immunoproteasome subunits LMP2 and LMP7; bars, 
±SE. 
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Overexpression of adipophilin (ADFP) and cyclin D1 (CCND1) and equal 
expression of ets-1 (ETS1) was confirmed. Relative expression levels detected by 
both techniques were roughly comparable: for example adipophilin was 
overexpressed in RCC01 by a factor of 29.1 by microarray, compared to 18.1 by 
qPCR. The corresponding numbers in RCC13 are 11.4 and 6.7 (Figure  2.1.2 A). 
Galectin 2 (LGALS2) was overexpressed in RCC01 and keratin 18 (KRT18) in 
RCC13, but not vice versa. An exception to the congruence between microarray 
and qPCR was the overexpression of KIAA0367 and met proto-oncogene (MET) 
in RCC13. Analysis of pure tumor and normal cell populations obtained by LCM 
revealed the expression of adipophilin and galectin 2 in the tumors of both 
patients but not in normal tissue (data not shown). To confirm that LMP2 and 
LMP7 are indeed upregulated in tumor cells, we also performed qPCR on LCM-
derived cells (Figure  2.1.2 B). 
 
2.1.4.2 77 MHC Class I Ligands are Identified from One Individual RCC 
HLA class I-associated peptides were isolated from tumor RCC01. Sequence 
analysis by nanoESI tandem mass spectrometry allowed the identification of 77 
ligands of either HLA-A*02, HLA-A*68, HLA-B*18, or HLA-B*44, according to the 
HLA-typing of patient RCC01 and the respective peptide motifs (Table  2.1.2). To 
our knowledge, this is the largest number of ligands identified from a single solid 
tumor.  
Table  2.1.2 Identified MHC class I-ligands 
 
    SEREX Fold 
Sequencea Gene Nameb Acc. No. Position databasecChanged 
      
Solid renal cell carcinoma from patient RCC01 
 
HLA-A*02      
      
YVDPVITSI MET (met proto-oncogene) J02958 654-662 - nc 
SVASTITGV ADFP (adipose differentiation-related protein) X97324 129-137 - 29.1 
ALLNIKVKL KRT18 (keratin 18) M26326 365-373 - nc 
ALFDGDPHL KIAA0367 AB002365 1-9 + 11.3 
RLLDYVVNI FLJ20004 (hypothetical protein FLJ20004) AB040951 679-687 -  
ALANGIEEV APOL3 (apolipoprotein L, 3) AY014906 101-109 -  
QLIDKVWQL SEC14L1 (SEC14 (S. cerevisiae)-like 1) D67029 593-601 - 1.9 
ALSDLEITL MIG2 (mitogen inducible 2 ) Z24725 389-397 - nc 
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Table  2.1.2 - continued 
 
    SEREX Fold 
Sequencea Gene Nameb Acc. No. Position databasecChanged 
      
ILDTGTIQL CML1( kidney- and liver-specific gene ) AB013094 174-182 -  
SLLGGDVVSV DSIPI (delta sleep inducing peptide, immunoreactor) AF153603 27-36 - nc 
FLDGNELTL CLIC1 (chloride intracellular channel 1) U93205 167-175 - nc 
NLLPKLHIV CLIC1 (chloride intracellular channel 1) U93205 179-187 - nc 
ALASHLIEA EHD2 (EH-domain containing 2) AF181263 507-515 -  
SLYGGTITI FLJ11189 (hypothetical protein FLJ11189) AK000697 296-304 +  
FLLDKKIGV CCT2 (chaperonin containing TCP1, subunit 2 (beta)) AF026166 218-226 -  
FLDGNEMTL CLIC4 (chloride intracellular channel 4) AF097330 178-186 -  
AIVDKVPSV LOC51137 (coat protein gamma-cop) AF100756 147-155 -  
DVASVIVTKL SRP54 (signal recognition particle 54kD) U51920 241-250 - nc 
LASVSTVL HBA2 (hemoglobin, alpha 2) AF230076 130-137 - nc 
VMAPRTLVL HLA-A  3-11   
LLFDRPMHV HNRPM (hnRNP M) L03532 267-275 - nc 
SLAGGIIGVe HNRPK (hnRNP K) BC000355 154-162 - nc 
TLWVDPYEVe BTG1 (B-cell translocation gene 1, anti-proliferative) X61123 103-111 - 1.8 
ALSDHHIYLe ALDOA (aldolase A, fructose-bisphosphate) X12447 216-224 + 1.8 
LLDVPTAAVe IFI30 (interferon, gamma-inducible protein 30) J03909 27-35 - nc 
      
HLA-A*68      
      
MTSALPIIQK ADFP (adipose differentiation-related protein) X97324 62-71 - 29.1 
MAGDIYSVFR ADFP (adipose differentiation-related protein) X97324 349-358 - 29.1 
ETIPLTAEKL CCND1 (cyclin D1/PRAD1) X59798 115-124 - 4.9 
DVMVGPFKLR AKAP2 (A kinase (PRKA) anchor protein 2) AJ303079 934-943 -  
TIIDILTKR ANXA1 (annexin A1) X05908 64-72 - -2.6 
TIVNILTNR ANXA2 (annexin A2) BC001388 55-63 + -2.0 
TIIDIITHR ANXA6 (annexin A6) J03578 385-393 - nc 
SIFDGRVVAK LOC54499 (putative membrane protein) AB020980 107-116 -  
STIEYVIQR SEC23B (Sec23 (S. cerevisiae) homolog B) BC005032 115-123 - nc 
ELIKPPTILR AP3M1 (adaptor-related protein complex 3) AF092092 132-141 -  
EIAMATVTALR ALDOA (aldolase A, fructose-bisphosphate) X12447 248-258 + 1.8 
EVAQLIQGGRe LOC51660 (brain protein 44-like) AF125101 88-97 -  
DTIEIITDRe HNRPA2B1 (hnRNP A2/B1) M29065 127-135 - nc 
ETIGEILKK HNRPK (hnRNP K) BC000355 95-103 - nc 
DVFRDPALKe RPL27 (ribosomal protein L27)  L19527 99-107 - nc 
SLADIMAKR RPL24 (ribosomal protein L24) BC000690 86-94 -  
EVILIDPFHKe RPL15 (ribosomal protein L15) L25899 131-140 +  
      
HLA-B*44 or HLA-B*18      
      
EEIAFLKKL VIM (vimentin) M14144 229-237 - nc 
DEAAFLERL CALD1 (caldesmon 1) M64110 92-100 - nc 
DEMKVLVL SPTBN1 (spectrin, beta, non-erythrocytic 1) M96803 545-552 - nc 
DEVKFLTV ANXA4 (annexin A4) M82809 191-198 - 3.1 
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Table  2.1.2 - continued 
 
    SEREX Fold 
Sequencea Gene Nameb Acc. No. Position databasecChanged 
      
NENSLFKSL CLTC (clathrin, heavy polypeptide (Hc)) D21260 935-943 - nc 
DEFKVVVV LOC51137 (coat protein gamma-cop) AF100756 373-380 -  
EEVKLIKKM FTL (ferritin, light polypeptide) M11147 137-145 - nc 
DEVKLPAKL PTRF (polymerase I and transcript release factor) AF312393 158-166 -  
KESTLHLVLe UBB (ubiquitin B) X04803 63-71 - nc 
TERELKVAY FLJ20004 (hypothetical protein FLJ20004) AB040951 637-645 -  
NEFSLKGVDF ETS1 (ets-1) J04101 86-95 - nc 
NEQDLGIQY CTNNA1 (catenin alpha 1) D13866 169-177 + 1.8 
EERIVELF STAT3 (signal transducer and activator of transcription 3 ) BC000627 306-313 - nc 
EEIREAFRVF CALM3 (calmodulin 3) J04046 84-93 - nc 
DEYIYRHFF CPR8 (cell cycle progression 8 protein) AF011794 344-352 -  
DELELHQRF BS69 (adenovirus 5 E1A binding protein) X86098 308-316 + nc 
SEVKFTVTF LGALS2 (galectin 2) M87842 80-88 - EET 
IETIINTF S100A9 (calgranulin B) M26311 12-19 - nc 
KENPLQFKF VIL2/RDX (villin 2 (ezrin))/(radixin) J05021/L02320f61-69/72-80 +/- 3.2/-2.3 
DEVRTLTY HRMT1L2 (hnRNP methyltransferase, S. cerevisiae-like 2) Y10807 41-48 - -1.6 
GEAVVNRVF PSMB9 (large multifunctional protease 2, LMP2) Z14977 43-51 - 2.6 
EEVLIPDQKY FBXL3A (F-box and leucine-rich repeat protein 3A) AF126028 385-394 -  
DEGRLVLEF SOAT1 (sterol O-acyltransferase 1) L21934 163-171 - nc 
DEVELIHF FACTP140 (chromatin-specific transcription elongation factor) AF152961 838-845 -  
VEVLLNYAY NS1-BP (NS1-binding protein ) AF205218 83-91 -  
TENDIRVMF CUGBP1 (CUG triplet repeat, RNA-binding protein 1) AF267534 120-128 - nc 
LEGLTVVY LOC51644 (coatomer protein complex, subunit zeta 1) AF151878 62-69 -  
NELPTVAF FLJ10613 (hypothetical protein) AK001475 192-199 -  
EEFGQAFSF HLA-DPA1 (MHC, class II, DP alpha 1) X03100 77-85 - nc 
VEAIFSKY HNRPC (hnRNP C (C1/C2)) M29063 33-40 - nc 
DERTFHIFY MYH10 (myosin, heavy polypeptide 10, non-muscle) M69181 277-285 + -1.8 
TEKVLAAVY ALDOB (aldolase B, fructose-bisphosphate) K01177 206-214 - EEN 
VESPLSVSF FLJ22318 (hypothetical protein FLJ22318 ) AK025971 159-167 -  
SEAGSHTLQW MHC-I     
DEGKVIRF EST (rf -1) BF431469 56-63 +  
 
Solid renal cell carcinoma from patient RCC13 
 
HLA-A*02      
      
YVDPVITSI MET (met proto-oncogene) J02958 654-662 - nc 
ALLNIKVKL KRT18 (keratin 18) M26326 365-373 - 3.7 
ALAAVVTEV frameshift, DDX3 reading frame +2 AF061337  - ncg 
TLIEDILGV DKFZP727M231(transient receptor protein 4 associated protein)AL132825 209-217 -  
ALFGALFLA PLTP (phospholipid transfer protein) L26232 2-10 -  
VLATLVLLL EST AA483794 72-80 -  
TLDDLIAAV FLJ10042 (hypothetical protein FLJ10042) AK000904 325-333 -  
YLDNGVVFV DDB1 (damage-specific DNA binding protein 1 (127kD)) U18299 316-324 - nc 
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Table  2.1.2 - continued 
 
    SEREX Fold 
Sequencea Gene Nameb Acc. No. Position databasecChanged 
      
SVFAGVVGV GUCY1A3 (guanylate cyclase 1, soluble, alpha 3) U58855 581-589 - nc 
SLINVGLISV SSP29 (acidic protein rich in leucines) BC000476 48-57 - nc 
ALADGVQKV APOL1 (apolipoprotein L, 1)) AF323540 176-184 -  
FLGENISNFLe APOL1 (apolipoprotein L, 1)) AF323540 273-282 -  
GLVPFLVSVe KPNA2 (karyopherin alpha 2 (RAG cohort 1, importin alpha 1))BC005978 377-385 - nc 
LLDVPTAAVe IFI30 (interferon, gamma-inducible protein 30) J03909 27-35 - 3.5 
MVDGTLLLLe HLA-E (major histocompatibility complex, class I, E) M21533 1-9 - 2.2 
YLLPAIVHIe DDX5 (DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5) AF015812 148-156 + nc 
SLLPAIVELe PP2R1A (protein phosphatase 2, regulatory subunit A, alpha) J02902 403-411 - nc 
ALSDHHIYLe ALDOA (aldolase A, fructose-bisphosphate) X12447 216-224 + 1.9 
      
HLA-A*24      
      
TYGEIFEKF NDUFC2 (NADH dehydrogenase (ubiquinone) 1, ( B14.5b)) AF070652 107-115 -  
YYMIGEQKF NNMT (nicotinamide N-methyltransferase) U08021 203-211 - EET 
      
HLA-B*40      
      
KESTLHLVLe UBB (ubiquitin B) X04803 63-71 - nc 
a peptides printed in bold letters are encoded by overexpressed genes. 
b gene symbols and names refer to GeneCards (http://bioinformatics.weizmann.ac.il/cards); whenever possible symbols 
approved by the HUGO Gene Nomenclature Committee were used. 
c Internet address: http://www.licr.org/SEREX.html. 
d expression in tumor relative to corresponding normal tissue; fold change is only given for genes included on the array; nc 
no change; EET exclusively expressed in tumor, not in normal tissue; EEN exclusively expressed in normal tissue. 
e ligands already published, see SYFPEITHI database (http://www.syfpeithi.de/) for references. 
f peptide derived from sequence homologous in VIL2 and RDX. 
g no change for DDX3. 
 
Peptides assigned to HLA-A*02 reflected the allele-specific peptide motif 
(L/V/I/A/M in position 2, L/V/I/A at the C-terminus) (Table  2.1.2). 21 of 25 identified 
HLA-A*02 restricted ligands were new, 4 have been reported before. Most ligands 
were derived from abundantly expressed housekeeping proteins, but we could 
also detect ligands from proteins with reported tumor association such as 
(YVDPVITSI), derived from met proto-oncogene, (ALLNIKVKL) from keratin 18, 
and (SVASTITGV) from adipophilin. HLA-A*68 ligands were recognized by their 
anchor amino acids T/I/V/A/L in position 2 and C-terminal R/K, which also 
indicated that the subtype was most probably HLA-A*6801. Two other ligands 
from adipophilin, (MTSALPIIQK) and (MAGDIYSVFR), were found among HLA-
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A*68-presented peptides, as well as (ETIPLTAEKL), derived from tumor-
associated cyclin D1. Annexin II, from which the peptide (TIVNILTNR) was 
identified, has been shown to be immunogenic in the context of MHC class II in 
melanoma patients [29].  
All other 35 ligands carried E in position 2, an anchor residue of HLA-B*44. The 
peptide motif of HLA-B*18 is still unknown; therefore, a distinction between 
ligands of these two HLA-B-molecules was not possible. Fragments of vimentin 
(EEIAFLKKL) and caldesmon (DEAAFLERL), both overexpressed in RCC [13], 
were identified as well as ligands derived from ets-1 (NEFSLKGVDF), alpha-
catenin (NEQDLGIQY) and galectin 2 (SEVKFTVTF). 
Comparison with microarray data indicated 10 overexpressed genes as sources of 
MHC ligands: adipophilin, KIAA0367, SEC14-like 1, B-cell translocation gene 1, 
aldolase A, cyclin D1, annexin A4, catenin alpha 1, galectin 2, and LMP2. Three of 
them were also included in the SEREX database: KIAA0367, aldolase A, and 
catenin alpha 1. 
 
2.1.4.3 Highest Expression Levels of Adipophilin In Tumors Compared to 
the Most Essential Human Organs and Tissues 
If the difference in expression of a particular antigen between tumor cells and all 
normal cells is high, this antigen should also have a greater potential as a possible 
vaccine candidate. To this aim we analyzed the expression of adipophilin and 
keratin 18 in 21 human tissues and organs in addition to the kidney. Adipophilin, 
selectively overexpressed in the two tumors tested for comparison, was only 
marginally expressed in all other organs. Kidney was the organ with the highest 
expression level among all analyzed normal tissues (Figure  2.1.3 A). In contrast to 
adipophilin, keratin 18 showed a more heterogeneous tissue distribution, in 
particular with high expression levels in colon and placenta (Figure  2.1.3 B). 
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Keratin 18 B
 
Figure  2.1.3 Tissue expression of adipophilin and keratin 18. 
Adipophilin was strongly expressed in tumors but only weakly in healthy organs and tissues (A) 
whereas keratin 18 was widely distributed among a variety of normal tissues (B). Expression was 
analyzed by qPCR using cDNA generated from a commercial total RNA tissue panel. Copy 
numbers are relative to 18S rRNA and normalized to kidney, which is set at 1; bars, ±SE. 
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2.1.4.4 Some of the New MHC Class I-Ligands Are Shared Between Tumors 
MHC class I-ligands can be analyzed with utmost sensitivity by on-line capillary 
LC-MS using the “predict, calibrate, detect” approach [10]. After eluting MHC class 
I ligands from RCC13 we were again able to detect the ligands derived from met 
proto-oncogene (Figure  2.1.4) and keratin 18 (not shown). Interestingly, the 
keratin 18-derived ligand was also presented on a solid colon carcinoma (data not 
shown). In addition, several other ligands were identified from RCC13 (Table 
 2.1.2). We found one ligand derived from nicotinamide N-methyltransferase 
(NNMT), a gene which is overexpressed in more than 95% of all RCC [14]. Some 
other ligands overlap with the peptide repertoire of RCC01. 
 
 
Figure  2.1.4 Presentation of ligand (YVDPVITSI) from MET on RCC13. 
Nanocapillary HPLC ESI MS was done on peptides eluted from RCC13. The mass chromatogram 
for 1006.54 ± 0.15 Da shows a peak at retention time 47.8 min. Collisionally induced decay mass 
spectrum from m/z 1006.54, recorded in a second LC-MS run at the given retention time and shown 
in the insert, confirmed the presence of (YVDPVITSI). 
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2.1.4.5 A New Frameshift-Derived MHC Class I-Ligand may Represent a 
Target Unique for one Patient 
The most interesting ligand from RCC13 is (ALAAVVTEV), encoded by a reading 
frame shifted by one nucleotide compared to the frame coding for DEAD/H box 
polypeptide 3 (DDX3). (ALAAVVTEV) is encoded by nucleotides 317-343 of the 
coding strand of DDX3, whereas nucleotides 316-342 code for GIGSRGDRS of 
the DDX3 protein. T cell reactivity against frameshift-derived epitopes in anti-
tumor response has been reported [30]. 
 
2.1.4.6 Keratin 18-Specific T Cells are Present in the Normal CD8+ T Cell 
Repertoire 
PBMC from patients RCC01 and RCC13 were not available, which prevented us 
from testing T-cell reactivity against the frameshift-derived peptide identified 
above. Nevertheless, we tested 6 HLA-A*02 positive RCC patients for reaction 
against 4 of the relevant peptides (HLA-A*02 restricted ligands from adipophilin, 
keratin 18, KIAA0367 and met proto-oncogene, see Table  2.1.2). We used a very 
sensitive qPCR assay for IFN-γ mRNA production by CD8+ T cells [17], following a 
7-day in vitro sensitization with peptide. In all patients, high production of IFN-γ 
mRNA was observed after stimulation with recall viral-derived peptides, showing 
that the cells were functional after isolation and stimulation. In contrast, responses 
against KIAA0367 were not detected, and sporadic but marginal responses were 
seen after stimulation with met proto-oncogene, keratin 18 or adipophilin peptides 
(data not shown). We also stained PBMC of few patients and healthy individuals 
with HLA-A*0201 tetramers folded either with the adipophilin, keratin 18 or met 
proto-oncogene peptides. A significant population of CD8+ T lymphocytes specific 
for keratin 18 (between 0.02% and 0.2% of CD8+ T cells) was found in 4 out of 22 
healthy individuals tested (Figure  2.1.5 shows the staining of two positive and two 
negative donors, 0.02% of CD8+ T cells for HD1 and 0.17% for HD6 bind to the 
keratin 18 tetramer). These results were reproduced in at least three independent 
experiments using two or more blood samples obtained at different time points 
and involving different batches of independently folded keratin 18 tetramers. 
Moreover, in a colabeling experiment it was shown that the binding of keratin 18 
tetramer was specific since this population did not stain with a CMV tetramer 
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(Figure  2.1.5, bottom row). We conclude that for the keratin 18 peptide at least, 
specific CD8+ T lymphocytes are contained in the human T cell repertoire. 
However, the 4 peptides identified on RCC are generally not recognized by 
spontaneously arising T cells detectable in the blood of patients using tetramers 
ex vivo or even qPCR after one in vitro stimulation with peptides. Vaccination, 
however, might lead to activation and expansion of specific CD8+ T cells against 
these peptides, which then could be detected by accurate T cell monitoring. 
 
 
 
Figure  2.1.5 Detection of keratin 18-specific CD8+ T lymphocytes. 
PBMC from four healthy HLA-A*02+ donors (HD1, 2, 4, 6) were stained simultaneously with HLA-
A2/keratin 18-PE tetramers, HLA-A2/CMV-APC tetramers, CD8-PerCP and CD4-FITC. Dot plots 
show results from 1 of 3 independent experiments for 1 x 106 counted PBMC gated on CD4- 
lymphocytes (top and middle row) or gated on CD4-CD8+ lymphocytes (bottom row). Percentage of 
tetramer+ cells within the CD8+CD4- population are indicated. 
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2.1.5 Discussion 
Gene expression analysis of the individual renal cell carcinomas revealed 
approximately 400 genes exclusively detected or overexpressed in tumor versus 
normal tissue. From tumor RCC01, 77 HLA class I-ligands were identified, 10 
derived from overexpressed genes. Some of the latter have a broad tissue 
distribution, whereas others are more restricted. Which of the HLA ligands 
detected would now be candidates for vaccination? According to previous 
experience in tumor immunology, gene products overexpressed in the tumor but 
otherwise only expressed in a few, possibly nonvital cell types, can be targets for 
tumor-directed T cells.  
Table  2.1.3 Candidates for peptide based immunotherapy of RCC01 
 
  HLA  expression in candidate 
Gene Name Sequence Restriction remarks normal tissues for vaccine 
      
New ligands 
Adipophilin SVASTITGV A*02 highly overexpressed in tumor lowa +++ 
Adipophilin MTSALPIIQK A*68 highly overexpressed in tumor low +++ 
Adipophilin MAGDIYSVFR A*68 highly overexpressed in tumor low +++ 
KIAA0367 ALFDGDPHL A*02 limited tissue distribution brain, prostateb +++ 
Galectin-2 SEVKFTVTF B*44/B*18 exclusively expressed in tumor n.tc ++ 
Cyclin D1 ETIPLTAEKL A*68 cell cycle involved lowb ++ 
 
Known epitopesd 
CA9 HLSTAFARV A*02 known TAA, overexpressed in RCC01T  n.t. +++ 
Cyclin D1 LLGATCMFV A*02 cell cycle involved lowb ++ 
Cyclin D1 RLTRFLSRV A*02 cell cycle involved lowb ++ 
a see Figure  2.1.3 A 
b based on qPCR analysis as shown in Figure  2.1.3, data not shown 
c not tested 
d reported T cell epitopes. These peptides were not detected in RCC01, but should be included because of overexpression 
of the encoding genes in RCC01 as revealed by the microarray data 
 
Apart from these more obvious points, additional considerations can be made, 
such as known cancer association, involvement in the oncogenic process or 
immunogenicity of the gene product. The analysis of existing databases should 
support this endeavour. For example, the SEREX database indicates that 
antibodies against alpha catenin have been found in renal cancer patients, 
antibodies against KIAA0367 in stomach cancer patients and antibodies against 
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vimentin in pancreas cancer patients, suggesting a spontaneous immune 
response. 
Based on the following detailed discussion of each new ligand, we would propose 
an individual combination of peptides for vaccination of patients RCC01 (Table 
 2.1.3) and RCC13 (Table  2.1.4). 
Table  2.1.4 Candidates for peptide based immunotherapy of RCC13 
 
  HLA  expression in candidate 
Gene Name Sequence Restriction remarks normal tissues for vaccine 
 
New ligands 
NNMT YYMIGEQKF A*24 limited tissue distribution livera,b +++ 
MET YVDPVITSI A*02 proto-oncogene lowa. ++ 
DDX3 rf +2c ALAAVVTEV A*02 frameshift-derived n.t.d ++ 
Adipophilin SVASTITGV A*02 highly overexpressed in tumor lowe +++ 
KIAA0367 ALFDGDPHL A*02 limited tissue distribution brain, prostatea +++ 
 
Known epitopesf 
Cyclin D1 LLGATCMFV A*02 cell cycle involved lowa ++ 
Cyclin D1 RLTRFLSRV A*02 cell cycle involved lowa ++ 
PRAME VLDGLDVLL A*02 cancer testis antigen testis +++ 
PRAME SLYSFPEPEA A*02 cancer testis antigen testis +++ 
PRAME ALYVDSLFFL A*02 cancer testis antigen testis +++ 
PRAME SLLQHLIGL A*02 cancer testis antigen testis +++ 
PRAME LYVDSLFFL A*24 cancer testis antigen testis +++ 
CA9 HLSTAFARV A*02 known TAA, overexpressed in RCC13T  n.t. +++ 
a based on qPCR analysis as shown in Figure  2.1.3, data not shown 
b expression in liver was about 3x lower compared to RCC13, expression in all other tissues tested was more than 16x 
lower 
c reading frame +2 
d not tested 
e see Figure  2.1.3 A 
f reported T cell epitopes. These peptides were not detected in RCC13, but should be included because of overexpression 
of the encoding genes in RCC13 as revealed by the microarray data 
 
Adipophilin is an interesting candidate for a vaccine component for several 
reasons: First, it is only expressed in a few cell types [31] such as adipocytes, 
lactating mammary epithelial cells, adrenal cortex cells, Sertoli and Leydig cells, 
and pathological hepatocytes in alcoholic liver cirrhosis. Second, this gene was 
reported to be overexpressed in cancer [13, 32]. Third, we demonstrated that 
adipophilin is selectively expressed in the tumor cells of RCC01 and RCC13 but 
not in LCM-derived pure normal kidney cell populations. We also found that 
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expression in all analyzed normal tissues is much lower than in tumor cells (Figure 
 2.1.3 A). Finally, we identified 3 MHC class I ligands from this protein. KIAA0367 
was overexpressed in patient RCC01 and according to the SAGEmap1, a public 
database for gene expression [33], KIAA0367 is mainly expressed in prostate 
carcinoma and in the brain. Expression analysis by qPCR also showed that the 
highest levels were to be found in brain and in prostate (data not shown). Since 
the brain expresses low MHC and is partially immunoprivileged, and since patient 
RCC01 was female thus lacking prostate, the KIAA0367 peptide (ALFDGDPHL) 
would seem to be a first-class choice of vaccine component in this patient. 
According to analysis of LCM-derived samples, galectin 2, the source protein of 
(SEVKFTVTF), was selectively expressed in both tumors and not in normal kidney 
cells. Other members of the galectin gene family, including galectin-1, galectin-3 
and galectin-12, are overexpressed in malignancies [13, 34]. Cyclin D1 is also 
overexpressed in several malignancies, including renal cell carcinoma [24]. We 
found an overexpression of cyclin D1 in RCC01, from which (ETIPLTAEKL) has 
been eluted, as well as in RCC13. The expression of cyclin D1 in all analyzed 
healthy organs and tissues was lower compared to RCC01 and RCC13 (data not 
shown). 
For RCC13, three new ligands were identified which could have been used for 
vaccination: The ligand from met proto-oncogene was found in both tumor 
samples analyzed, whereas the gene was only overexpressed in RCC13 (Figure 
 2.1.2 A). Thus, this gene is an interesting vaccine candidate for RCC13, especially 
because of its oncogenic property. Expression analysis in healthy organs and 
tissues showed the highest level in normal kidney followed by brain and trachea 
(data not shown). Nicotinamide N-methyltransferase (NNMT) was exclusively 
expressed in RCC13 compared to the corresponding normal tissue and 
expression in other tissues was limited to liver, which still expressed lower 
amounts compared to the tumor (data not shown). It is highly probable that the 
frameshift-derived ligand was presented exclusively on tumor cells and for this 
reason should be included in the vaccine. 
We identified ligands from keratin 18 and from vimentin, (ALLNIKVKL) and 
(EEIAFLKKL), respectively. Both genes were overexpressed in RCC13 but not in 
                                            
1 Internet address: http://www.ncbi.nlm.nih.gov/SAGE 
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RCC01. Keratin 18 has been shown to be overexpressed in carcinomas, and the 
coexpression of keratin 18 and 8 together with vimentin augments tumor cell 
motility [35, 36]. But because of the rather high expression of keratin 18 in colon, 
we would not recommend the keratin 18-derived ligand for vaccination. We also 
found MHC class I-ligands from 3 members of the annexin gene family, 
(TIIDILTKR) derived from annexin I, (TIVNILTNR) from annexin II and 
(DEVKFLTV) from annexin IV. Annexin II-specific CD4+ T cells were reported to 
specifically recognize melanoma cells overexpressing annexin II [29], but we did 
not find overexpression in RCC01 from which this ligand has been eluted. In 
RCC01, annexin IV was overexpressed and a ligand from this protein was eluted. 
But since annexin IV is mainly expressed in all epithelial cells [37], this ligand is 
excluded from the proposed vaccine. All other new ligands derived from 
overexpressed genes and not discussed in detail (SEC14L1, BTG1, ALDOA, 
CTNNA1, PSMB9, IFI30, HLA-E) were not considered to be suitable for 
vaccination because they either displayed a broad tissue expression pattern or the 
level of overexpression was too low. 
As a second source of vaccine components, known epitopes from described TAA 
can be included without hesitation in the vaccine provided that they match the 
patient’s HLA type and the TAA are expressed in the individual tumor (Table  2.1.3 
and Table  2.1.4). This can be checked by referring to the expression data. Thus, 
in our microarray data we looked for expression of known TAA such as NY-ESO-
1, LAGE-1, Hom-Mel-40, SSX2, SSX4, CT7, MAGE-1, SCP1, MUC-1, RAGE, 
GAGE, survivin, hTERT, RU1, Her-2/neu, CEA, WT1, SART3, gp75, PRAME, and 
CA9. In RCC01, CA9 was expressed exclusively in the tumor (Table  2.1.1); the 
vaccine for this particular patient could thus contain the CA9-derived epitope 
(HLSTAFARV) [25]. Similarly, the two known epitopes of cyclin D1 [38] could also 
be applied. These three epitopes would have been relevant for RCC13 as well. In 
addition, the exclusive expression of PRAME in RCC13 became clear. Thus, the 
four epitopes of PRAME restricted to HLA-A*02 [39] and the HLA-A*24-restricted 
epitope [40] can be classed as suitable for this patient. Finally, our new HLA-A*02 
restricted ligands from adipophilin and from KIAA0367 eluted from RCC01 should 
be included in the selection because of the overexpression of these genes in 
RCC13. 
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In addition to identified HLA ligands from overexpressed gene products, epitope 
prediction1 for the relevant HLA alleles combined with proteasomal cleavage 
prediction2 [41] can be applied to overexpressed genes (Figure  2.1.1). This 
provides more potential candidates for vaccination, which should be screened for 
presentation on the solid tumor as carried out for selected peptides in the tumor 
RCC13 by online LC-MS. The combination of expression profiling and epitope 
prediction has been suggested [42, 43] and reported before, but only one target 
gene alone has been used to predict mouse epitopes, and neither the 
presentation of the predicted epitopes on the cell surface nor the type of anti-
tumor activity has been shown [16]. 
There is increasing evidence that the peptide pool generated by 
immunoproteasome differs from that produced by the standard proteasome [44-
46]. As we could show upregulation of immunoproteasome subunits in tumor cells, 
one might expect differences among the MHC-ligands presented on tumor versus 
normal cells. 
All of our identified ligands except for the frameshift-derived peptide could be self 
peptides and as such also be presented on the surface of normal cells. If specific 
T cells against these peptides exist, they might induce autoimmunity once 
activated by vaccination. In all human vaccination studies published so far, no 
indication of autoimmunity has been reported. For example, TAAs such as 
carcinoembryonic antigen (CEA) or Her2/neu, which are broadly expressed by 
epithelial cells, are being targeted without any sign of autoimmunity in ongoing 
clinical trials. One exception might be T cell-mediated vitiligo after antigen-specific 
therapy of melanoma [47]. However, even in cases in which either whole tumor 
lysate was loaded onto DC for vaccination or autologous cancer-derived heat 
shock proteins were used, no evidence for autoreactivity towards normal tissue 
was observed [2, 48]. Therefore, we believe that the risk of inducing autoimmunity 
using our vaccine candidates is no greater than in these previous instances. 
Being aware of the fact that self-protein derived peptides might be subject to T-cell 
tolerance, we selected 4 of our interesting peptides to be screened for specific 
peripheral CD8+ T cells in patients and healthy donors: only in the case of keratin 
                                            
1 Internet address: http://www.syfpeithi.de 
2 Internet address: http://www.paproc.de 
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18 was a significant tetramer-positive population seen in 4/22 healthy donors 
tested. It is likely that such T cells can also be found in cancer patients, and more 
renal cell carcinoma patients must be screened to evaluate the frequency of this 
keratin 18-specific CD8+ population. It is not clear if these T cells specific for a self 
antigen are tolerized in vivo, and experiments are being carried out to characterize 
them functionally. For this reason, and considering the high expression of keratin 
18 in normal colon, at the present time this antigen does not constitute a first 
choice candidate target for immunotherapy. For those antigens which are shared 
among tumors from several patients, their immunogenicity should be tested, for 
example in classical in vitro priming experiments [9, 25]. Using tetramer staining or 
qPCR for IFN-γ, we could generally detect no spontaneous expansion of specific T 
cells against the peptides tested after one in vitro stimulation, suggesting either 
that these T cells are not activated in vivo, or that their frequency in the blood is 
too low to be detected in our assays. Here again, the number of RCC patients 
screened must be increased. However, we do not believe that the spontaneous in 
vivo response to these peptides in cancer patients is a prerequisite for their use as 
a vaccine. Indeed, previous research has shown that induction of tumor peptide-
specific CD8+ T cells (not detectable before vaccination) can correlate with clinical 
benefit [5, 49, 50]. Using qPCR, we also observed the induction of MUC1-specific 
CD8+ T cells in a vaccinated patient simultaneously to metastatic regression (C.G. 
unpublished data, and [5]).  
Moreover, most immunization protocols tested until now have used antigens 
defined by spontaneous immune responses in patients. One could argue that 
such spontaneous T or B cell responses, in most cases, are not efficient enough 
to destroy the tumor. We hypothesize that redirecting immunity to tumor-
associated structures not obviously attacked might result in more efficient 
responses. 
The combination of gene expression analysis and MHC ligand identification allows 
the selection of several peptide candidates for immunotherapy. This can be 
performed in an appropriate timeframe after surgical intervention to allow rapid 
subsequent vaccination. Analysis of the T-cell response before and during 
vaccination, together with clinical monitoring, will help to determine those peptides 
which induce a beneficial immune response for the patient. Thus, we have 
demonstrated that it is possible to extract information from a single excised tumor 
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specimen that leads to an optimized design of a multi-epitope, peptide-based 
vaccine directed against the tumor of an individual patient and considering all 
expressed HLA-alleles. 
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HD  healthy donor 
PBMC peripheral blood mononuclear cells 
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2.2 Identification of c-MET oncogene as a broadly 
expressed tumor associated antigen recognized by 
cytotoxic T-lymphocytes 
The author of this dissertation, Toni Weinschenk, identified the MHC ligand 
analyzed in this chapter. 
 
2.2.1 Summary 
C-Met protooncogene is a transmembrane heterodimeric receptor tyrosine kinase 
that mediates the potentially oncogenic activities of the hepatocyte growth 
factor/scatter factor. In chapter  2.1, identification of an MHC class I-ligand 
restricted to HLA-A*02 and encoded by c-Met protooncogene was shown. We 
used this novel HLA-A*02 binding peptide for the induction of c-Met specific 
cytotoxic T-lymphocytes (CTL) in vitro in order to analyze the presentation of this 
epitope by human tumor cells. After several restimulations the in vitro induced 
CTL efficiently lysed target cells pulsed with the cognate peptide while they spared 
cells presenting an irrelevant peptide. Furthermore, c-Met specific CTL recognized 
allogeneic HLA matched tumor cell lines including melanoma, breast, colon and 
renal cell carcinomas as well as multiple myeloma cells in an antigen specific and 
HLA-restricted manner. To further analyze the effector function of the generated 
CTL in an autologous system we used DC from the same donor as target cells in 
a 51Cr-release assay. The in vitro induced c-Met peptide specific CTL lysed 
autologous DC pulsed with the antigenic peptide or transfected with whole tumor 
mRNA purified from a c-Met expressing cell lines. In our study we demonstrate 
that c-Met oncogene is a tumor rejection antigen recognized by CTL and 
expressed on a broad variety of epithelial and hematopoetic malignancies.  
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2.2.2 Introduction 
C-Met encodes a heterodimeric transmembranous receptor with tyrosine kinase 
activity that is composed of an α-chain that is disulfide-linked to a β subunit [1, 2]. 
Both subunits are expressed on the surface, the heavy β subunit is responsible for 
the binding of the ligand, hepatocyte growth factor (HGF), the α subunit contains 
an intracellular domain that mediates the activation of different signal transduction 
pathways. Met signaling is involved in organ regeneration, as demonstrated for 
liver and kidney, embryogenesis, hematopoesis, muscle development, and in the 
regulation of migration and adhesion of normally activated B-cells and monocytes. 
Furthermore, numerous studies indicated the involvement of c-Met overexpression 
in malignant transformation and invasiveness of malignant cells [3-12]. 
Using an integrated functional genomics approach that combines gene expression 
profiling with analysis of MHC ligands by mass spectrometry to identify genes and 
corresponding MHC ligands that are selectively expressed or overexpressed in 
malignant tissues a HLA-A*02 binding peptide derived from the c-Met 
protooncogene could be identified [13, see chapter  2.1]. In our study we analyzed 
the possible function of this peptide as a T-cell epitope and its presentation by 
malignant cells using antigen specific cytotoxic T-lymphocytes (CTL) that were 
generated by in vitro priming with monocyte derived dendritic cells (DC) as antigen 
presenting cells. We show here that the CTL generated from several healthy 
donors elicited an antigen specific and HLA-A*02 restricted cytolytic activity 
against tumor cells endogenously expressing the c-Met protein including renal cell 
carcinomas, breast cancer, colon cancer, melanoma and multiple myeloma cells. 
Furthermore, they lysed autologous DC pulsed with the antigenic peptide or 
electroporated with RNA isolated from c-Met expressing tumor cell lines indicating 
that this peptide is also expressed upon transfection of DC. Our results 
demonstrate that c-Met oncogene is a tumor rejection antigen recognized by CTL 
and expressed on a broad variety of epithelial and hematopoetic malignancies.  
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2.2.3 Materials and Methods 
2.2.3.1 Tumor cell lines 
Tumor cell lines used in the experiments were grown in RP10 medium (RPMI 
1640 supplemented with 10% heat inactivated FCS and antibiotics). The following 
c-Met expressing tumor cell lines were used in experiments: MCF-7 (breast 
cancer, HLA-A*02+, purchased from ATCC), A 498 (RCC, HLA-A*02+) and MZ 
1257 (RCC, HLA-A*02+, kindly provided by Prof. A. Knuth, Frankfurt, Germany), U 
266 (multiple myeloma, HLA-A*02+), HCT 116 (colon cancer, HLA-A*02+), Mel 
1479 (malignant melanoma, HLA-A*02+, kindly provided by Prof. G. Pawelec, 
Tübingen, Germany), SK-OV-3 (ovarian cell line, HLA-A*03+, kindly provided by 
O. J. Finn, Pittsburgh, USA). The c-Met negative cell lines T2 (HLA-A*02+, TAP-
deficient) and Croft (EBV-immortalized B-cell line, kindly donated by O. J. Finn, 
Pittsburgh, USA, HLA-A*02+) were used as controls. K 562 cells were utilized to 
determine the NK-cell activity. 
 
2.2.3.2 Cell isolation and generation of dendritic cells (DC) from adherent 
peripheral blood mononuclear cells 
Generation of DC from peripheral blood monocytes was performed as described 
previously [14]. In brief, peripheral blood mononuclear cells (PBMNC) were 
isolated by Ficoll/Paque (Biochrom, Berlin, Germany) density gradient 
centrifugation of heparinized blood obtained from buffy coat preparations of 
healthy volunteers from the blood bank of the University of Tübingen. Cells were 
seeded (1x107 cells/3 ml per well) into 6 well plates (Falcon, Heidelberg, Germany) 
in RP10 media. After 2 h of incubation at 37°C, nonadherent cells were removed 
and the adherent blood monocytes were cultured in RP10 medium supplemented 
with the following cytokines: human recombinant GM-CSF (Leukomax, Novartis, 
100 ng/ml), IL-4 (R&D Systems, Wiesbaden, Germany, 1000 IU/ml), and TNF-α 
(R&D Systems, Wiesbaden, Germany, 10 ng/ml).  
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2.2.3.3 RT-PCR 
RT-PCR was performed with some modifications as recently described [14]. Total 
RNA was isolated from cell lysates using QIAGEN RNeasy “Mini” anion-exchange 
spin columns (QIAGEN GmbH, Hilden, Germany) according to the instructions of 
the manufacturer and was subjected to a 20 µl cDNA synthesis reaction 
(Invitrogen, Karlsruhe, Germany). Oligo(dT) was used as primer. 1 µl of cDNA was 
used for PCR amplification. To control the integrity of the RNA and the efficiency 
of the cDNA synthesis, 1 µl of cDNA was amplified by an intron-spanning primer 
pair for the ß2-microglobulin gene. The PCR temperature profiles were as follows: 
2 minutes pre-treatment at 94°C and 30 cycles at 94°C for 30 seconds, annealing 
at 59°C for 30 seconds and 72°C for 60 seconds for the c-Met and ß2-
microglobulin cDNA. Primer sequences were deduced from published cDNA 
sequences: ß2-microglobulin: 5’ GGGTTTCATCCATCCGACAT 3’ and 5’ 
GATGCTGCTTACATGTCTCGA 3’, c-Met: 5’ AGTCAAGGTTGCTGATTTTGGT 3’ 
and 5’ ATGTGCTCCCCAATGAAAGTAGA 3’. 10 µl of the RT-PCR reactions were 
electrophoresed through a 2.5% agarose gel and stained with ethidium bromide 
for visualization under UV light.  
 
2.2.3.4 Induction of antigen specific CTL response using HLA-A*02 
restricted synthetic peptides 
The HLA-A*02 binding peptides derived from c-Met (YVDPVITSI, amino acids 
654-662) [13], survivin (ELTLGEFLKL) [15], and HIV (ILKEPVHGV, pol HIV-1 
reverse transcriptase peptide, amino acids 476-484) were synthesized using 
standard F-moc chemistry on a peptide synthesizer (432A, Applied Biosystems, 
Weiterstadt, Germany) and analyzed by reversed-phase HPLC and mass 
spectrometry.  
For CTL induction, 5x105 DC were pulsed with 50 µg/ml of the synthetic c-Met 
peptide for 2 h, washed, and incubated with 2,5x106 autologous PBMNC in RP10 
medium. After 7 days of culture, cells were restimulated with autologous peptide 
pulsed PBMNC and 1 ng/ml human recombinant IL-2 (R&D Systems) was added 
on days 1, 3 and 5. The cytolytic activity of induced CTL was analyzed on day 5 
after the last restimulation in a standard 51Cr-release assay.  
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2.2.3.5 CTL assay 
The standard 51Cr-release assay was performed as described [14]. Target cells 
were pulsed with 50 µg/ml peptide for 2 h and labelled with [51Cr]-sodium 
chromate in RP10 for 1 h at 37°C. 104 cells were transferred to a well of a round-
bottomed 96-well plate. Varying numbers of CTL were added to give a final 
volume of 200 µl and incubated for 4 h at 37° C. At the end of the assay 
supernatants (50 µl/well) were harvested and counted in a beta-plate counter. The 
percent specific lysis was calculated as: 100 x (experimental release - 
spontaneous release / maximal release-spontaneous release). Spontaneous and 
maximal release were determined in the presence of either medium or 2% Triton 
X-100, respectively.  
Antigen specificity of tumor cell lysis was further determined in a cold target 
inhibition assay [14] by analyzing the capacity of peptide pulsed unlabeled T2 cells 
to block lysis of tumor cells at a ratio of 20:1 (inhibitor to target ratio). 
 
2.2.3.6 PAGE and Western Blotting  
Protein concentration of cell lysates were determined using a BCA assay (Pierce, 
Rockford, IL). 30 µg of total protein were separated on 7.5% polyacrylamide gel, 
blotted on nitrocellulose membrane, and probed with a c-Met specific polyclonal 
antibody (h-Met, clone 28, sc-161, polyclonal rabbit, Santa Cruz Biotechnology, 
Heidelberg, Germany). Bands were visualized by ECL staining (Amersham 
Pharmacia, Freiburg, Germany).  
 
2.2.3.7 Electroporation of DC with whole tumor derived RNA 
Total RNA was isolated from tumor cell lysates using RNeasyTM Maxi anion-
exchange spin columns (Qiagen GmbH, Germany) according to the protocol for 
isolation of total RNA from animal cells provided by the manufacturer. Quantity 
and purity of RNA were determined by UV spectrophotometry. Prior to 
electroporation on day 6, immature DC (grown in RP10 medium in the presence of 
IL-4 and GM-CSF) were washed twice with serum-free X-VIVO 20 medium 
(BioWhittaker,Apen. Germany) and resuspended to a final concentration of 2 x 
107 cells/ml. Subsequently, 200 µl of the cell suspension were mixed with 10 µg of 
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total RNA and electroporated in a 4 mm cuvette using an Easyject Plus™ unit 
(Peqlab, Erlangen, Germany). The physical parameters were: voltage of 300 V, 
capacitance of 150 µF, resistance of 1540 Ω and pulse time of 231 ms [16]. After 
electroporation the cells were immediately transferred into RP10 medium and 
returned to the incubator.  
 
2.2.4 Results 
2.2.4.1 Induction of c-Met specific cytotoxic T-lymphocytes (CTL) using 
peptide pulsed DC 
C-Met protooncogene was shown to be overexpressed in a variety of malignant 
cells of epithelial and hematopoetic origin and to be involved in the malignant 
phenotype and invasiveness of these cells [3, 17-19]. As demonstrated in Figure 
 2.2.1, expression of c-Met mRNA and protein could be detected in several tested 
human tumor cell lines including malignant melanoma, renal cell carcinoma (RCC) 
and multiple myeloma. 
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Figure  2.2.1 C-Met expression in human tumor cell lines and peripheral blood B- and T-
lymphocytes. 
The expression of c-Met mRNA was analyzed in human tumor cell lines by RT-PCR (A). Total RNA 
was subjected to cDNA synthesis. PCR products were run on a 2.5 % agarose gel and visualized by 
ethidium bromide staining. Western blot analysis using a c-Met specific polyclonal antibody was 
performed to determine the protein expression (B). 
 
Comparative analysis of gene expression profiling of a tumor sample of a patient 
with renal cell carcinoma and the corresponding autologous renal tissue using 
DNA microarray technology followed by the characterization of MHC ligands 
present in the tumor by mass spectrometry resulted in the identification of a HLA-
A*02 binding peptide derived from the c-Met protein (YVDPVITSI, aminoacids 
654-662) [13, see chapter  2.1]. 
To analyze the presentation of this epitope by tumor cells and its recognition by 
CTL we induced c-Met specific CTL in vitro using DC derived from adherent 
PBMNC of HLA-A*02 positive healthy donors. These monocyte derived DC were 
pulsed with the HLA-A*02 binding c-Met peptide and utilized as antigen presenting 
cells for in vitro priming. The cytotoxicity of the induced CTL was analyzed in a 
standard 51Cr-release assay using peptide loaded T2 cells and autologous DC as 
targets. The CTL line obtained after two weekly restimulations demonstrated 
antigen specific killing. The T-cells only recognized T2 cells or DC coated with the 
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cognate peptide while they did not lyse target cells pulsed with irrelevant HLA-
A*02 binding peptides derived from survivin protein or HIV-1 reverse transcriptase 
confirming the specificity of the cytolytic activity (data not shown).  
 
2.2.4.2 C-Met peptide specific CTL efficiently recognize tumor cells 
endogeneously expressing the c-Met protooncogene 
We next analyzed the ability of the in vitro induced CTL to lyse tumor cells that 
express the c-Met protein. We used the HLA-A*02 positive cell lines HCT 116 
(colon cancer), A498, MZ 1257 (renal cell carcinoma, RCC), MCF-7 (breast 
cancer), Mel 1479 (malignant melanoma) and U266 (multiple myeloma) that 
express c-Met as targets in a standard 51Cr-release assay. The EBV-transformed 
B-cell line Croft (HLA-A*02+/c-Met-) and the ovarian cancer cell line SK-OV-3 
(HLA-A*03+/c-Met+) were included to determine the specificity and HLA-restriction 
of the CTL. As demonstrated in Figure  2.2.2 A-D, the c-Met peptide specific CTL 
were able to efficiently lyse malignant cells expressing both HLA-A*02 and c-Met. 
There was no recognition of the ovarian cancer cells SK-OV-3 or Croft cells 
demonstrating that the presentation of c-Met peptide in context of HLA-A*02 
molecules on the tumor cells is required for the efficient lysis of target cells and 
confirm the antigen specificity and MHC restriction of the CTL. The in vitro 
induced T-cells did not recognize the K 562 cells indicating that the cytotoxic 
activity was not NK-cell mediated. 
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Figure  2.2.2 Antigen specific lysis of human tumor cell lines endogenously expressing c-Met 
by c-Met specific CTL. 
Human HLA-A*02+/c-Met+ colon cell carcinoma cells HCT 116, renal cell carcinoma (MZ 1257, 
A498), melanoma (Mel 1479), breast cancer cell line MCF-7, multiple myeloma (U266) cell line and 
the EBV-immortalized Croft cells (HLA-A*02+/c-Met-) as well as the ovarian cancer cell line SK-OV-
3 (HLA-A*02-/c-Met+) were used as targets in a stardard 51Cr-release assay. K 562 cells were 
included to determine the NK-cell activity. 
 
To further verify the antigen specificity and MHC restriction of the in vitro induced 
CTL lines we performed cold target inhibition assays. The lysis of the target cells 
(U 266 and A 498) could be blocked in cold target inhibition assays. The addition 
of cold (not labeled with 51Cr) T2-cells pulsed with the cognate peptide reduced 
the lysis of tumor cells whereas T2-cells pulsed with an irrelevant peptide showed 
no effect (data not shown). 
 
2.2.4.3 C-Met specific CTL can lyse autologous DC transfected with whole 
tumor RNA 
To analyze the cytotoxic activity of the CTL in an autologous setting and test the 
presentation of c-Met specific T-cell epitopes upon transfection of whole tumor 
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RNA we used autologous DC, generated from the same PBMNC that were utilized 
for CTL induction, as target cells. As shown in Figure  2.2.3, CTL efficiently lysed 
autologous DC electroporated with the whole tumor RNA isolated from the c-Met 
expressing A498 or MCF-7 tumor cell lines indicating that the identified c-Met 
peptide is processed and presented after transfection of DC with RNA derived 
from c-Met positive tumor cells. 
 
 
Figure  2.2.3 C-Met specific CTL recognize autologous dendritic cells transfected with the 
total RNA isolated from A 498 or MCF-7 tumor cells. 
Autologous DC from a healthy HLA-A*02+ donor generated from peripheral blood monocytes with 
GM-CSF and IL-4 were electroporated with the total tumor RNA isolated from the c-Met expressing 
MCF-7 or A498 cells were utilized as target cells in a standard 51Cr-release assay (closed 
symbols). DC electroporated with RNA derived from the c-Met negative Croft cell line were used as 
controls in the assay (open symbols).  
 
2.2.5 Discussion 
Therapeutic vaccinations of patients with malignant diseases aim at stimulation of 
anti-tumor directed immune responses, mainly cytotoxic T-lymphocytes, capable 
to recognize and eliminate malignant cells. During the last years considerable 
efforts have been made to identify antigens specifically recognized by CTL using 
reverse immunology, expression cloning or SEREX technology. However, with the 
exception of some tumor associated antigens most of the identified T-cell epitopes 
are restricted to a limited set of malignancies [20-22]. 
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Comparative expression profiling of a tumor and its corresponding autologous 
healthy tissue by DNA microarray technology allows the identification of antigens 
selectively expressed or overexpressed in malignant cells making these proteins 
suitable targets for immunotherapeutic approaches. Combination of this genetic 
analysis with mass spectrometry enables the characterization of antigenic 
peptides encoded by these antigens. Using this integrated functional genomics 
approach a HLA-A*02 binding peptide derived from the c-Met protooncogene was 
identified [13]. 
 
C-Met is a heterodimeric tyrosine kinase receptor that mediates the multifunctional 
and potentially oncogenic activities of the hepatocyte growth factor/scatter factor 
including promotion of cell growth, motility, survival, extracellular matrix dissolution 
and angiogenesis [1-3]. Binding of HGF to the receptor induces 
autophosphorylation of c-Met and activates downstream signaling events including 
the ras, PI3 kinase, PLC-γ and MAPK related pathways [4,5, 23-26]. The c-Met 
gene is predominantly expressed in epithelial cells and is overexpressed in 
several malignant tissues and cell lines [27-35]. An increasing number of reports 
have shown that nonepithelial cells such as hematopoetic, neural and skeletal 
cells respond to HGF and hematological malignancies like multiple myeloma, 
Hodgkin disease, leukemias and lymphomas express the c-Met protein [36-40]. 
Deregulated control of the invasive growth phenotype by oncogenically activated 
c-Met provoked by c-Met activating mutations, c-Met amplification/overexpression, 
and the acquisition of HGF/c-Met autocrine loops confers invasive and metastatic 
properties to malignant cells. Notably, constitutive activation of c-Met in HGF-
overexpressing transgenic mice promotes broad tumorigenesis [41, 42]. 
Therefore, targeting of c-Met and/or c-Met oncogenic transduction pathways could 
represent a promissing therapeutic option. 
 
In our study we show that c-Met specific CTL recognizing tumor cells in an antigen 
specific and MHC restricted manner can be induced in vitro suggesting that c-Met 
protooncogene is a novel tumor rejection antigen. We used the previously 
identified c-Met derived HLA-A*02 binding peptide for CTL induction and were 
able to demonstrate that this c-Met epitope is expressed on a broad spectrum of 
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epithelial and hematological malignancies including renal cell carcinomas, breast 
cancer, colon cancer, malignant melanoma and multiple myeloma indicating that 
this c-Met peptide is an interesting candidate for the development of a broadly 
applicable vaccination therapy. The specificity of the elicited CTL responses was 
confirmed in cold target inhibition assays. Furthermore, we performed the 
experiments in an autologous setting and utilized autologous DC that were either 
pulsed with the cognate peptide or electroporated with the RNA isolated from c-
Met expressing tumor cell lines as targets. The in vitro induced c-Met peptide 
specific CTL efficiently lysed peptide pulsed autologous DC and DC transfected 
with whole tumor RNA, thus demonstrating that the peptide used for CTL 
induction is also processed and presented upon transfection of DC with whole 
tumor RNA. 
 
Previous studies have shown that under normal conditions c-Met gene can be 
found in many epithelial tissues and its expression can be induced by treatment 
with phorbol esters, serum, and in a paracrine fashion by mesenchymally derived 
HGF. HGF/SF-Met signaling is required for normal development of liver, skeletal 
muscle and placenta [36]. In the hematopoetic system, HGF is produced by 
stromal bone marrow cells and induces together with other cytokines and growth 
factors proliferation and differentiation of a subset of c-Met positive progenitor 
cells. The c-Met/HGF interaction plays an important role in the lymphoid 
microenvironment and induces adhesion as well as migration of normally activated 
B-cells and monocytes [3-12]. 
These observations indicate that the c-Met/HGF network promotes pleiotropic 
effects in normal cells and is not a cancer-specific antigen and caution is required 
when targeting this protein in clinical vaccination trials.  
 
In several clinical vaccination trials using dendritic cells presenting tumor 
associated antigens or adoptive transfer of tumor reactive CTL generated ex vivo, 
it was shown that these approaches can induce antitumor immunity in patients 
with malignant diseases [21, 22, 43-47]. However, with the exception of some 
reports in malignant melanoma trials where induction of vitiligo was observed after 
vaccinations with DC even when antigens that are expressed in normal tissues 
like MUC1 or Her-2/neu were applied there has been so far no evidence for the 
 2.2. TUMOR IMMUNOLOGY   111 
 
 
development of autoimmune reactions in these patients [48]. In conclusion, in our 
study we describe the identification of a novel broadly expressed T-cell epitope 
derived from a protooncogene that is an interesting candidate to be applied in 
immunotherapies of a broad variety of human malignancies. 
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2.2.7 Abbreviations 
CTL  cytotoxic T lymphocyte 
HLA  human leukocyte antigen 
DC  dendritic cell 
HGF  hepatocyte growth factor 
GM-CSF granulocyte-makrophage colony stimulating factor 
IL  interleukin 
TNF  tumor necrosis factor 
RT-PCR reverse-Transcriptase Polymerase chain reaction 
PBMNC peripheral blood mononuclear cells 
PAGE  polyacrylamide gel electrophoresis 
MHC  major histocompatibility complex 
EBV  Epstein-Barr virus 
NK-cell natural killer cell 
SEREX serological identification of antigens by recombinant expression  
  cloning 
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2.3 Induction of adipophilin specific cytotoxic T 
lymphocytes using a novel HLA-A*02 binding 
peptide that mediates tumor cell lysis 
The author of this dissertation, Toni Weinschenk, identified the MHC ligand this 
chapter is dealing with. 
 
2.3.1 Summary 
Identification of tumor associated antigens (TAA) and recent advances in tumor 
immunology resulted in the development of vaccination strategies to treat patients 
with malignant diseases. However, most of the so far identified T-cell epitopes are 
restricted to certain malignancies or HLA alleles. Using a novel approach that 
combines high-density oligonucleotide microarray analysis of tumor samples with 
isolation and sequencing of peptides from the surface of tumor cells, a peptide 
derived from the adipophilin protein was recently identified (see chapter  2.1). In 
the present study we sought to develop specific cytotoxic T-lymphocyte (CTL) 
responses directed against adipophilin using this novel HLA-A*0201 binding 
peptide. The in vitro induced CTL efficiently lysed cells pulsed with the adipophilin 
peptide and allogeneic HLA-matched tumor cell lines, including melanoma, breast, 
and renal cell carcinomas as well as multiple myeloma cells in an antigen specific 
and HLA-restricted manner. Finally, the in vitro induced CTL recognized 
autologous DC pulsed with the antigenic peptide or transfected with whole tumor 
mRNA purified from an adipophilin expressing tumor cell line. To further analyze 
the possible use of this peptide in immunotherapies of malignancies, we induced 
adipophilin specific CTL using PBMNC and DC from a patient with chronic 
lymphatic leukemia (CLL). The in vitro generated T-cells efficiently recognized 
autologous malignant CLL cells while they spared autologous purified non-
malignant B-cells or DC. Our results demonstrate that this peptide might represent 
a novel important candidate for the development of cancer vaccines designed to 
target adipophilin derived epitopes in a wide range of malignancies. 
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2.3.2 Introduction 
The discovery of tumor associated antigens (TAA) and recent advances in the 
identification of T-cell epitopes using expression cloning, SEREX technology or 
the “reverse immunology” approach opened new perspectives to treat malignant 
diseases. Several Phase I/II studies have demonstrated that cancer vaccines 
designed to target epitopes derived from these TAA by cytotoxic T-lymphocytes 
(CTL) can be successful in several types of malignancies such as renal cell 
carcinoma (RCC), melanoma, prostate and breast cancer or Non-Hodgkin 
lymphoma resulting in immunological and clinical responses. However, the 
application of these immunotherapeutical approaches is restricted by the limited 
number of known tumor antigens and epitopes, by patients HLA-type or availability 
of tumor tissue. 
DNA microarray analysis of tumor samples in comparison to the corresponding 
non-malignant autologous tissue provides a promissing new technology to identify 
large numbers of possible TAA. Using gene expression profiling with analysis of 
MHC ligands by mass spectrometry, an HLA-A*0201-presented peptide derived 
from the adipophilin protein was recently described (see chapter  2.1). In the same 
study it was demonstrated that in line with other previous reports, adipophilin, a 
protein involved in lipid homeostasis of adipocytes and macrophages, is 
overexpressed in renal cell carcinomas while only marginally found in non-
malignant tissues. 
We analyzed the possible function of this peptide as a T-cell epitope and its 
presentation by malignant cells using antigen specific cytotoxic T-lymphocytes 
(CTL) that were generated by in vitro priming with monocyte derived dendritic cells 
(DC) as antigen presenting cells. We show here that the CTL generated from 
several healthy donors elicited an antigen specific and HLA-A*0201 restricted 
cytolytic activity against tumor cells endogenously expressing the adipophilin 
protein including renal cell carcinomas, breast cancer, melanoma, multiple 
myeloma cells and primary autologous chronic lymphatic leukemia cells. 
Furthermore, they lysed autologous DC electroporated with RNA isolated from 
adipophilin expressing tumor cell lines. This indicates that this peptide is also 
presented upon transfection of DC. Our results demonstrate that adipophilin is a 
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tumor rejection antigen recognized by CTL and expressed on a broad variety of 
epithelial and hematopoetic malignancies. 
 
2.3.3 Materials and Methods 
2.3.3.1 Tumor cell lines 
Tumor cells were essentially the same as in chapter  2.2.3.1. MZ 1774 (kindly 
provided by Prof. A. Knuth, Frankfurt, Germany) was a renal cell carcinoma cell 
line which was positive for adipophilin and HLA-A*0201. B-cells from a patient with 
chronic lymphatic leukemia (CLL) were grown in RP10 medium for 24 hours 
before they were used as target cells in a standard 51Cr-release assay. 
 
2.3.3.2 Cell isolation and generation of dendritic cells (DC) from adherent 
peripheral blood mononuclear cells 
All steps have already been described in chapter  2.2.3.2. 
 
2.3.3.3 RT-PCR 
See chapter  2.2.3.3. 
 
2.3.3.4 Induction of antigen specific CTL response using HLA-A*02 
restricted synthetic peptides. 
The HLA-A*0201 binding peptides derived from adipophilin (SVASTITGV) and 
from survivin (ELTLGEFLKL) and pol HIV-1 reverse transcriptase (ILKEPVHGV), 
both used as irrelvant controls, were synthesized using standard F-moc chemistry 
on a peptide synthesizer (432A, Applied Biosystems, Weiterstadt, Germany) and 
analyzed by reversed-phase HPLC and mass spectrometry. For CTL induction, 
5x105 DC were pulsed with 50 µg/ml synthetic adipophilin peptide for 2 h, washed, 
and incubated with 3x106 autologous PBMNC in RP10 medium. After 7 days of 
culture, cells were restimulated with autologous peptide pulsed PBMNC and 1 
ng/ml human recombinant IL-2 (R&D Systems) was added on days 1, 3 and 5. 
The cytolytic activity of induced CTL was analyzed on day 5 after the last 
restimulation in a standard 51Cr-release assay. 
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2.3.3.5 CTL assay 
This assay has been described in chapter  2.2.3.5. For antibody blocking 
experiments, cells were incubated for 30 minutes with 10 µg/ml of monoclonal 
antibody BB7.2 (IgG2b, kindly provided by Stefan Stefanović, Tübingen, 
Germany) recognizing HLA-A*02 or isotype control antibody (ChromPure Mouse 
IgG, Dianova, Hamburg, Germany, 0,2µg/ml) before seeding in 96-well plates. 
 
2.3.3.6 PAGE and Western Blotting 
PAGE and western blot was performed as already described in chapter  2.2.3.6. 
Briefly, 30 µg of total protein were separated on 12% polyacrylamide gel, blotted 
on nitrocellulose membrane (Schleicher & Schuell), and probed with an 
adipophilin specific antibody (Mouse monoclonal, AP 125, Hybridoma culture 
supernatant, Research Diagnostics, Flanders, USA). 
 
2.3.3.7 Electroporation of DC with EGFP in vitro transcript (IVT) or whole 
tumor derived RNA.  
EGFP-IVT was synthesized from the plasmid pSP64 Poly(A) EGFPII (generously 
provided by V.F.I. Van Tendeloo, Antwerp, Belgium). Total RNA was isolated from 
tumor cell lysates using QIAGEN RNeasy “Mini” anion-exchange spin columns 
(QIAGEN, Hilden, Germany) according to the protocol for isolation of total RNA 
from animal cells provided by the manufacturer. Quantity and purity of RNA was 
determined by UV spectrophotometry. RNA samples were routinely checked by 
formaldehyde/agarose gel electrophoresis for size and integrity and stored at -
80°C in small aliquots. 
Prior to electroporation on day 6, immature DC were washed twice with serum-
free X-VIVO 20 medium (BioWhittaker, Walkersville, MD) and resuspended to a 
final concentration of 2 x 107 cells/ml. Subsequently, 200 µl of the cell suspension 
were mixed with 10 µg of total RNA and electroporated in a 4 mm cuvette using an 
Easyject Plus™ unit (Peqlab, Erlangen, Germany). The physical parameters were: 
voltage of 300 V, capacitance of 150 µF, resistance of 1540 W and pulse time of 
231 ms. After electroporation the cells were immediately transferred into RP10 
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medium and returned to the incubator. More than 80% of the cells were still alive 
after electroporation. 
 
2.3.4 Results 
2.3.4.1 Generation of adipophilin specific cytotoxic T-lymphocytes (CTL) 
using peptide pulsed DC 
As demonstrated in Figure  2.3.1, expression of adipophilin mRNA and protein 
could be detected in all tested human tumor cell lines. 
 
 
Figure  2.3.1 Expression of adipophilin in human tumor cell lines. 
RT-PCR (A) and Western blot analysis (B) using adipophilin specific primers and an adipophilin 
recognizing monoclonal antibody were performed to analyze the adipophilin expression. 
 
To analyze the presentation of the adipophilin derived HLA-A*0201 restricted 
peptide by human tumor cells, we induced specific CTL in vitro using dendritic 
cells (DC) derived from adherent PBMNC of HLA-A*0201 positive healthy donors 
as antigen presenting cells. The cytotoxicity of the in vitro induced CTL was 
assessed after several restimulations in a standard 51Cr-release assay. As shown 
in Figure  2.3.2, the CTL line obtained after several weekly restimulations 
demonstrated peptide specific killing. T-cells only recognized T2-cells or 
autologous DC coated with the cognate adipophilin peptide while they did not lyse 
target cells pulsed with an irrelevant peptide confirming the specificity of the 
cytolytic activity. 
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Figure  2.3.2 Induction of adipophilin specific CTL responses in vitro. 
DC generated from adherent PBMNC in the presence of GM-CSF, IL-4 and TNF-α were pulsed 
with the synthetic adipophilin peptide and used to generate a CTL response in vitro. Lytic activity of 
induced CTL was assessed in a standard 
51
Cr-release assay using T2-cells or autologous DC 
pulsed with the cognate peptide (Ad, closed symbols) or an irrelevant peptide (Sv, survivin derived, 
or HIV peptide, open symbols) as targets. 
 
2.3.4.2 The identified adipophilin peptide is endogenously processed and 
presented in tumor cells and mediates tumor cell lysis 
We next assessed presentation of the endogenously synthesized adipophilin 
peptide in the context of the HLA-A*0201 molecule. To this end, in vitro induced 
CTL specific for the adipophilin peptide were tested for their ability to lyse human 
tumor cells expressing adipophilin. The adipophilin positive and HLA-A*0201 
expressing cell lines A498, MZ 1257 and MZ 1774 (renal cell carcinoma, RCC), 
MCF-7 (breast cancer), Mel 1479 (malignant melanoma) and U266 (multiple 
myeloma) were used as target cells in a standard 51Cr-release assay. As 
demonstrated in Figure  2.3.3 A-B the peptide induced adipophilin specific CTL 
were able to efficiently recognize malignant cells expressing adipophilin in the 
context of HLA-A*0201. There was no killing of the ovarian cancer cells SK-OV-3 
(HLA-A*03+, adipophilin+) or the K562 cells indicating that the cytotoxic activity 
was not NK-cell mediated. 
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Figure  2.3.3 Adipophilin peptide induced CTL are able to lyse human tumor cell lines 
endogenously expressing the antigen. 
Human renal cell carcinoma (MZ 1774, MZ 1257, A498), malignant melanoma (Mel 1479), breast 
cancer carcinoma (MCF-7) and multiple myeloma (U 266) cell lines expressing adipophilin and 
HLA-A*0201 as well as the ovarian cancer cell line SK-OV-3 (HLA-A*02-/ adipophilin+) were used 
as targets in a stardard 51Cr-release assay (A-B). K 562 cells were included to determine the NK-
cell activity. The antigen specific and HLA-A*02 restricted lysis of the A498 tumor cells by the CTL 
lines was confirmed using a blocking HLA-A*02 specific monoclonal antibody and in cold target 
inhibition assays (C) using unlabeled T2-cells pulsed with the cognate adipophilin (Ad) or the 
irrelevant survivin (Sv) peptide at an inhibitor:target ratio of 20:1. 
 
The antigen specificity and MHC restriction of the cytotoxic activity mediated by 
the peptide induced CTL lines was further confirmed by using an HLA-A*02 
specific monoclonal antibody and in cold target inhibition assays (Figure  2.3.3 C). 
The lysis of the A498 tumor cells could be blocked by incubation of target cells 
with the antibody specific for the HLA-A*02 molecule or the addition of cold (not 
labeled with 51Cr) T2-cells pulsed with the cognate peptide (Ad). T2 cells pulsed 
with an irrelevant survivin derived peptide showed no effect. 
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2.3.4.3 Adipophilin specific CTL can lyse autologous DC transfected with 
whole tumor RNA purified from an adipophilin positive A498 tumor 
cell line 
Next, we analyzed the extent to which the CTL are able to recognize target cells in 
an autologous setting and investigated the presentation of the identified 
adipophilin peptide upon transfection of autologous HLA-A*0201+ DC with whole 
tumor RNA. As shown in Figure  2.3.4, CTL efficiently lysed autologous DC pulsed 
with the cognate adipophilin peptide or electroporated with the whole tumor RNA 
isolated from the survivin expressing A498 tumor cell line indicating that the 
adipophilin peptide is processed and presented after transfection of DC with RNA. 
 
 
Figure  2.3.4 Peptide induced CTL recognize autologous dendritic cells (DC) transfected with 
the total RNA isolated from A498 tumor cells. 
Autologous DC from a healthy HLA-A*0201 donor generated from peripheral blood were pulsed 
with the cognate peptide (Ad) or electroporated with the total tumor RNA isolated from the 
adipophilin positive A498 tumor cell line. Then they were utilized as target cells in a stardard 
51
Cr-
release assay (closed symbols). DC electroporated with in vitro transcribed EGFP-RNA were used 
as controls in the assay (open symbols). 
 
2.3.4.4 Induction of adipophilin specific CTL in a patient with CLL  
Using RT-PCR analysis we found that primary malignant B-cells from a patient 
with chronic lymphocytic leukemia express adipophilin (data not schown). We 
therefore generated adipophilin specific CTL from PBMNC of a HLA-A*0201 
positive patient with CLL who was in remission after treatment with fludarabine 
and utilized autologous primary CLL cells as targets in a standard 51Cr-release 
assay. 
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Figure  2.3.5 In vitro generated adipophilin specific CTL recognize autologous malignant 
chronic lymphocytic leukemia cells. 
Malignant autologous CLL cells from a HLA-A*0201+ patient and autologous DC pulsed with the 
cognate adipophilin peptide (Ad) or an irrelevant survivin peptide (Sv) were used as targets. 
Autologous non-malignant B-cells and the K 562 cells were included as controls. The antigen 
specificity of the CTL lines was analyzed in cold target inhibition assays using unlabeled T2-cells 
pulsed with the adipophilin (Ad) peptide or an irrelevant survivin (Sv) at an inhibitor:target ratio of 
20:1. 
 
As demonstrated in Figure  2.3.5, the in vitro peptide induced CTL efficiently lysed 
autologous DC from this patient that were pulsed with the cognate peptide as well 
as the autologous CLL cells while they spared the non-malignant B-cells or the 
K562 cell line. The specificity of the mediated cytotoxic T-cell responses was 
further confirmed in a cold target inhibition assay using T2-cells pulsed with the 
cognate or an irrelevant peptide. 
 
2.3.5 Discussion 
Adipophilin, officially called adipose differentiation-related protein, was originally 
thought to be selectively expressed only in adipocytes, but it can be found at the 
surface of lipid droplets in several other cell types such as monocytes and 
macrophages or human tumor cells. Comparative expression analysis of normal 
kidney and renal cell carcinomas (RCC) by the differential display approach, 
quantitative RT-PCR or DNA microarray technology revealed that adipophilin is 
highly overexpressed in malignant RCC samples. However, only low levels of 
adipophilin expression were detected in normal tissues, therefore peptides from 
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this protein might be interesting candidates as components of cancer vaccines 
aimed to target this antigen. 
Recently, an HLA-A*0201 binding peptide derived from the adipophilin protein was 
identified in tumors of RCC patients by applying an integrated functional genomics 
approach (see chapter  2.1). This procedure combines comparative expression 
profiling of a tumor sample with the corresponding autologous normal tissue using 
high-density oligonucleotide microarray technology to find genes overexpressed in 
the malignant cells with mass spectrometry to identify MHC class I ligands derived 
from these selectively expressed or overexpressed antigens.  
In our study we analyzed the possible use of this peptide as a T-cell epitope that 
can induce antigen specific CTL and mediate tumor cell lysis. To accomplish this, 
we used PBMNC from HLA-A*0201 positive donors in an in vitro immunization 
protocol. CTL induction was carried out by using monocyte derived DC pulsed with 
the identified adipophilin peptide as antigen presenting cells. After several rounds 
of restimulations, cultures were tested for their lytic activity against target cells 
pulsed with the cognate peptide or human tumor cell lines. Using RT-PCR and 
western blot analysis expression of adipophilin was found in different human 
tumor cell lines, indicating that this protein is expressed in a broad variety of 
human malignancies. The in vitro induced peptide specific CTL were able not only 
to lyse target cells pulsed with the antigenic peptide but also recognized tumor 
cells endogenously expressing the adipophilin protein in an antigen specific and 
HLA-A*02 restricted manner including RCC, malignant melanoma, breast cancer 
and multiple myeloma cells. The specificity of the lytic activity was confirmed by 
the addition of monoclonal antibodies blocking the HLA-A*02 molecules to the 
assay or by performing cold target inhibition assays.  
To further analyze the specificity of the elicited CTL responses we utilized 
autologous DC that were either pulsed with the antigenic peptide or electroporated 
with the RNA isolated from an adipophilin expressing tumor cell line. The in vitro 
generated CTL efficiently lysed peptide pulsed autologous DC and DC transfected 
with whole tumor RNA, demonstrating that the peptide used for CTL induction is 
also processed and presented upon transfection of DC with whole tumor RNA. 
 
Finally, we tested the ability of the identified adipophilin peptide to elicit CTL 
responses in patients with malignant diseases. CTL lines were generated from the 
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PBMNC of an HLA-A*0201 positive patient with chronic lymphatic leukemia by a 
first round of in vitro immunization with peptide pulsed autologous DC followed by 
two rounds of restimulations. The peptide specific CTL were used as effectors 
against the malignant CLL cells. The expression of adipophilin in malignant B-cells 
that represented more than 90% of the peripheral blood lymphocytes and were 
cryopreserved before treatment with fludarabine was confirmed by RT-PCR (data 
not shown). The in vitro induced CTL efficiently lysed in an MHC restricted and 
antigen specific manner the malignant leukemia cells but spared purified B-cells or 
autologous DC from this patient thus demonstrating that adipophilin specific CTL 
are able to recognize primary autologous tumor cells. 
In conclusion, we have characterized a novel HLA-A*0201 restricted T-cell epitope 
derived from adipophilin, a protein involved in accumulation and storage of lipid. 
Adipophilin occurs in a wide range of cultured tumor cell lines, is overexpressed in 
some malignant tissues such as RCC while only marginally expressed in non 
malignant organs. Our results demonstrate that adipophilin is a tumor rejection 
antigen expressed in a wide range of solid and hematopoetic malignancies and 
extend the number of possible CTL epitopes that can be used for the design of 
cancer vaccines. 
 
2.3.6 Abbreviations 
TAA  tumor associated antigens 
CTL  cytotoxic T-lymphocyte 
DC  Dendritic cell 
HLA  Human leukocyte antigen 
CLL  chronic lymphatic leukemia 
SEREX serological identification of antigens by recombinant expression  
  cloning 
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2.4 RCC frequently overexpress genes involved in the 
presentation of MHC ligands 
Reports about tumor escape mechanisms often include down-regulation of MHC 
class I-molecules or genes involved in antigen processing. Using the 
oligonucleotide microarray data generated for some renal cell carcinomas and few 
colon carcinomas, we analyzed the expression of genes involved in antigen 
processing and MHC class I-ligand presentation (Table  2.4.1). In five of six renal 
cell carcinomas, we found increased expression of MHC class I α-chain together 
with stronger expression of β2m. This is in accordance with the observation that 
also many other genes known to be induced by γ-IFN were upregulated. 
Interestingly, some of the RCCs might also express MHC class II-molecules. It 
was known before that melanomas in some cases do express MHC class II-
molecules. Immunoproteasomal subunits LMP2 and LMP7 were frequently 
upregulated as already shown even in samples collected by laser capture 
microdissection (Figure  2.1.2), whereas the constitutive subunits were either 
unchanged, decreased or only in two cases increased. TAP1 was increased in all 
cases but two. 
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Table  2.4.1 Expression of genes involved in MHC ligand presentation1 
       CCA CCA CCA 
 RCC2 RCC RCC RCC RCC RCC 130 132 132 
 01 20 13 19 40 44 LCM bulk LCM 
 
MHC class I I I I NC/D I I NC D D 
 
MHC class II NC I I I  NC  NC NC 
B2M I I I D I I D NC D 
          
LMP2 I I I NC I D I I D 
LMP7 I I I NC I I I MD D 
MECL-1 NC I I NC I NC D NC D 
Delta NC NC D NC I D I I I 
MB1 NC NC NC I I D I I I 
Z NC NC D I NC D I I I 
          
TAP1 I I I NC I D I I MD 
TAP2 NC NC NC NC NC NC NC NC NC 
 
1 Expression in tumor compared to autologous normal tissue: I increased, D decreased, NC no change 
2 RCC renal cell carcinoma, CCA colon carcinoma, LCM laser capture microdissection 
 
Only two colon carcinomas were analyzed, one of them by using LCM samples. 
No MHC class II-expression was detected and class I was either not changed or 
decreased, even in the LCM samples. LMPs and TAP were increased in CCA130 
but decreased in CCA132. LMP2, which finally was found to be decreased in 
CCA132, was considered to be increased, when bulk tissue was analyzed. In 
comparison to renal cell carcinoma, where the cell populations in bulk tissue 
samples are quite homogenous, it is important to use purified cell populations in 
colon carcinoma. The expression levels of genes involved in MHC class I-
presentation reflect the probability to isolate reasonable amounts of peptides, 
which is higher in RCC compared to CCA. 
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2.5 Integrated functional genomics approach: renal cell 
carcinoma RCC44 
2.5.1 Materials and Methods 
Please refer to chapter  2.1.3. 
 
2.5.2 Results 
Patient RCC44 was typed positive for HLA-A*11, B*2705, B*40, and HLA-C*0202 
by cloning and sequencing the α-chains. Peptides were eluted as described in 
 2.1.3.2, separated off-line and analyzed by nanoESI mass spectrometry. Table 
 2.5.1 shows the identified peptides together with the relative expression 
differences between the tumor and the corresponding autologous normal kidney 
tissue analyzed by a high-density oligonucleotide chip U133A from Affymetrix (see 
chapter  2.1.3.5). 
Some of the identified MHC class I-ligands were interesting because of the strong 
overexpression of the respective genes: (SSLPTQLFK) from insulin-like growth 
factor 1 (IGF1), (FRFENVNGY) from asparagine synthetase (ASNS), 
(QRYGFSAVGF) from Rh type C glycoprotein (RHCG), (ARLSLTYERL) from 
ATPase lysosomal interacting protein 1 (ATP6IP1), and (GRYQVSWSL) from 
signal sequence receptor delta (SSR4). 
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Table  2.5.1 MHC class I-ligands from RCC44 
 
    Fold 
Sequencea Gene Symbolb Gene Nameb LocusIDc Changed 
     
HLA-A*11     
     
SSLPTQLFK IGF1 insulin-like growth factor 1 (somatomedin C) 3479 32.0 
ATFPDTLTY ITGA6 integrin, alpha 6 3655 1.6 
SIFDGRVVAK LOC54499 putative membrane protein 54499 nc 
     
HLA-B*27     
     
FRFENVNGY ASNS asparagine synthetase 440 17.1 
QRYGFSAVGF RHCG Rh type C glycoprotein 51458 9.0 
ARLSLTYERL ATP6IP1 ATPase, H+ transporting, lysosomal interacting protein 1 537 8.6 
GRYQVSWSL SSR4 signal sequence receptor, delta 6748 6.5 
QRKKAYADFe COX6C cytochrome c oxidase subunit VIc 1345 2.2 
KRFDDKYTL KIAA0102 KIAA0102 9789 1.7 
TRWNKIVLK UBL5 ubiquitin-like 5 59286 1.4 
LRFDGALNV TUBA2 tubulin, alpha 2 7278 1.3 
ARFSGNLLV SEC61A1 protein transport protein SEC61 alpha subunit isoform 1 29927 1.2 
NRIKFVIKR GTF2I general transcription factor II, i 2969 1.1 
GRVFIIKSY HGRG8 high-glucose-regulated protein 8 = NY-REN-2 51441 nc 
GRFDVKIEVe ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 481 nc 
SRFGNAFHL PRPF8 PRP8 pre-mRNA processing factor 8 homolog (yeast) 10594 nc 
GRTGGSWFK ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 481 nc 
a peptides printed in bold letters are encoded by overexpressed genes. 
b gene symbols and names refer to LocusLink (http://www.ncbi.nlm.nih.gov/LocusLink); whenever possible symbols 
approved by the HUGO Gene Nomenclature Committee were used. 
c Internet address: http://www.ncbi.nlm.nih.gov/LocusLink. 
d expression in tumor relative to corresponding normal tissue; nc no change;. 
e ligands already published, see SYFPEITHI database (http://www.syfpeithi.de/) for references. 
 
 
2.5.3 Discussion 
The reports about insulin-like growth factor 1 (IGF1) and its receptor in cancer 
have a long history [1]. The IGF1/IGF1R system is strongly involved in the control 
of proliferation, differentiation and transformation in several cancer entities. The 
potential usage of the ligand derived from IGF1 and all other ligands from RCC44 
for vaccination is discussed in chapter 2.5. 
Asparagine synthetase is frequently discussed in the context of L-asparaginase-
treatment in acute lymphocytic leukemia (ALL) [2, 3]. Up-regulation of ASNS 
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happens in cells as a result of limited access to asparagine, as induced by L-
asparaginase-therapy. 
Rh type C glycoprotein (RHCG) is a nonerythroid Rh glycoprotein homologue, 
which acts as an ammonia transporter [4, 5]. Recently it was shown that RHCG 
within the kidney is dominantly expressed in the connecting tubules and the 
cortical and outer medullary collecting ducts [6]. Therefore, if the tumor has 
developed from one of these particular regions, it might be the case that the 
dissected normal bulk tissue was low in the content of these structures and, 
therefore, the overexpression was biased.  
The ATPase lysosomal interacting protein 1 (ATP6IP1)-derived ligand deserves 
special attention because this gene was shown being a SEREX antigen in 
melanoma patients. Moreover, antibody-levels against ATP6IP1 correlate with 
tumor destruction [7]. Hodi and collegues vaccinated melanoma patients with 
irradiated autologous melanoma cells engineered to secrete GM-CSF. They 
observed dense infiltration of CD8+ and CD4+ T cells in metastatic lesions after 
vaccination in 11 out of 16 patients. They applied the SEREX approach to a long 
term responder and identified antibodies against ATP6S1. Longitudinal analysis of 
one patient showed increases in serum antibody-levels against ATP6IP1 in 
parallel to tumor destruction. This correlation was also shown in 3 additional 
melanoma patients, in 3 metastatic non-small cell lung carcinoma patients and in 
a CML patient with a complete remission after a CD4 donor lymphocyte infusion. 
This was seen also in a murine tumor model: C57BL/6 mice vaccinated with 
irradiated GM-CSF-secreting B16 melanoma cells but not naïve mice generated 
high-titer IgG antibodies to ATP6S1. In conclusion, it seems that ATP6S1 is at 
least able to induce CD4+ T cell responses, but the relevance for CD8+ T cell 
responses is still not clear. Anyway, for many reported SEREX antigens, also 
CD8+ T cell responses could be induced. 
Signal sequence receptor delta (SSR4) is one subunit of a tetrameric complex 
called translocon-associated protein (TRAP), formerly called signal sequence 
receptor [8, 9]. Its function within this complex is not clear so far. 
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2.6 A gene expression database: 22.000 genes in 21 
human healthy tissues 
This database was built by the author of this thesis together with Oliver Schoor. 
 
2.6.1 Materials and Methods 
RNA sources 
Total RNA from human tissues were obtained commercially (Ambion, Huntingdon, 
UK; Clontech, Heidelberg, Germany; Stratagene, Amsterdam, The Netherlands). 
Total RNA from several individuals (Table  2.6.1) was mixed in a way that RNA 
from each individual was equally weighted. Quality and quantity was confirmed on 
the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 
Nano LabChip Kit (Agilent). 
Table  2.6.1 Total RNA used for expression analysis 
 Number of total RNA 
Tissue Individuals [µg] RNA source 
 
Adrenal gland 62 5 Clontech 
Bladder 2 5 Stratagene 
Bone marrow 7 5 Clontech 
Whole brain 3 5 Clontech 
Colon 4 5 Clontech, Stratagene 
Heart 2 5 Clontech, Ambion 
Kidney 6 5 Clontech 
Liver 2 5 Clontech, Ambion 
Lung 8 5 Clontech, Stratagene 
Placenta 21 5 Clontech 
Prostate 32 5 Clontech 
Salivary gland 24 5 Clontech 
Small intestine 5 5 Clontech 
Skeletal muscle 9 5 Clontech 
Spleen 20 5 Clontech 
Stomach 33 5 Stratagene 
Testis 45 5 Clontech 
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Table  2.6.1 - continued 
 Number of total RNA 
Tissue Individuals [µg] RNA source 
 
Thymus 12 5 Clontech 
Thyroid 65 5 Clontech 
Trachea 86 5 Clontech 
Uterus 11 5 Clontech 
 
High-Density Oligonucleotide Microarray Analysis 
Double-stranded DNA was synthesized from 5 µg of total RNA using SuperScript 
RTII (Life Technologies, Inc., Karlsruhe, Germany) and the primer (Eurogentec, 
Seraing, Belgium) as given by the Affymetrix manual. In vitro transcription using 
the BioArray™ High Yield™ RNA Transcript Labeling Kit (ENZO Diagnostics, Inc., 
Farmingdale, NY), fragmentation, hybridization on Affymetrix U133A GeneChips 
(Affymetrix, Santa Clara, CA), and staining with streptavidin-phycoerythrin and 
biotinylated anti-streptavidin antibody (Molecular Probes, Leiden, The 
Netherlands) followed the manufacturer’s protocols (Affymetrix). The Affymetrix 
GeneArray Scanner was used and data were analyzed with the Microarray 
Analysis Suite 5.0 software. For normalization, 100 housekeeping genes provided 
by Affymetrix were used1. Pairwise comparisons were calculated using the 
expression values in kidney as baseline. Accordingly, all expression values 
calculated from signal log ratios are relative to kidney, which was set at 1. 
Significance of differential expression was judged by the “change” values given by 
the statistical algorithms implemented in the Microarray Analysis Suite 5.0 
software. For absolute detection of expression, data were analyzed again using 
the statistical algorithms. Presence or absence of gene expression was 
determined by the absolute call algorithms. Error bars were given as 95% 
confidence intervals computed using the one-step Tukey’s Biweight method by 
taking a mean of the signal log ratios of probe pair intensities across the two 
arrays. 
 
                                            
1 http://www.affymetrix.com/support/technical/mask_files.affx 
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2.6.2 Example: Tissue expression profiles of candidate target 
genes in RCC44 
Knowledge about the expression of a given gene in any kind of organ or tissue is 
very important for the decision about the quality of a candidate gene as a target in 
cancer immunotherapy. The first criterium for the selection of candidate peptides 
useful for vaccination is the overexpression of the coding genes in the tumor 
compared to the autologous normal renal tissue. After this first filter, of course it is 
necessary to make sure that the selected genes are not stronger expressed in 
other vital organs because of the risk of induction of autoreactivity. The best way 
to get this information at short notice is the presented gene expression database 
covering about 22.000 genes. It allows to call for the tissue expression pattern of 
any gene included on the chip within a second. This database is not closed but 
rather should be enlarged with data from additional tissues and organs. 
In the following, the usage of this database within the presented integrated 
functional genomics approach is demonstrated. For the decision which of the 
identified MHC class I-ligands shown in chapter  2.5.2 would have been useful for 
vaccination of patient RCC44, the expression profiles of the genes coding for 
these peptides were displayed. 
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Figure  2.6.1 Tissue expression of insulin-like growth factor 1 (IGF1). 
Expression was analyzed by oligonucleotide microarrays. Copy numbers are relative to kidney, 
which is set at 1.0. P means that the gene is present, A absent and M marginal according to the 
statistical absolute call algorithms. When the expression in a tissue is computed as being not 
significantly changed in the pairwise comparison with the kidney, the value is set at 1.0. For 
significant changes (increases or decreases), the expression value relative to kidney is calculated 
from the signal log ratio and displayed on top of the bars. In the case that the gene is considered 
not to be expressed in the kidney (A above the bar for kidney), all other expression values are given 
relative to the background signal in the kidney. Nevertheless, in this case expression differences 
between two other organs remain untouched. Error bars show upper and lower 95% confidential 
intervals. 
 
IGF1 was expressed 3 fold higher in the tumor of RCC44 compared to the organs 
with the highest expression, uterus, liver, and prostate (Figure  2.6.1). Therefore, 
the HLA-A*11 restricted ligand from IGF1 would have been a candidate for 
vaccination. 
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Figure  2.6.2 Tissue expression of asparagine synthetase (ASNS). 
Please refer to legend of Figure  2.6.1 
 
Expression of ASNS in the tumor is twice as high as in the organ with the second 
highest expression level, whole brain (Figure  2.6.2). As brain is an immune 
privileged region and ASNS is either expressed at much lower levels in all other 
analyzed tissues or not at all, it would have been possible to include the ligand 
derived from ASNS in a vaccine tailored to meet the needs of patient RCC44. 
 
 
Figure  2.6.3 Tissue expression of Rh type C glycoprotein (RHCG). 
Please refer to legend of Figure  2.6.1 
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RHCG was only expressed in few tissues and high in the tumor (Figure  2.6.3). As 
already mentioned above, within the kidney, RHCG is dominantly expressed in the 
connecting tubules and the cortical and outer medullary collecting ducts. 
Therefore, if the tumor has developed from one of these particular regions, it 
might be the case that the dissected normal bulk tissue was low in the content of 
these structures and, therefore, the expression value for kidney is just a mean 
value from part of the cells not expressing RHCG and some cells expressing 
RHCG at the same level as the tumor does. This possibility cannot be ruled out 
easily as one does not know from which single cell the tumor developed. 
 
 
Figure  2.6.4 Tissue expression of ATPase lysosomal interacting protein 1 (ATP6IP1). 
Please refer to legend of Figure  2.6.1 
 
ATP6IP1 is already discussed as a promising vaccine candidate in chapter  2.5.3. 
The tissue expression profile shows expression in most of the tissues, but a 5 fold 
higher expression in the tumor (Figure  2.6.4). Placenta, where the expression 
level is about half of the tumor, is an immune privileged organ. Thus, 
(ARLSLTYERL) from ATP6IP1 would have been a good vaccine candidate. 
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Figure  2.6.5 Tissue expression of signal sequence receptor delta (SSR4). 
Please refer to legend of Figure  2.6.1 
 
SSR4 is broadly expressed and the expression differences between the tumor and 
other organs like stomach or trachea are rather small. Therefore this ligand should 
probably be omitted. 
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2.7 Integrated functional genomics approach: a 
personalized cancer vaccine clinical trial 
This trial is conducted by Dr. Brossart from the Department of Hematology, 
Oncology and Immunology, University of Tübingen. Patients were from the 
Department of Urology, University of Tübingen, headed by Prof. Stenzl. 
Sequencing of MHC class I-ligands was done (beside the author of this thesis) by 
Claudia Lemmel, Jörn Dengjel, and Oliver Schoor. MHC class I precipitation was 
done by Christian Reichle. Oliver Schoor also performed the expression profiling 
experiments.  
 
2.7.1 Results 
A monocentric clinical phase I/II trial using the integrated functional genomics 
approach presented in detail in chapter  2.1 was initiated. Advanced metastatic 
renal cell carcinoma patients are currently recruited. Until now, four patients were 
analyzed, RCC68, RCC70, RCC73, and RCC75. Peptide and expression analysis 
were performed as described in chapter  2.1.3. Three patients were vaccinated 
using autologous dendritic cells loaded with peptides at days 0, 14, 28, 42. 
 
2.7.1.1 Patient RCC68 
HLA typing for RCC68 was HLA-A*02, A*29, B*15, and B*45. Tumor weight was 
about 20 g, the patient was male. More than 100 MHC class I-ligands could be 
identified from this patient. Because the gene expression database was not 
finished when this patient was analyzed, newly identified peptides derived from 
overexpressed genes could not be included due to the missing tissue expression 
profiles. The peptides shown in Table  2.7.1 were chosen because they were 
already known before and the genes coding for these peptides were found to be 
overexpressed in the tumor of this particular patient. 
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Table  2.7.1 Peptides included in the vaccine for patient RCC68 
HLA-Allele Gene Position Sequence Length 
A*0201 BIRC5 94-103 ELTLGEFLKL 10 
 MET 654-662 YVDPVITSI 9 
 CA9 254-262 HLSTAFARV 9 
 ADFP 129-137 SVASTITGV 9 
 CCND1 101-109 LLGATCMFV 9 
 CCND1 228-236 RLTRFLSRV 9 
 MUC1 950-958 STAPPVHNV 9 
 MUC1 12-20 LLLLTVLTV 10 
 PRAME 425-433 SLLQHLIGL 9 
DR (PADRE)1 - aKXVAAWTLKAAa 13 
1 this peptide is not derived from a gene; PADRE (Pan DR epitope) has promiscuous HLA-DR binding capacity. 
 
2.7.1.2 Patient RCC70 
HLA typing for RCC70 was HLA-A*01, A*02, B*07, B*0806, and B*42. Tumor 
weight was about 8.5 g, the patient was male. Unfortunately, no peptides could be 
identified from this tumor. Nevertheless, known peptides were chosen for 
vaccination according to the gene expression data obtained from this patient 
(Table  2.7.2). 
Table  2.7.2 Peptides included in the vaccine for patient RCC70 
HLA-Allele Gene Position Sequence Length 
A*0201 MET 654-662 YVDPVITSI 9 
 CA9 254-262 HLSTAFARV 9 
 ADFP 129-137 SVASTITGV 9 
 CCND1 101-109 LLGATCMFV 9 
 CCND1 228-236 RLTRFLSRV 9 
 MUC1 950-958 STAPPVHNV 9 
 MUC1 12-20 LLLLTVLTV 10 
 PRAME 425-433 SLLQHLIGL 9 
DR (PADRE)1 - aKXVAAWTLKAAa 13 
1 this peptide is not derived from a gene; PADRE (Pan DR epitope) has promiscuous HLA-DR binding capacity. 
 
2.7.1.3 Patient RCC73 
HLA typing for RCC73 was HLA-A*02, A*03, B*07, B*57. Tumor weight was about 
10 g, the patient was male. Selection of the peptides shown in Table  2.7.3 was 
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done considering the gene expression data from this patient, because peptide 
identification failed in this case. 
Table  2.7.3 Peptides suggested for patient RCC73 
HLA-Allele Gene Position Sequence Length 
A*0201 ADFP 129-137 SVASTITGV 9 
 MET 654-662 YVDPVITSI 9 
 CA9 254-262 HLSTAFARV 9 
 CCND1 101-109 LLGATCMFV 9 
 CCND1 228-236 RLTRFLSRV 9 
 MUC1 950-958 STAPPVHNV 9 
 MUC1 12-20 LLLLTVLTV 9 
DR (PADRE)1 - aKXVAAWTLKAAa 13 
1 this peptide is not derived from a gene; PADRE (Pan DR epitope) has promiscuous HLA-DR binding capacity. 
 
This patient changed his mind at a later point of time, after the analysis had 
already been done, and preferred not to be immunized. 
 
2.7.1.4 Patient RCC75 
HLA typing for RCC75 was HLA- A*03, B*07, B*40. Tumor weight was about 16 g, 
the patient was male. More than 100 MHC class I-ligands could be identified from 
this patient. Peptides listed in Table  2.7.4 were chosen for the vaccine. 
 
Table  2.7.4 Peptides included in the vaccine for patient RCC75 
HLA-Allele Gene Position Sequence Length 
A*0301 EF1e 114-122 TLADILLYY 9 
 FACL4 81-90 KLFDHAVSKF 10 
 NSAP1 269-277 GLTDVILYH 9 
 unknown - SVASISLTK 9 
B*0702 FACL4 617-626 VPNQKRLTLL 10 
DR (PADRE)1 - aKXVAAWTLKAAa 13 
1 this peptide is not derived from a gene; PADRE (Pan DR epitope) has promiscuous HLA-DR binding capacity. 
 
Until now, none of the patients showed a clinical response. Monitoring of T cell 
responses against the vaccinated peptides as a surrogate marker was not 
analyzed yet. 
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Results, Part 2: Antigen Processing 
2.8 A role for a novel luminal endoplasmic reticulum 
aminopeptidase in final trimming of 26S 
proteasome-generated major histocompatability 
complex class I antigenic peptides 
The author of this dissertation, Toni Weinschenk, contributed the relative 
quantification of SIINFEKL containing peptides by liquid-capillary mass 
spectrometry analysis shown in Table  2.8.1 to this work. 
 
2.8.1 Summary 
Peptides presented to cytotoxic T lymphocytes by class I major histocompatability 
complex are 8-11 residues long. While proteasomal activity generates the precise 
C-termini of antigenic epitopes, the mechanism(s) involved in generation of the 
precise N-termini is largely unknown. To investigate the mechanism of N-terminal 
peptide processing, we utilized a cell-free system in which two recombinant 
ornithine decarboxylase constructs, one expressing the native H2-Kb-restricted 
ovalbumin-derived epitope SIINFEKL (ODC-ova), whereas the other the extended 
epitope, LESIINFEKL (ODC-LEova), were targeted to degradation by 26S 
proteasomes followed by import into microsomes. We found that the cleavage 
specificity of the 26S proteasome was influenced by the N-terminal flanking amino 
acids leading to significantly different yields of the final epitope SIINFEKL. 
Following incubation in the presence of purified 26S proteasome, ODC-LEova 
generated largely ESIINFEKL that was efficiently converted to the final epitope 
SIINFEKL following translocation into microsomes. The conversion of ESIINFEKL 
to SIINFEKL was strictly dependent on the presence of H2-Kb, and was 
completely inhibited by the metalloaminopeptidase inhibitor 1,10-phenanthroline. 
Importantly, the converting activity was resistant to a stringent salt/EDTA wash of 
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the microsomes and was only apparent when TAP transport was facilitated. These 
results strongly suggest a crucial role for a lumenal ER-resident metallo-
aminopeptidase in the N-terminal trimming of major histocompatibility complex 
class I-associated peptides. 
 
2.8.2 Introduction 
MHC class I molecules associate with peptides of 8-11 amino acids derived from 
the proteolytic degradation of intracellular protein antigens and present them to 
CD8+ T cells on the cell surface [1-3]. While the vast majority of class I ligands are 
translocated from the cytosol into the endoplasmic reticulum (ER) by the ATP-
dependent transporter associated with antigen processing, TAP [3], alternative 
pathways have been described including the liberation of minigene-encoded 
peptides from ER signal sequences [4-6], TAP-independent processing of signal 
sequences [7, 8], and processing of membrane-associated or soluble proteins in 
the secretory pathway [9-12]. Peptides that are not retained in the ER by binding 
to class I or glycosylation are released back into the cytosol through the Sec61 
channel [13-15]. Studies using membrane-permeable inhibitors of proteasomes 
have indicated that the proteasome is the major proteolytic activity responsible for 
the generation of antigenic peptides [16-21] although the incomplete inhibition of 
antigen processing by proteasome inhibitors has also documented the 
involvement of nonproteasomal cytosolic proteases [22-28]. The proteasome is an 
abundant cytosolic multisubunit protease consisting of the proteolytic 20S core 
particle that associates with PA700 regulatory complexes to form 26S 
proteasomes, or with PA28 complexes [29]. The 26S proteasome usually 
degrades ubiquitinylated proteins [30]. Ornithine decarboxylase1 (ODC) 
constitutes an exception as it is targeted to 26 proteasomes by antizyme in an 
ubiquitin-independent fashion [31-33]. The 26S proteasome seems to mediate the 
degradation of most antigenic proteins in living cells [34-36] and, therefore, 
deserves particular interest. The in vitro cleavage specificities of purified 20S 
proteasomes and the relevance of proteasomal processing for the generation of 
immunodominant epitopes have been investigated in great detail [1, 37]. While 
20S proteasomes have been shown to precisely cleave a number of known class I 
ligands out of model polypeptide substrates, a minor part of cleavage products is 
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longer than the canonical length of class I-binding peptides [38-41]. Limited 
information is, however, so far available about protein processing by 26S 
proteasomes. A direct comparison of 26S and 20S proteasomes revealed 
overlapping but substantially different cleavage patterns for the protein substrate 
β-casein [41]. On average, the 26S proteasomal cleavage products were found to 
be slightly shorter than peptides generated by 20S proteasomes containing 
greater proportions of peptides that are too short for efficient TAP-mediated 
translocation as well as for class I binding [40, 41]. Proteasomes seem to be the 
dominant, if not the only, protease that generates the correct C-terminus of class I 
ligands, whereas the N-terminal trimming of proteasomal products is insensitive to 
proteasome inhibitors [20, 42, 43]. Leucine aminopeptidase, puromycin-sensitive 
aminopeptidase, and bleomycin hydrolase have been implicated in the 
cytoplasmic trimming of proteasomal products [44, 45]. In addition, tri-peptidyl 
peptidase II has been suggested to play a role in the generation of class I ligands 
or precursors [46]. Different lines of evidence suggest that precursors of class I 
ligands can be trimmed in the ER lumen to their final lengths. Processing of 
peptide imported into microsomes was directly shown by biochemical methods 
[14, 47]. The broad but not random substrate specificity of TAP precludes that 9-
mer peptides containing a proline residue at position 2 or 3 are efficiently bound 
and transported by TAP [48- 50], which can be rescued by extending such 
peptides with N- and/or C-terminal flanking residues [49]. Nevertheless, several 
MHC class I alloforms in man and mouse prefer a proline residue at position 2 or 
3 in the associated 9-mer peptide [51]. Also for some peptides not containing 
proline, addition of flanking residues to minimal epitopes strongly improved TAP 
affinities [50, 52, 53] implicating that precursors become trimmed in the ER. The 
analysis of extended minimal epitopes or tandem arrays of epitopes that were 
directed into the ER of TAP-deficient T2 cells by a leader sequence have clearly 
indicated the predominance of an aminopeptidase activity [10, 47, 53-55], 
whereas the carboxypeptidase activity in the ER lumen seems to be very poor [5, 
11, 53-55]. N-terminal trimming of a precursor peptide was recently suggested to 
depend on the presence of the correct class I restriction element [47]. However, 
the identity and biochemical properties of the aminopeptidase(s) in charge 
remains elusive. To investigate the relative contribution of the proteasome, 
cytosolic and ER peptidases to the generation of the definite class I epitope, we 
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have developed an in vitro system in which recombinant ODC containing 
ovalbumin (ova) peptides are targeted to degradation by 26S proteasomes 
followed by import into purified microsomes. We find that the yield of a finally 
processed H2-Kb-binding epitope was strongly influenced by N-terminal flanking 
amino acids in the protein sequence. We show that a slightly extended ova 
epitope precursor was efficiently trimmed following TAP-mediated import into 
microsomes. The conversion into the definite epitope could be blocked by the 
aminopeptidase inhibitor 1,10-phenanthroline (PNT) and was strictly dependent on 
the presence of MHC class I molecules known to associate with the epitope.  
 
2.8.3 Materials and Methods 
2.8.3.1 Peptides 
The peptide SIINFEKL was synthesized by Anaspec (San Jose, CA). The peptide 
ESIINFEKL was synthesized by Dr. M. Fridkin at the Department of Organic 
Chemistry, The Weizmann Institute, Rehovot, Israel. The peptides HESIINFEKL, 
HLESIINFEKL, QSHESIINFEKL and QSHLESIINFEKL were synthesized at the 
peptide synthesis core facility of the DKFZ (Heidelberg, Germany). All peptides 
were purified to ~95% homogeneity by HPLC and their identity confirmed by mass 
spectrometry. To accurately determine the concentration of peptides used in this 
study each peptide solution in double-distilled water was analyzed by Edman 
degradation. 
 
2.8.3.2 Chemicals 
Bestatin and lactacystin were from Calbiochem (San Diego, CA). CompleteTM 
EDTA-free protease inhibitors (referred to as protease inhibitors) were from Roche 
Molecular Biochemicals (Mannheim, Germany). 1,10-phenanthroline, all standard 
reagents and reagents for cell culture were from Sigma (St. Louis, MO) 
 
2.8.3.3 Cell lines and mice 
The B3Z T-cell hybridoma and the antigen presenting cell line Kb-L have been 
described by Karttunen et al. [56] and were granted by Dr. Chris Norbury (NIH, 
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Bethesda, MD). C57BL/6 (B6) and BALB/c mice were from local breeding in the 
animal facility of the Sackler Faculty of Medicine, Tel Aviv University (Tel Aviv, 
Israel). H2-Db-/- (B6.Kb) and H2-Kb-/- (B6.Db) knockout mice [57] were a kind gift of 
Dr. Lea Eisenbach, (Weizmann Institute, Rehovot, Israel). TAP1-/- mice [58] were 
courtesy of Dr. Natalio Garcia-Garbi (DKFZ, Heidelberg, Germany). 
 
2.8.3.4 Preparation of 26S proteasome, maltose-binding protein antizyme-
fusion protein (MBP-Az) and recombinant ODC-ova derivatives 
The 26S proteasome was purified from B6 livers, and the recombinant proteins, 
MBP-Az and the ODC-ova derivatives were expressed in bacteria and purified by 
affinity chromatography as previously described [59]. In order to generate the 
ODC-LEova expression vector, an adaptor encoding the peptide LESIINFEKL with 
BstXI-compatible ends was generated by annealing the two synthetic 
oligonucleotides 5’-ATCTGGAAAGTATAATCAACTTCGAAAAACTGAGCC-3’ and 
5’- CAGTTTTTCGAAGTTGATTATACTTTCCAGATGGCT-3’. The adaptor was 
then inserted into the ODC sequence as previously described for ODC-ova [59]. 
Production of 35S-labeled ODC-ova and ODC-LEova was in the methionine 
auxotroph strain B834(DE3) (Novagen Inc., Madison, WI) and purification of the 
35S-labeled proteins was carried out as previously described [59]. 
 
2.8.3.5 Preparation of sub-cellular fractions 
Lactacystin-treated cytosol: 
Preparation of cytosol (100,000 x g supernatant) from RMA cells was carried out 
as previously described [60]. To inhibit proteasome activity, a 2 ml aliquot of the 
cytosol (20 mg of protein) was incubated with 35 µM lactacystin for 30 min at 
37°C. The lactacystin-treated cytosol was then dialyzed for 16 hours at 4°C 
against 500 ml of 20 mM Tris-HCl (pH 7.5), 0.5 mM DTT and stored in aliquots at -
70°C. Inhibition of proteasome activity in the cytosol was greater than 90% as 
determined by the inhibition of fluorogenic peptide suc-LLVY-MCA hydrolyzing 
activity [61]. 
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Microsomes:  
Microsomes were prepared according to the protocol described by Shepherd et al. 
[58]. Briefly, mice (8-10 weeks old) were injected intraperitoneally with 0.2 
mg/mouse of poly-inosine-cytosine 24 hours prior to sacrifice. The livers and 
spleens were thoroughly washed with phosphate buffered saline and then 
homogenized in a motor-driven Potter-Elvehjem Teflon tissue grinder. 
Homogenization was in 3 ml/liver of buffer A containing: 50 mM triethanolamine-
Ac (pH 7.5), 1 mM DTT, 5 mM Mg(Ac)2, 50 mM KAc, 250 mM sucrose and 1:25 
(w/v) solution of protease inhibitors. The extract was then subjected to fractional 
centrifugation at 1000 x g and then at 10,000 x g. The supernatant from the 
10,000 x g spin was then placed on top of a sucrose cushion containing 1.3 M in 
buffer A at a ratio of 2:1 (sample:cushion) and then centrifuged at 140,000 x g for 
2.5 hours. The resulting pellet was then re-suspended in buffer C (50 mM 7.5, 1 
mM DTT and 250 mM sucrose) to a concentration of 200 OD280nm units/ml. The 
microsome suspension was then stored in aliquotes at -70°C. 
 
2.8.3.6 Stripping off microsomes-associated proteins 
The microsome suspension was incubated on ice for 15 min in 10 volumes of 
buffer D containing: 50 mM Hepes-KOH (pH 7.5), 1 mM DTT, 0.5 M KCl and 15 
mM EDTA. The membrane suspension was then centrifuged at 10,000 x g in a 
microfuge. The membrane pellet was then re-suspended in 10 volumes of buffer 
D without EDTA and immediately centrifuged as described above. The final 
membrane pellet was resuspended in the processing reaction mixture. The protein 
content of the stripped microsomes was less than 40% of that of untreated 
membranes as determined by measurement of the optical density at 280nm. 
 
2.8.3.7 Assay of TAP-mediated peptide transport 
TAP-mediated peptide transport was determined by measuring the ATP-
dependent transport of the radio-iodinated peptide TNKTRIDGQY into isolated 
microsomes as previously described [63]. Purified microsomes (1 unit) were 
incubated in a reaction mixture containing the following components in a final 
volume of 100µl: 50 mM Hepes-KOH (pH 7.5), 1 mM DTT, 5 mM MgCl2, 10 mM 
creatine phosphate, 2.5 units creatine phosphokinase and 125I-labeled peptide (40 
 2.8. ANTIGEN PROCESSING   155 
 
 
ng, 106 cpm). In reactions without ATP, 2- deoxyglucose (20 mM) and hexokinase 
(3 µg) were added instead of ATP and the ATP regenerating system. Following 
incubation for 10 min at 37°C the microsomes were pelleted by centrifugation at 
10,000 x g in a microfuge. The supernatant was removed and the membrane 
pellet was re-suspended in 1 ml lysis buffer (20 mM Hepes-KOH (pH 7.5), 5 mM 
MgCl2 and 1% NP-40) and then sonicated for 30 sec at 50% output power in a 
water bath sonicator (Ultrasonic Processor, Heat Systems Inc., Farmingdale, NY). 
The detergent extract was centrifuged for 10 min at 10,000 x g in a microfuge. The 
resulting supernatant was then mixed with 25 µl concanavalin A (ConA)-
Sepharose beads (Amersham-Pharmacia Biotech AB, Uppsala, Sweden) and the 
mixture was then mixed gently for 16 hours at 4oC. The beads were then pelleted 
by centrifugation at 1000 x g in a microfuge and then washed twice with 1 ml 
portions of lysis buffer. The ATP-dependent transport of peptide was then 
determined by measuring the amount of radioactivity associated with the beads in 
the presence of ATP after subtraction of the ConA-associated radioactivity 
obtained in a parallel reaction carried out in the absence of ATP. 
 
2.8.3.8 Antigen processing assays 
Antigen processing reaction mixtures contained the following components in a 
final volume of 75 µl: 50 mM Hepes-KOH (pH 7.5), 5 mM MgCl2, 0.5 mM DTT, 1 
mM ATP, 10 mM creatine phosphate, 1.8 units creatine phosphokinase, 10 µg of 
recombinant ODC, 15 µg MBP-Az and 10 units of 26S proteasome (for the 
definition of proteasome units see ref. 59). Where indicated purified microsomes 
(1 OD280 unit) and lactacystin-treated RMA lysate (60 µg of protein) were also 
supplemented. Following incubation for 10 min at 37°C, the reaction was extracted 
in 400 µl ice-cold lysis solution (0.5% trifluoroacetic acid, 1% NP-40). The mixture 
was then sonicated for 60 sec at 50% output power in an ice-cooled bath 
sonicator. In processing reactions containing microsomes the membranes were 
first pelleted by centrifugation at 4°C for 15 min at 10,000 x g in a microfuge and 
then extracted in lysis buffer as described above. The acid extract was then 
filtered through a 10kDa cut-off filter (Microcon 10 concentrator, Millipore Corp. 
Bedford, MA) and the filtrate was collected and lyophilized. The lyophilized 
material was then chromatographed by reverse phase-HPLC and the fractions 
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corresponding the elution position of synthetic SIINFEKL were pooled and 
lyophilized exactly as previously described [59]. 
 
2.8.3.9 Peptide processing assays 
Reactions were carried out in a final volume of 100 µl containing the following 
components: 50 mM Hepes-KOH (pH 7.5), 5 mM MgCl2, 0.5 mM DTT, 1 mM ATP, 
10 mM creatine phosphate, 2.5 units of creatine phosphokinase, microsomes (1 
unit) and 50 fmoles of synthetic ESIINFEKL or HLESIINFEKL. Where indicated, 
1,10-phenanthroline (2 mM) or bestatin (250 µM) were added. In reaction without 
ATP, hexokinase (3 µg) (Roche Molecular Biochemicals) and 2-deoxyglucose (20 
mM) were added instead of ATP and the ATP regenerating system. The reaction 
was pre-incubated for 4 min at 37°C and then ESIINFEKL was added for a further 
incubation for 8 min at 37°C. The reaction was then stopped by addition of 450 µl 
lysis buffer and then processed as described above. We detected low SIINFEKL 
activity even in the absence of microsomes. This activity was probably due to 
residual SIINFEKL present in the synthetic ESIINFEKL preparation that we 
estimate ~5%. Therefore, the conversion of ESIINFEKL to SIINFEKL was 
calculated after subtraction of the value obtained in a parallel experiment without 
microsomes. 
 
2.8.3.10 Quantification of SIINFEKL 
Except for Figure  2.8.1 B where the amount of SIINFEKL was quantified by flow 
cytometry using the H2-Kb-SIINFEKL-specific monoclonal antibody 25.D1-16 [62], 
SIINFEKL was quantified by the B3Z Tcell hybridoma activation assay [56]. 
Briefly, B3Z cells (5 x 104) were co-cultured overnight in 100 µl phenol red-free 
RPMI-1640 at 37°C with KbL cells (3 x 104) and in the presence of either synthetic 
peptides or HPLC-purified processed peptides. After activation, cells were lysed 
by addition of 50 µl to each well of stop buffer (50 mM Na2HPO4, 34 mM 
NaH2PO4, 10 mM KCl, 1 mM MgSO4, 0.125% NP-40, 150 mM β- 
mercaptoethanol) containing 0.45 mM CPRG (chlorophenol red β-
galactopyranoside, Calbiochem, San Diego CA.). The cells were then further 
incubated for 4 hours at 37°C and the absorbance at 595 nm in each well was 
subsequently determined using a 96-well ELISA reader. The amount of SIINFEKL 
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was calculated based on the activity of known amounts of synthetic peptide that 
were tested in parallel.  
 
2.8.3.11 HPLC mass spectrometry 
Synthetic and proteasomal digest-derived peptide mixtures were analyzed by a 
reversed phase HPLC system (ABI 140D, Applied Biosystems) coupled to a 
hybrid quadrupole orthogonal acceleration time of flight tandem mass 
spectrometer (Q-TOF, Micromass, Manchester, England) equipped with an ESI 
source. Solvent A was 4 mM ammonium acetate adjusted to pH 3.0 with formic 
acid. Solvent B was 2 mM ammonium acetate in 70% acetonitrile/water adjusted 
to pH 3.0 with formic acid. Loading and desalting of typical sample volumes of 100 
µl was achieved by preconcentration on a 300 µm x 5 mm C18 µ-Precolumn (LC 
Packings, San Francisco, CA). A syringe pump (PHD 2000, Harvard Apparatus, 
Inc., Holliston, MA), equipped with a gastight 100 µl syringe (1710 RNR, Hamilton, 
Bonaduz, Switzerland), was used to deliver solvent and sample at a flow rate of 2 
µl/min. For peptide separation, the preconcentration column was switched in line 
with a 75 µm x 250 mm C-18 column (LC Packings, San Francisco, CA). A binary 
gradient of 25%-60% B within 70 min was performed, applying a flow rate of 27 
µl/min reduced to approximately 300 nl/min with a pre-column split using a TEE-
piece (ZT1C, Valco, Schenkon, Switzerland) and a 300 µm x 150 mm C-18 
column as a backpressure device. A gold-coated glass capillary (PicoTip, New 
Objective, 11 Cambridge, MA) was used as the needle in the ESI source. A blank 
run was performed prior to any subsequent HPLC MS run in order to ensure that 
the system was free of any residual peptide. 
For on-line nanocapillary HPLC tandem mass spectrometry experiments, 
fragmentation of the parent ion was achieved at the given retention time by 
collision with argon atoms. Q1 was set to the mass of interest +/- 0.5 Da and 
collision energy was applied for 1-2 min. 
Quantitative analysis of different compounds in HPLC mass spectrometry is 
possible by calibrating with synthetic substances of known amounts. For 
quantifying relative amounts of different SIINFEKL-containing peptides in one 
digest, relative signal intensities have been evaluated by calibration with different 
amounts of the corresponding synthetic peptides. 
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For comparison of the amounts of SIINFEKL and ESIINFEKL in the digests of the 
two different substrates, the efficiencies of the digests were normalized using 
three proteasomal cleavage products from various parts of ODC, which for this 
reason should be generated in equal amounts in all digests. 
 
2.8.4 Results 
2.8.4.1 The efficiency of generation of the H2-Kb ova-derived epitope is 
dependent upon its N-terminal flanking residues 
We have generated two recombinant ODC derivatives that express the optimal 
H2-Kb epitope SIINFEKL (ODC-ova), and the naturally extended ovalbumin-
derived peptide LESIINFEKL (ODC-LEova). We have previously shown that ODC-
ova is processed very efficiently to generate almost exclusively the optimal epitope 
SIINFEKL [59]. When we compared the proteolytic processing of ODC-ova with 
ODC-LEova by purified 26S proteasome under linear kinetic conditions we noticed 
that the amount of SIINFEKL produced from ODC-ova was consistently 3-4 fold 
higher than that produced from ODC-LEova (Figure  2.8.1 A). The difference was 
not due to decreased proteolysis of ODC-LEova since the rate of degradation of 
the two derivatives was similar (Figure  2.8.1 B). Consequently, mass spectrometry 
analysis indicated that the distribution of the SIINFEKL-containing peptides 
produced by the two derivatives was markedly different in respect to the 
proportion of the optimal epitope relative to the other SIINFEKL containing 
peptides. Indeed, the proportion of SIINFEKL relative to the overall SIINFEKL-
containing peptides from ODC-ova and ODC-LEova was 90% and 25% 
respectively. Instead, the predominant peptide produced from ODC-LEova was 
ESIINFEKL (62%). 
Consistent with previous observations that the proteasome is the sole proteolytic 
activity that generates the correct C-terminus of MHC class I-restricted epitopes, 
no SIINFEKL-containing peptides with C-terminal extensions could be detected 
(Table  2.8.1). The finding that ESIINFEKL became the dominant peptide 
generated from ODC-LEova is probably due to the introduction of the leucine 
residue, a preferential proteasomal cleavage site [39], upstream of the epitope in 
ODC-LEova.  
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Figure  2.8.1 Proteolytic processing of 35S-labeled ODC-ova and ODC-LEova by purified 26S 
proteasome. 
35S-Labeled recombinant ODC-ova (squares) and ODC-LEova (triangles) were incubated for the 
indicated time periods with purified 26S proteasome and MBP-Az. To quantify the amount of 
SIINFEKL (A), 4 µg of each of the 35S-labeled proteins was incubated in a final volume of 100 µl in a 
standard reaction mixture. The peptides were then isolated as described under “Experimental 
procedures” and then tested for recognition by mAb 25-D1.16 as previously described [59]. To 
determine the percentage of degradation (B), 35S-labeled recombinant ODC derivatives (1 µg of 
protein being 11,000 cpm for ODC-ova and 6,000 cpm for ODC-LEova) were incubated in a volume 
of 25 µl in a standard reaction mixture. The percentage of degradation of 35S labeled ODC 
derivative was then determined as previously described [59] by measuring the amount of soluble 
radioactivity after addition of trichloroacetic acid and after subtraction of the soluble radioactivity 
obtained at time zero. The degradation results are the mean of duplicate incubations.  
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Table  2.8.1 Mass spectrometric analysis 
of SIINFEKL containing peptides generated by the 26S proteasome 
Antigen Processed peptide Relative amount (%) 
ODC-ova SIINFEKL 90 
 HSIINFEKL 5.5 
 QSHSIINFEKL 4.5 
ODC-LEova SIINFEKL 25 
 ESIINFEKL 62 
 HLESIINFEKL 6 
 QSHLESIINFEKL 7 
Mass spectrometric analysis and quantification of processed peptides was carried out as described 
in  2.8.3.11. 
 
2.8.4.2 Processing of ODC-ova and ODC-LEova in the presence of cytosol 
and isolated microsomes 
It has been previously reported that antigenic peptide precursors with N-terminal 
extensions are further processed either in the cytoplasm or in the ER (see 
Introduction). To investigate the role of cytoplasmic and ER peptidases in the 
generation of the final antigenic epitope, we subjected the recombinant antigens 
to proteolytic processing by the 26S proteasome in the presence of a cytosolic 
fraction and isolated microsomes. Following incubation of the antigens in the cell-
free system, the microsomes were pelleted and the yield of SIINFEKL measured 
by the ability to activate the Kb/SIINFEKL-specific T cell hybridoma B3Z. 
 When ODC-ova was incubated in the presence of 26S proteasome and B6.Kb 
microsomes, 54% of the SIINFEKL, initially produced by the proteasome alone 
was recovered (6 out of 11.2 fmoles) (Figure  2.8.2 A). However, when ODC-
LEova was processed under the same conditions, the yield of SIINFEKL was 
175% (6.3 compared with 3.6 fmoles) (Figure  2.8.2 B). These results proposed 
that the N-terminally extended SIINFEKL precursors generated from ODC-LEova 
and specifically ESIINFEKL were further trimmed by the microsomes to produce 
the optimal epitope. To exclude the possibility that the augmentation in SIINFEKL 
yield was due to exceedingly higher affinity of ESIINFEKL to TAP resulting in 
preferential transport followed by further trimming in the ER, we tested the 
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affinities of the extended peptides to TAP. Using a radio-iodinated and 
glycosylatable reporter peptide [63], we determined the IC50 values of SIINFEKL, 
ESIINFEKL, HLESIINFEKL, and QSHLESIINFEKL to be 4.5 µM, 3.0 µM, 2.3 µM, 
and >1 mM, respectively. Thus, we found that the affinity of all the N-terminally 
extended ova peptides generated from ODC-LEova was similar to that of 
SIINFEKL (except for the 13-mer) suggesting that the increment in the recovery of 
SIINFEKL was mainly owing to processing of the predominant proteasomal 
product, ESIINFEKL. The increment in SIINFEKL activity when ODC-LEova was 
processed could also not be explained by recognition of Kb-bound ESIINFEKL 
since the B3Z T-cell hybridoma recognized this peptide at least ten-fold less 
efficiently than SIINFEKL (Figure  2.8.2 D). The addition of cytosol to the 
processing reaction caused a considerable reduction in the yield of SIINFEKL 
from both substrates (compare + and - cytosol in Figs. 2A and B). These results 
indicated that the proteasome-processed peptides were subjected to non-specific 
degradation in the cytosol. Nevertheless, the significant recovery of SIINFEKL in 
microsomes indicated that the transport of peptides into the ER lumen rescues a 
significant amount of peptides from complete cytosolic degradation. When 
processing was performed with B6.Db microsomes no SIINFEKL could be 
recovered (Figure  2.8.2 A, B). Furthermore, SIINFEKL could not be detected when 
ODC-LEova was processed in the presence of BALB/c microsomes (Figure  2.8.2 
C). These results clearly indicate that the correct restriction element was essential 
for precursor peptide processing and retention of the definite epitope. These 
results are also consistent with previous reports that, unless the peptide is 
retained in the ER by binding to the appropriate MHC class I molecule it is 
degraded either in the microsomal lumen or after release to the cytosol [14]. 
 No SIINFEKL could be recovered when processing of ODC-LEova was carried 
out in the presence of TAP1-deficient microsomes instead of B6.Kb microsomes, 
indicating that entry of the peptides into the microsomal lumen was necessary for 
further processing (Figure  2.8.2 C). 
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Figure  2.8.2 Processing of ODC-ova and ODC-LEova by the 26S proteasome in the presence 
of cytosol and microsomes. 
ODC-ova (A) and ODC-LEova (B and C) were incubated in a standard antigen processing reaction 
mixture with the indicated additions as described in  2.8.3.8. Following incubation at 37°C for 10 min, 
microsomes were isolated and extracted. The peptides were then purified by RP-HPLC and the 
amount of processed SIINFEKL was then quantified based on the ability to activate the B3Z T-cell 
hybridoma as described in  2.8.3.10. Results of A-C were calculated as the mean value of duplicate 
incubations. (D) Recognition of synthetic ODC-ova peptides by B3Z. Various amounts of synthetic 
peptides were incubated with KbL cells and then tested for recognition by the B3Z. Squares, 
SIINFEKL; triangles, ESIINFEKL; circles, HLESIINFEKL. 
 
2.8.4.3 Processing of synthetic ESIINFEKL by isolated microsomes 
In order to investigate the peptidase activity responsible for the N-terminal 
trimming, we studied the conversion of synthetic ESIINFEKL to SIINFEKL by 
isolated microsomes. As observed in the antigen processing experiments, 
incubation of synthetic ESIINFEKL with isolated B6.Kb microsomes resulted in a 
remarkable enhancement of SIINFEKL recovery (Figure  2.8.3). 
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Figure  2.8.3 Processing of synthetic ESIINFEKL by isolated microsomes. 
Synthetic ESIINFEKL was incubated with 1 OD280 unit of the indicated microsomes either in the 
presence or absence of ATP. Microsomes were then extracted and the peptides were isolated as 
described in “Experimental procedures” and in the legend to Figure  2.8.2. The amount of SIINFEKL 
was then determined by the B3Z activation assay as described under “Experimental procedures”. 
Results were calculated as the mean value of duplicate incubations. 
 
In agreement with the results of the ODC-LEova processing experiment, TAP1-/-, 
BALB/c as well as B6.Db microsomes could not generate SIINFEKL (Figure  2.8.3 
and data not shown). To further characterize the specific trimming activity 
associated with the microsomes, we tested the sensitivity of the putative peptidase 
to the metallo-aminopeptidase inhibitor bestatin [64] as well as to the ion chelator 
PNT that was previously shown to inhibit various metallopeptidases [65]. We 
found that when both inhibitors were present, the ESIINFEKL to SIINFEKL 
conversion was completely blocked (Figure  2.8.4). 
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Figure  2.8.4 Effect of peptidase inhibitors on processing of synthetic ESIINFEKL by isolated 
microsomes. 
Synthetic ESIINFEKL was incubated with with 1 OD280 unit of B6.Kb microsomes with the indicated 
additions. Microsomes were then extracted and the amount of SIINFEKL was determined by the 
B3Z activation assay. Results were calculated as the mean value obtained in two independent 
experiments. 
 
PNT alone was sufficient to sustain the block. Surprisingly however, in the 
presence of bestatin alone, there was a significant augmentation in the yield of 
SIINFEKL. These results propose that at least two types of peptidases influence 
the fate of ESIINFEKL: a bestatin-sensitive peptidase that had a deleterious effect 
and a PNTsensitive "trimmase“ that converted ESIINFEKL to SIINFEKL. The 
PNT-mediated inhibition was not due to inhibition of peptide transport into the ER 
because the compound even slightly stimulated TAP-mediated peptide transport 
(data not shown). Although the processing of ESIINFEKL was dependent on TAP 
transport and was class I-specific it was still possible that peptidases operating at 
the cytoplasmic leaflet of the microsomes initially converted ESIINFEKL to 
SIINFEKL and that only subsequent transport into the ER lumen and binding to 
the correct class I molecule prevented further degradation of the peptide epitope. 
While the ultimate proof for lumenal localization of the trimming aminopeptidase 
would have been resistance to proteolysis, this approach could not have been 
applied, as treatment of microsomes with trypsin, for example, would have also 
digested TAP and prevented peptide transport. Thus, to establish the localization 
of the ESIINFEKL to SIINFEKL converting enzyme, we attempted to remove the 
external peptidases. To this end the microsomes were washed with 15 mM EDTA 
and 500 mM KCl. This washing procedure removed over 60% of the proteins 
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associated with the microsomes (data not shown) and should have removed 
almost entirely any peptidase activity associated with the outer face of the 
microsomes. 
 
 
Figure  2.8.5 Inhibition of peptidase activity by 1, 10-phenanthroline (PNT). 
(A) Synthetic SIINFEKL was incubated in the absence of ATP, and (B) synthetic ESIINFEKL was 
incubated in the presence of ATP with B6.Kb microsomes and with the indicated concentrations of 
PNT. Microsomes were then extracted and the amount of SIINFEKL was determined by the B3Z 
activation assay. (C) Quantification of the inhibition of peptidase activity. The percent inhibition of 
the external peptidase activity (squares) was calculated according to the following formula: 
( ) ( )[ ]
( ) ( )[ ]microsomeswithSIINFEKLmicrosomeswithoutSIINFEKL
PNTplusmicrosomeswithSIINFEKLmicrosomeswithoutSIINFEKL
−
×− 100
 
The percent inhibition of ESIINFEKL processing (triangles) was calculated as the ratio between the 
activity observed in the absence of PNT relative to that observed in the presence of the inhibitor 
after subtraction of the activity measured in the absence of microsomes in each case. The results 
were calculated as the mean of the values obtained in two independent experiments. 
 
As shown in Figure  2.8.5, when synthetic SIINFEKL was incubated with the 
washed microsomes in the absence of ATP (i.e. when TAP transport was blocked) 
there was only a small reduction in the amount of SIINFEKL relative to the input 
level obtained in the control incubation with buffer alone (Figure  2.8.5 left and next 
to the left columns). Low and intermediate PNT concentrations (50-200 µM) were 
sufficient to restore the input level of SIINFEKL indicating that the remaining 
peptidase activity on the cytosolic face was completely inhibited (Figure  2.8.5 A 
and C). However, when ESIINFEKL was incubated with the washed microsomes 
in the presence of ATP, the conversion of ESIINFEKL to SIINFEKL was 
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significantly inhibited only at higher PNT concentrations (Figure  2.8.5 B and C). 
These results demonstrate that under conditions where the activity of the 
peptidase on the external surface of the microsomes was completely inhibited, 
there was an additional PNT-sensitive activity that became only apparent in the 
presence of ATP (see also Figure  2.8.4). We conclude that an ER-lumenal 
metallopeptidase contributes to the conversion of ESIINFEKL to SIINFEKL. 
 
2.8.5 Discussion 
In this work we have reconstituted in vitro the entire antigen processing pathway, 
from proteolysis of the antigen by the 26S proteasome to the binding of the final 
epitope to the specific MHC class I molecule in the ER. This cell-free system that 
is comprised of the 26S proteasome, a protein antigen, cytosol and isolated 
microsomes enables the analysis of the relative contribution of the proteasome, 
cytosolic and microsomal peptidases to the generation of the definite epitope. The 
major impediment for the analysis of the mechanism of the 26S proteasome in 
antigen processing lies in the difficulty to produce large enough ubiquitinated 
protein antigen for in vitro processing experiments to allow mass spectrometrical 
analysis of the cleavage products. We have overcome this crucial problem by 
targeting the protein antigen to the 26S proteasome through the ubiquitin-
independent mechanism employed by ODC [31, 59]. By varying the amino acid 
residues immediately N-terminal to SIINFEKL we were able to generate an ODC-
ova derivative ODC-LEova that was degraded at a similar rate by the 26S 
proteasome, however, the proteolytic processing resulted in a significant reduction 
in the abundance of SIINFEKL (see Figure  2.8.1 and Table  2.8.1). The fact that 
ESIINFEKL, the dominant extended SIINFEKL, was a poor activator of B3Z T cells 
allowed us to follow for the first time post-proteasomal processing activity in a 
physiologically relevant fully reconstituted cell-free system. Consistent with our 
previous results [59], we found by mass-spectrometrical quantification that the 
26S proteasome efficiently liberates the SIINFEKL peptide from the ODC 
sequence context (...WQLMKQIQSH-SIINFEKL-SHGFPPEVEE...) while the N-
terminal extended peptides HSIINFEKL and QSHSIINFEKL were only minor 
products. When introducing the extended epitope LESIINFEKL into the same 
ODC sequence context, the predominant cleavage now occurred between the N-
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terminal Leu and Glu residues which is in full agreement with the cleavage 
specificities of both the 20S and the 26S human proteasome assayed on the 
model proteins enolase and β-casein, respectively [39, 41]. The 26S-processed 
SIINFEKL is efficiently delivered into the ER lumen despite losses that are due to 
the activity of peptidases co-purifying with ER membranes. The cytosolic origin of 
the SIINFEKL degrading peptidases is suggested by the finding that addition of 
cytosol led to further degradation (see Figure  2.8.2 A). Nevertheless, the 
significant proportion of SIINFEKL that was retained in the microsomes suggested 
that the TAP-mediated translocation of peptide occurred at a higher rate. Three 
cytosolic peptidases have thus far been implicated in the trimming of N-terminally 
extended peptide epitope precursors to their final size. Rock and co-workers have 
shown that a bestatin-sensitive leucine aminopeptidase can cleave SIINFEKL 
precursors to generate the final 8-mer [43, 44]. In a recent study, puromycin-
sensitive aminopeptidase and bleomycine hydrolase have been implicated in the 
N-terminal trimming of a VSV nucleoprotein-derived epitope precursor [45]. These 
observations indicate that individual peptidases contribute to limited N-terminal 
trimming of epitope precursors. Nevertheless, the cumulative effect of cytosolic 
peptidases on SIINFEKL and its precursors seems to be deleterious. This can be 
concluded from our finding that addition of cytosol to the antigen processing 
reaction caused a major reduction in the amount of SIINFEKL retained in the ER 
(see Figure  2.8.2). In other experiments not presented in this study we found that 
cytosol completely destroyed 26S proteasome-processed peptides in the absence 
of microsomes, and that this degradation could not be inhibited by bestatin. The 
stimulatory effect of bestatin on the yield of SIINFEKL in the absence of cytosol 
(see Figure  2.8.4) likely resulted from inhibition of a particular membrane-
associated peptidase(s). This also suggested that the bestatin-sensitive peptidase 
acted prior to TAP transport and thus limited the availability of peptide substrates. 
López and co-workers have recently provided evidence for a PNT-sensitive 
cytosolic aminopeptidase activity [28]. When the metallopeptidase inhibitor PNT 
was administered to cells infected with recombinant vaccinia virus expressing an 
HIV env epitope either in the context of the natural HIV envelope protein or of a 
recombinant HBV core protein, the authors noticed efficient blockade of antigen 
presentation. However, the processing of another recombinant HBc construct or a 
long epitope precursor targeted to the ER in a TAP-independent manner was not 
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affected by PNT suggesting that a PNT-sensitive peptidase was operative prior to 
TAP transport. We have also identified a PNT-sensitive peptidase associated with 
the external leaflet of the microsomal membranes. However, in addition we show 
that a distinct PNT-sensitive peptidase is operative in the lumen of the ER and 
that this lumenal peptidase is involved in the final processing of 26S proteasome 
processed peptides subsequent to introduction into the ER by TAP. This follows 
from our observation that the final epitope SIINFEKL was generated by EDTA/salt-
stripped microsomes from ESIINFEKL when the activity of the external peptidase 
was inhibited and when peptide translocation was facilitated (see Figure  2.8.5). 
The presence of H2-Kb was strictly required to convert ESIINFEKL to SIINFEKL 
whereas only background levels could be recovered from H2-Db- or H2-Kd/Dd- 
expressing microsomes (Figure  2.8.2 B, C and Figure  2.8.3). This would invoke a 
model according to which N-terminal trimming is initiated by binding of the 
precursor peptide to the appropriate class I receptor followed by recruitment of the 
aminopeptidase to the class I/peptide complex as originally proposed by 
Rammensee and co-workers [51]. In this model, the class I molecules would 
prevent N-terminal trimming beyond the optimal peptide length. Earlier work has 
provided evidence that selected peptides could only be extracted from tissues 
expressing class I molecules able to associate with these peptides [66]. 
Furthermore, it has been shown that antigenic peptides that are not retained in the 
ER undergo retrotranslocation to the cytosol for degradation [13- 15, 58]. The 
herein presented findings that SIINFEKL processed from ODC-ova was 
undetectable in reactions containing H2-Db- but not H2-Kb-expressing B6 
microsomes (Figure  2.8.2 A), or H2-Kd-expressing BALB/c microsomes 
(unpublished result) are fully consistent with the idea that class I molecules retain 
and protect TAP-translocated peptides. Recently, Shastri and colleagues 
demonstrated the efficient conversion of an N-terminally extended SIINFEKL 
derivative in H2-Kb- but not H2-Kd-expressing cells [47]. We have shown that in a 
cell-free system the presence of H2-Kb is essential for the recovery of SIINFEKL 
following processing of ESIINFEKL by a microsomal metallo-aminopeptidase. 
However, we cannot conclusively decide whether binding of the precursor peptide 
to the correct restriction element is strictly required for the initiation of the 
processing, or whether class I molecules merely capture partially digested 
peptides released from slowly acting luminal aminopeptidases in a random 
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process and protect them from further degradation. Additional work is required to 
distinguish between these two potential mechanisms. Furthermore, the general 
role of this aminopeptidase will have to be dissected using additional protein 
antigens. 
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2.9 An essential role for tripeptidyl peptidase in the 
generation of an MHC class I epitope 
The author of this dissertation, Toni Weinschenk, contributed the analysis of the 
major cleavage products generated by 26S proteasomes from the Nef-ODC-OVA 
fusion protein by liquid-capillary mass spectrometry, shown in Figure  2.9.1b, to 
this work. 
 
2.9.1 Summary 
Most of the peptides presented by major histocompatibility complex (MHC) class I 
molecules require processing by proteasomes. Tripeptidyl peptidase II (TPPII), an 
aminopeptidase with endoproteolytic activity, may also have a role in antigen 
processing. Here, we analyzed the processing and presentation of the 
immunodominant human immunodeficiency virus epitope HIV-Nef (73-82) in 
human dendritic cells. We found that inhibition of proteasome activity did not 
impair Nef (73-82) epitope presentation. In contrast, specific inhibition of TPPII led 
to a reduction of Nef (73-82) epitope presentation. We propose that TPPII can act 
in combination with or independent of the proteasome system and can generate 
epitopes that evade generation by the proteasome-system. 
 
2.9.2 Introduction 
The ability of an organism to eliminate viral infections relies largely on its capacity 
to generate peptides from viral antigens, which, in the context of major 
histocompatibility complex (MHC) class I molecules, can be presented on the cell 
surface to CD8+ cytotoxic T lymphocytes (CTLs). To allow binding to MHC 
molecules, intracellular proteins must be processed to smaller fragments, which 
are translocated by TAP (transporter associated with antigen processing) into the 
endoplasmic reticulum (ER). Finally, peptides of 8-11 residues in length, called 
epitopes, containing an appropriate binding motif bind to MHC class I molecules 
for transportation to the cell surface1-5. Most peptides that bind to MHC class I 
molecules are generated from cellular proteins by the 26S ubiquitin-proteasome 
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system, the major proteolytic machinery in the cytosol5. Its proteolytic activity is 
exerted by the 20S core proteasome1,3 by three of the seven β-subunits in the two 
inner rings of the four-ring particle. The 20S core proteasomes are usually found 
associated with a 19S regulatory complex that binds to the outer α-rings of the 
20S core to form the 26S proteasome. This complex is responsible for the binding 
of ubiquitin-tagged substrates and transportation of the substrates into the 20S 
core complex for processing. Stimulation of cells with interferon (IFN)-γ results in 
an exchange of the catalytic subunits, the formation of so-called 
immunoproteasomes and an adaptation of the proteasome to the specific 
requirements of an enhanced cellular immune response1,3,5. Apart from its ability 
to generate peptides of the appropriate length, the central role of the proteasome 
in the antiviral CD8+ T cell-dependent immune response is largely based on its 
intrinsic ability to efficiently generate the C-terminal anchor residue of an epitope, 
which allows its proper binding to the peptide binding groove of the MHC class I 
protein1,3,5. Many epitopes are generated as precursor peptides that carry the 
correct C terminus and an N-terminal extension of several residues3,6-8. These 
epitope precursor peptides require N-terminal trimming by aminopeptidases either 
in the ER9-12 or in the cytosol13,14. MHC class I-associated epitope generation from 
the Nef protein encoded by human immunodeficiency virus 1 (HIV-1 Nef) has 
been extensively studied, as this protein may be a good target for vaccination 
against AIDS. The Nef protein is expressed early and its processed MHC class I 
epitopes are recognized by CD8+ T lymphocytes on the cell surface before 
structural proteins are synthesized. Thus, infected cells could potentially be lysed 
and viral replication inhibited before virus release. The proteasome is known to 
produce a substantial number of MHC class I-restricted epitopes from HIV-1 Nef 
in the context of different HLA haplotypes15,16. However, production of the HIV Nef 
epitope from amino acids 73-81 (HIV Nef (73-82)) that is restricted to both HLA-
A*03 and HLA-A*11 (HLA-A*03/A*11) appeared to be insensitive to proteasome 
inhibition16. In agreement with this, it had been suggested that epitopes carrying a 
lysine residue at its C terminus, as is the case for HIV Nef (73-82), may be 
generated by proteasomes with strongly reduced efficiency17. These data 
indicated that there may be additional proteolytic pathways that are involved in the 
cytosolic processing of MHC class I epitopes. A protease that was previously 
suggested to also have a role in MHC class I antigen processing is the cytosolic 
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subtilisin-like tripeptidyl peptidase II (TPPII)18,19. Due to its aminopeptidase 
activity, TPPII was suggested to function as a post-proteasomal trimpeptidase for 
epitope precursor molecules20. In addition to its exo-peptidase activity, TPPII also 
exhibits endo-proteolytic cleavage properties and it is able to cleave after lysine 
residues19. Thus, TPPII may be a candidate protease for the generation of those 
epitopes that cannot be produced by the proteasome. We undertook these studies 
to identify the proteases that were essential for the generation of the HLA-
A*03/A*11-restricted HIV Nef (73-82) epitope (QVPLRPMTYK) in human dendritic 
cells (DCs) expressing the full-length Nef protein. DCs are probable ports of entry 
for HIV during mucosal infection, which is the most frequent transmission mode, 
and they are the only antigen-presenting cells (APCs) that can stimulate naïve T 
lymphocytes (that is, at the onset of infection as well as for vaccination). Using 
biochemical and immunological approaches, we found that purified 20S or 26S 
proteasomes were unable to generate the HIV Nef (73-82) epitope in vitro from 
larger synthetic polypeptides or from an ODC-Nef fusion protein, and that specific 
inhibition of proteasomes in human DCs did not affect epitope presentation. We 
found that purified high-molecular weight TPPII generates the HIV Nef (73-82) 
epitope in vitro from a synthetic polypeptide, and that inhibition of TPPII by AAF-
CMK or by TPPII-specific small interfering RNA (siRNA) resulted in abrogation of 
epitope presentation in vivo. We propose that TPPII can work in combination with 
the proteasome or independent of the proteasome system to generate a subset of 
those epitopes that evade generation by the proteasome. 
 
2.9.3 Materials and methods 
Cells  
DCs, Josk-M, T2 (TAP-deficient), T2-217 (T2 + immunoproteasome subunits33) 
and EBV-transformed lymphoblastoid cells were maintained in RPMI-1640 with 
10% fetal calf serum (FCS). Nef (73-82)-specific CD8+ T cell lines were generated 
from HIV+ individuals from cohort studies established with approval of Cochin 
Hospital’s ethics committee as described34. DCs were differentiated from 
elutriated monocytes cultured for 7 d in the presence of GM-CSF and IL-434.  
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Antigen presentation assays 
HLA-*02+ and HLA-A*03+ DCs were infected with recombinant Copenhagen 
Vaccinia viruses encoding HIV-1 Lai nef or pol (VV.TG.1147 or 3167, Transgène, 
5 plaque forming units (PFU) per cell, 5% FCS), or incubated with peptides 
overnight, then washed and assessed for viability. DCs were incubated with the 
CD8+ T cell lines and assayed for intracellular IFN-γ production in CD3+CD8+ 
lymphocytes by flow cytometry as described34. 
 
Peptides, Nef-ODC fusion protein and inhibitors 
The peptides EEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGL (HIV Lai 
Nef amino acids 64-100), PVTPQVPLRPMTYKAAVDL (Nef amino acids 69-87) 
and QVPLRPMTYK (Nef amino acids 73-82) were synthesized using standard 
Fmoc methodology on an Applied Biosystems (Norwalk, CT) 433A automated 
synthesizer at >90% purity by the peptide synthesis group of the Institute of 
Biochemistry-Charité. The peptide ILKEPVHGV (RT 476-484) was obtained from 
Neosystem (Strasbourg, France). Expression and purification of Nef-ODC-OVA 
and purification of the maltose binding protein-antizyme (MBP-AZ) were 
performed as described22. Protease inhibitors were epoxomicin (added at 10 µM 
30 min before infection, then diluted to 2 µM; Alexis, Grünberg, Germany), and 
MG 132, bestatin, E64, AAFCMK (Sigma, Taufkirchen, Germany), ALLM, LLnL 
(Calbiochem, Schwalbach, Germany) and butabindide26 (added 30 min after 
vaccinia infection). The fluorogenic calpain substrate II (Calbiochem) and the L-
leucine p-nitroanilide substrate (Sigma) were used as controls to check for 
enzyme inhibitor activities in human DCs. 
 
Proteasome isolation  
The 20S and 26S proteasomes were essentially purified as described22,35. The 
20S constitutive proteasomes were isolated from Josk-M and T2 (TAPdeficient) 
cells, and 20S immunoproteasomes were isolated from T2-217 (T2 + 
immunoproteasome subunits33) cells and from Josk-M cells stimulated for 72 h 
with 200 U/ml IFN-γ. The 26S proteasomes were purified from human red blood 
cells.  
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TPPII purification 
TPPII was purified from human erythrocytes at 4°C. The 100,000g supernatant 
obtained from washed and lysed erythrocytes was mixed with 100 g DEAE-
Cellulose SERVACEL (SERVA, Heidelberg, Germany) in TEAD buffer (20 mM 
Tris/HCL (pH 7. 5), 1 mM EDTA, 1 mM NaN3, 1 mM Dithioerythrit). After washing 
with TEAD, bound proteins were eluted with 500 mM NaCl in TEAD, then further 
fractionated by ammonium sulfate. Proteins precipitating between 35% and 70% 
saturation were pelleted at 15,000g, resuspended, dialyzed against TEAD and 
applied to a DEAE-Sephacel-column in 50 mM NaCl, TEAD. Proteins were eluted 
with a linear gradient of 50-500 mM NaCl, TEAD. Fractions containing H-AAF-
MCA hydrolyzing activity were pooled. Residual proteasomes were removed by 
affinity chromatography with monoclonal antibody mcp2136. Unbound TPPII 
exhibiting H-AAFMCA hydrolyzing activity inhibited by H-AAF-CMK was further 
purified by successive chromatography on MonoQ, arginine-Sepharose 4B and 
Superose 6B. All columns were equilibrated in 20 mM HEPES (pH 7.2), 15% 
glycerol and 1 mM ATP. TPPII was eluted from Mono Q and arginine-Sepharose 
columns with linear increasing gradients (0-400 mM NaCl in HEPES, ATP, 
glycerol). The purity of TPPII was checked by SDS-PAGE combined with 
immunoblot analysis using polyclonal chicken anti-(human TPPII) Ig 
(Immunsystem, Uppsala, Sweden). In some preparations minor amounts of 
spectrin (major erythrocyte component) and α-actin copurified as judged by mass 
spectrometric sequencing (MS/MS) analysis. TPPII activity was confirmed by 
digestion of fluorogenic peptide substrate and its complete inhibition by 
butabindide. TPPII activity was insensitive to the proteasome inhibitor N-acetyl-L-
leucinyl-L-leucinal-L-norleucinal (LLnL). 
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Peptide digestion and mass spectrometry 
Nef (64-100) polypeptide (20 µg) and 20S proteasomes (2 µg) were incubated in 
300 µl assay buffer (20 mM HEPES/KOH, pH 7.8, 2 mM MgAc2, 1 mM 
dithiothreitol) at 37°C for different times. Nef-ODC-OVA fusion protein was 
incubated with 26S proteasome22. Nef (64-100) and Nef (69-87) (10 µg) were 
incubated with 100 ng or 1 µg TPPII in 50 µl assay buffer and incubated for 3, 24 
and 48 h at 37°C in the presence of the proteasome inhibitor LLnL. TPPII-
dependent processing was sensitive to butabindide. Reversed-phase 
chromatography and mass spectrometric (MS) analyses performed online with an 
ion trap mass spectrometer (LCQ, Thermo-Finnigan, Engelsbach, Germany) 
equipped with an electrospray ion source were performed as described35. 
Peptides were identified by tandem mass spectrometry experiments. Cleavage 
products from the Nef- ODC-OVA fusion protein were analyzed as described28. 
 
siRNAs and electroporation 
We synthesized 21-nucleotide interfering RNA duplexes with two 3’ end overhang 
dT nucleotides in the antisense strand. The sequences of the antisense strands of 
the siRNAs targeting TPPII were 5’- GUGGCGAUGUGAAUACUGCdTdT-3’, and 
the control scrambled oligoribonucleotide scrambled-siRNA was 5’-
UGUAUAGGUGUG GGCACACdTdT-3’ (Eurogentec, Seraing, Belgium). TPPII 
expression was decreased in transfected HeLa cells in fluorogenic substrate 
digestion assays and in immunoblots. Transfection used an ECM 830 square 
wave electroporation system (BTX, San Diego, CA). Briefly, 4 × 105 EBV-
transformed lymphoblastic cells were washed twice in PBS and placed in 4-mm 
gap cuvettes in the presence of oligonucleotides, subjected to 5 cycles of 20 V for 
10 ms separated by 500-ms gaps in electroporation buffer (120 mM KCl, 0.15 mM 
CaCl2, 10 mM K2HPO4/KH2PO4, 25 mM HEPES, 2 mM EGTA, 5 mM MgCl2, 50 
mM glutathione, 2 mM ATP, pH 7.6). Cells were washed again and transferred to 
culture medium for 48 h before incubating with Vaccinia viruses and performing 
antigen presentation assays. 
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2.9.4 Results 
2.9.4.1 HIV-1 Nef (73-83) is not generated by proteasomes 
The HIV-1 Nef (73-82) epitope is an immunodominant CTL epitope recognized in 
60% of infected patients in the context of both HLA-A*03 and HLA-A*11 MHC 
molecules16,21. To study the proteasome-mediated generation of this peptide, we 
digested a synthetic polypeptide derived from the Nef central immunodominant 
region (Nef amino acids 64-100) with 20S proteasomes in vitro. Independent of 
whether standard proteasomes or immunoproteasomes were used, we failed to 
generate the correct C terminus of the HLA-A*03-restricted Nef (73-82) epitope. In 
agreement with previous observations16, we identified a dominant cleavage at 
residue Nef-Y81 that destroyed this major HLA-A*03 epitope. Dominant cleavages 
were also observed at residues Nef-F68, Nef-A84 and Nef-L87 within the two 
flanking regions of the epitope (Figure  2.9.1). 
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Figure  2.9.1 Proteasomes do not generate the HLA-A*03/A*11-restricted HIV-1 Nef (73-82) 
epitope, but TPPII does. 
(a) Major cleavage products generated by 20S proteasomes from the Nef (64-100) polypeptide. (b) 
Major cleavage products generated by 26S proteasomes from the Nef-ODC-OVA fusion protein. (c) 
Major fragments generated by TPPII from the Nef (64-100) polypeptide. (d) Fragments generated 
by TPPII from a synthetic Nef (69-87) polypeptide. In both experiments, fragments directly flanking 
the epitope were identified. Dotted arrows mark fragments that are the result of a tripeptidyl 
trimming reaction. Solid arrows mark major cleavage sites. Dotted lines underline the location of the 
Nef (73-82) epitope. 
 
To exclude that the inability to generate the epitope was due to the use of 20S 
proteasome that is not the enzyme involved in antigen processing in vivo, we took 
advantage of the ornithine decarboxylase (ODC) system, which allows the 
ubiquitin-independent degradation of an ODC-fusion protein by 26S proteasomes 
in the presence of a chaperoning protein called antizyme22. Therefore, we 
constructed an ODC-Nef fusion protein containing the ovalbumin (OVA) epitope 
SIINFEKL as an internal control for antigen processing activity (Nef-ODC-OVA)22. 
Recombinant Nef-ODC-OVA was degraded in vitro by the 26S proteasome in the 
presence of recombinant antizyme, allowing the analysis of the degradation 
products of full-length Nef in a physiologically relevant system22. Although 26S 
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proteasomes produced the OVA epitope, they failed to produce the Nef (73-82) 
epitope or a peptide carrying the correct C-terminal residue (Figure  2.9.1). The 
26S proteasome degradation products also included the longer peptides Nef (69-
84) and Nef (69-87), suggesting that these longer peptides were authentic Nef 
processing products. Thus, two different experimental approaches, which used 
either the 20S core complex in combination with a Nef (64-100) polypeptide or the 
26S proteasomes in the context of an ODC-Nef fusion protein, resulted in the 
generation of an almost identical peptide pattern for the Nef region analyzed, but 
did not produce the desired epitope. 
 
2.9.4.2 Nef (73-82) presentation was insensitive to epoxomicin 
To test Nef (73-82) presentation by professional APCs, we infected HLA-A*03 
human monocyte-derived DCs with the recombinant Vaccinia virus Vac-Nef, or as 
a control with Vac-RT, to induce the synthesis of HIV-1 Nef and reverse 
transcriptase, respectively. After overnight culture, Nef (73-82)-specific CD8+ T cell 
lines derived from HIV-infected patients were added to the DCs and tested for 
intracellular production of IFN-γ. Flow cytometric measurement of the expression 
of IFN-γ in CD8+ cells allows the assay of an effector response actually mediated 
by CD8+ T cells. In accordance with the in vitro processing data that showed the 
inability of proteasomes to generate the Nef epitope, HIV-Nef (73-82) presentation 
was not inhibited by the 20S and 26S proteasome inhibitors epoxomicin or MG132 
(Figure  2.9.2 a, b).  
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Figure  2.9.2 Proteasome-independent presentation of the HLA-A*03/A*11-restricted HIV-1 
Nef (73-82) epitope in human DCs. 
DCs infected with recombinant Vaccinia viruses or incubated with peptides were cultured overnight, 
then cocultured with CD8+ T cells that were tested for intracellular IFN-γ secretion; epoxomicin was 
added at 10 µM for 30 min before Vaccinia or peptide incubation, then diluted to 2 µM. (a, b) Nef 
(73-82)-specific T cells. (c) RT (476-484)-specific CD8+ T cells, to test the same DCs as in (a) in 
parallel. (d) TAP-negative (ST-EMO37) or TAP-positive (EBV-1) HLA-A*03 B lymphoblastoid cells 
were infected or incubated with peptides overnight, then tested with Nef (73-82)-specific T cells. All 
experiments are representative of at least two experiments, except epoxomicin was tested at least 
six times at similar concentrations for Nef-specific responses. The average response percentages 
in the presence of epoxomicin compared with the noninhibited control were, for anti-Nef (73-82) 
responses, 115 ± 38% for Vac-Nef versus 115 ± 46% for Nef (73-82) (not significant). 
 
In contrast, recognition of the RT (476-484) epitope on Vac-RT infected, HLA-
A*02+, HLA-A*03+ DCs by specific T cells was completely inhibited (Figure  2.9.2 
c), as expected from its known proteasome-dependent generation23. These results 
raised the question of whether, in fact, HIV Nef (73-82) was generated by a 
cytosolic protease and therefore required transport from the cytosol into the ER by 
TAP for its presentation. We tested whether Nef (73-82) presentation after Vac-
Nef infection was dependent on the presence of TAP. Surface presentation of Nef 
(73-82) was only observed in TAP-positive, EBV-transformed lymphoblastoid cells 
demonstrating the requirement for cytosolic Nef processing (Figure  2.9.2 d). The 
observed TAP dependence of Nef (73-82) presentation indicated that processing 
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of the peptide took place in the cytosol. This result, combined with the proteasome 
inhibitor independence of Nef (73-82) presentation, suggested that the 
proteasome system is either not rate-limiting or not responsible for the generation 
of this epitope. In an attempt to identify the proteases involved in Nef-epitope 
generation, we tested various inhibitors of cytosolic proteases that were previously 
discussed to have a role in antigen presentation2,4,13,14. Treatment of DCs with 
ALLM (inhibits calpains)2, bestatin (inhibits various aminopeptidase including 
leucine amino peptidase and puromycin sensitive aminopeptidase)14 or E64 
(inhibits cysteine proteases, calpains and the exo- and endoproteolytic activities of 
bleomycin hydrolase)14 revealed no effect on Nef (73-82) presentation (Fig. 3a, b).  
 
 
Figure  2.9.3 Irreversible inhibition of HLA-A*03- Nef (73-82) presentation by the TPPII 
inhibitor AAF-CMK. 
(a, b, c) DCs were tested as in Figure  2.9.2 a. (d) AAF-CMK (2 µM) was added for 30 min, washed 
and then added again (or not) for overnight culture. All experiments are representative of at least 
two experiments, except ALLM dose response curve and bestatin were tested only once, and AAF-
CMK was tested six times at similar concentrations. The average response percentage in the 
presence of AAF-CMK compared with the noninhibited control was decreased for Vac-Nef 
compared with Nef (73-82): 32 ± 17% versus 94 ± 12% (P = 0. 01). 
 
At the concentrations used in these experiments, the inhibitors were active in 
human DCs, as ALLM and E64 inhibited fluorogenic calpain substrate II digestion, 
and bestatin inhibited L-leucine p-nitroanilide substrate digestion in vitro with cell 
extracts of inhibitor-treated DCs (data not shown). Thus, the involvement of 
186   2.9. ANTIGEN PROCESSING 
 
 
calpains2, bleomycin hydrolase14 or other cysteine proteases and leucine 
aminopeptidase13 was unlikely. 
 
2.9.4.3 Inhibition of HIV Nef (73-82) epitope presentation 
The results of the experiments described above led us to speculate that the 
cytosolic protease TPPII19,24 may be responsible for Nef (73-82) epitope 
generation. Thus, DCs were treated with the known TPPII inhibitor Ala-Ala-Phe-
chloromethylketone (AAF-CMK). Low concentrations (1 µM) of AAF-CMK inhibited 
the presentation of Nef (73-82) by 60%, and 20 µM of AAF-CMK abolished 
epitope presentation (Figure  2.9.3 c). AAF-CMK also inhibited Nef-epitope 
presentation in EBV-transformed lymphoblastoid cells, indicating that the role of 
TPPII was not restricted to DCs (data not shown). To further substantiate the role 
of TPPII and exclude that of lysosomal TPPI, which is reversibly inhibited by AAF-
CMK25, AAF-CMK was added to Vac-Nef-infected human DCs for 30 min and then 
washed away. Even this short period of AAF-CMK treatment irreversibly inhibited 
the presentation of the Nef (73-82) epitope (Figure  2.9.3 d). Thus, our data 
suggested that TPPII might be the rate-limiting cytosolic protease involved in 
generation of the Nef (73-82) epitope. We hypothesized that if TPPII was 
responsible for Nef (73-82) epitope generation, then its endoproteolytic function 
would essentially be required for liberation of the Nef (73-82) epitope from a Nef 
(73-82)- containing polypeptide substrate. 
 
2.9.4.4 Generation of the Nef (73-82) epitope by TPPII 
To test the hypothesis that TPPII is responsible for Nef (73-82) epitope 
processing, we purified high-molecular-weight TPPII complexes to homogeneity 
from human erythrocytes. The identity of TPPII was verified by mass 
spectrometry, immunoblotting with TPPII antibody and its H-Ala-Ala-Phe-MCA 
hydrolyzing activity, which was completely inhibited by the TPPII-specific inhibitor 
butabindide26. The purity of the preparations was tested by SDS-PAGE (data not 
shown). To assay the antigen processing capacity of TPPII in in vitro processing 
experiments, we used the synthetic Nef (64-100) polypeptide containing the Nef 
(73-82) epitope as substrate (Figure  2.9.1 a). The analysis of the TPPII processing 
products showed that the enzyme generated the correct Nef (73-82) epitope with 
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high efficiency (Figure  2.9.1 c). This TPPII-dependent epitope generation seemed 
to be the consequence of two endoproteolytic cleavages behind residues Nef-P72 
and Nef-K82. Thus, in contrast to the 20S and 26S proteasomes, TPPII used the 
Nef K82-A83 peptide bond at the C terminus of the Nef epitope as a preferential 
endoproteolytic cleavage site. In addition, and allowing the liberation of the correct 
epitope from the polypeptide substrate, TPPII also generated the correct N 
terminus of the epitope by cleavage after residue Nef-P72 (Figure  2.9.1 c). To 
study whether the length of the substrate influenced the efficiency of TPPII-
dependent epitope production, we used a shorter polypeptide (Nef amino acids 
P69 through L87) that was shown to be a processing intermediate of the 20S and 
26S proteasomes as substrate for TPPII processing (Figure  2.9.1 a, b). Again, 
TPPII used the C-terminal K82-A83 peptide bond as the major cleavage site 
(Figure  2.9.1 d). As evidenced by the identification of the N-terminal leaving 
fragment 69PVTP72, the generation of the correct N terminus was again the result 
of an endoproteolytic cleavage behind the Nef-P72 residue. The generation of the 
Nef (73-82) epitope by purified TPPII was impaired by butabindide, a specific 
inhibitor of TPPII, which, unlike AAF-CMK, did not permeate the cells. 
 
2.9.4.5 TPPII siRNAs inhibit Nef (73-82) presentation 
Both the inhibitor data and our in vitro processing data suggested that TPPII is 
most likely the rate-limiting cytosolic protease involved in generation of the Nef 
(73-82) epitope. To demonstrate that TPPII was indeed responsible for the 
generation of the Nef (73-82) epitope, Epstein Barr virus (EBV)-transformed 
lymphoblastoid cells were transfected with siRNAs for 48 h, then infected with 
Vac-Nef. Epitope recognition was inhibited up to 60% in a dose-dependent 
manner using the TPPII-specific siRNAs. In contrast, the scrambled control 
siRNAs had no effect on epitope presentation (Figure  2.9.4). 
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Figure  2.9.4 TPPII-specific siRNAs inhibit Nef (73-82) epitope presentation. 
EBV-1 cells were transfected with either TPPII-specific or scrambled siRNAs (scr.) for 48 h, 
infected or incubated with peptides overnight, then tested with Nef (73-82)-specific T cells. The 
experiment shown is representative of two. 
 
Our combined in vivo and in vitro data presented evidence that TPPII can be the 
rate-limiting enzyme for the generation of a MHC class I epitope with the correct C 
terminus, which could not be supplied by the proteasome. 
 
2.9.5 Discussion 
Based on the findings of proteasome cleavage characteristics, inhibitor studies, 
and in vitro and in vivo antigen processing experiments1-5, the proteasome 
seemed to be the only cellular enzyme with the capacity to generate the correct C 
termini and anchor residues of MHC class I ligands with the required efficiency. 
The involvement of other proteases in MHC class I antigen processing seemed to 
be restricted to the TAP-independent pathway6,27 or the trimming of N-terminally 
extended epitope precursor peptides11,12,14,28. Previously it was found that loading 
of HLA-A*03 binding peptides or maturation of HLA-A*03, -A*11 and –B*35 
molecules was insensitive to proteasome inhibition17. As lysine is not a preferred 
cleavage site for proteasomes, it was proposed that the frequent presence of 
lysine residues at the C terminus of HLA-A*03 epitopes may interfere with 
proteasome function17,29. Here we showed that cytosolic TPPII is essential for the 
efficient generation of the immunodominant HLA-A*03 and –A*11-restricted HIV-1 
Nef (73-82) epitope, which possesses a lysine as the C-terminal anchor residue. 
From previous work in which proteasome activity was impaired by prolonged 
treatment of cells with the proteasome inhibitor lactacystin, it was proposed that 
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TPPII may be able to perform basic proteasome functions such as, for example, 
the removal of misfolded proteins and may support cell survival19,30. The analysis 
of an OVA-derived polypeptide showed that TPPII possessed endo-proteolytic 
activity in addition to its aminopeptidase activity and that it degraded larger 
polypeptides19. In agreement with this, we found that TPPII generated an 
immunodominant HLA-A*03 restricted CTL epitope by endo-proteolytic cleavages, 
indicating that TPPII can complement or even substitute proteasome function – 
also in the context of MHC class I antigen processing. It was suggested that the 
>2,000-kDa TPPII complex, which is composed of multiple 138-kDa subunits, may 
function as a compartmentalized enzyme like the proteasome31. Although TPPII is 
a relatively abundant protein, there is very little known so far about its 
physiological function. Our analysis of HIV-Nef protein processing supports the 
concept that, under physiological conditions, TPPII functions downstream of an 
active ubiquitin-proteasome system, because TPPII was able to generate the 
HLA-A*03 HIV Nef (73-82) epitope from proteasomal Nef-protein processing 
intermediates. An efficient peptide supply is essential for MHC class I antigen 
presentation. Therefore, a cooperative action between the proteasome system 
and TPPII would guarantee that the infected cell is able to generate epitopes that 
cannot be efficiently generated by the proteasome system. Our experiments, 
however, also demonstrated that inhibition of the proteasome system had no 
effect on TPPII-dependent production of the HLA-A*03 HIV-Nef (73-82) epitope. 
This suggests that TPPII can also work in parallel to the proteasome system and 
can contribute to the MHC class I peptide pool independent of the proteasome. 
Thus, HIV Nef (73-82) is most likely not the only epitope requiring TPPII activity. 
Such an independent role of TPPII may be of importance under conditions in 
which proteasome activity is impaired as a result of viral infections or metabolic 
stress. Thus, inhibition of proteasome activity seems to up-regulate TPPII 
activity30, and it has also been shown that viral proteins like HIV-TAT can directly 
interfere with proteasome function32. These observations suggest that within the 
MHC class I antigen processing pathway, TPPII possesses a ‘housekeeping’ 
function under normal physiological conditions by taking up proteasomal 
processing intermediates, but that under conditions of physiological stress TPPII 
can also work independent of the proteasome and process protein with the help of 
chaperones or other yet to be defined protein factors. 
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Results, Part 3: Protein Identification 
2.10 A Conserved Sequence in the Mouse Variable T Cell 
Receptor α Recombination Signal Sequence 23 bp 
Spacer Can Inhibit Recombination 
 
The author of this dissertation contributed the mass spectrometrical protein 
identification to this work.  
 
2.10.1 Summary 
Although the variable gene segments coding for the TCR α and δ chains are 
mixed together in the α/δ locus and are recombined by the same machinery 
(RAG1 and RAG2) through recognition of the same signal sequences 
(Recombination Signal Sequences, RSS, with a 23 bp spacer), some gene 
fragments are rearranged only with TCR Jα gene segments (classified then as 
TRAV gene segments), some only with TCR Dδ gene segments (TRDV gene 
segments) and some with both (TRADV gene segments). No molecular signal is 
known which can characterize these three different types of gene segments. 
Studying the RSS of TCR variable gene segments we observed that 80% of the 
mouse TRAV gene segments contain a palindrome sequence (CTGCAG) or its 
related variant CTGTAG in their 23 bp spacer. Using gel shift assays we could 
show that these sequences are specifically recognized by some nuclear proteins 
expressed by fresh thymocytes, fresh lymphocytes and tumor cells. Two distinct 
complexes recognize this conserved sequence: one is specific for palindrome 
structures and one is specific for the CTGPyAG sequence. Spacers from TRDV or 
TRADV gene segments do normally not contain this sequence (only 1 in a total of 
14 contains the CTGPyAG sequence) and are not recognized by the CTGPyAG-
binding complexes. Using a plasmid substrate and the RAG1, RAG2 expressing 
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transformed pre-B cell 18.8, we could show that RSS containing the CTGCAG 
sequence are less efficiently used for recombination than RSS having no such 
sequence in their 23 bp spacer. We could identify three proteins which associate 
in vitro to a DNA sequence containing the CTGCAG motif: G3BP1, a nucleic acid 
binding protein with a proposed helicase activity and two proteins from the HMG 
family: HMGB2 (already known to participate in RAG-mediated recombination) 
and HMGB3. We hypothesize that these proteins might prevent recombination of 
the TRAV gene segments at the thymocyte CD4CD8 double negative stage when 
only TRDV and TRADV genes can recombine although the TCR α/δ locus is 
accessible to RAG proteins. 
 
2.10.2 Materials and methods 
2.10.2.1 Protein Identification 
In gel tryptic digestion was performed as described [1] and modified as outlined 
below. Briefly, the protein band was excised from the gel, fully destained, and 
digested for 3 h with porcine trypsin (sequencing grade, modified; Promega) at a 
concentration of 67 ng/µl in 25 mM ammonium bicarbonate, pH 8.1, at 37°C. Prior 
to peptide mass mapping and sequencing of tryptic fragments by tandem mass 
spectrometry, the peptide mixture was extracted from the gel by 1% formic acid 
followed by two changes of 50% methanol. The combined extracts were vacuum-
dried until only 1-2 µl were left and the peptides were purified by ZipTip according 
to the manufacturers’ instructions (Millipore, Bedford, MA, USA). MALDI-TOF 
analysis from the matrix α-cyano-4-hydroxycinnamic acid/nitrocellulose prepared 
on the target using the fast evaporation method [2] was performed on a Bruker 
Reflex III (Bruker Daltonik, Bremen, Germany) equipped with a N2 337 nm laser, 
gridless pulsed ion extraction and externally calibrated using synthetic peptides 
with known masses. The spectra were obtained in positive ionization mode at 23 
kV.  
Sequence verification of some fragments was performed by nanoelectrospray 
tandem mass spectrometry on a hybrid quadrupole orthogonal acceleration time 
of flight tandem mass spectrometer (Q-Tof, Micromass, Manchester, England) 
equipped with a nanoflow electrospray ionization source. Gold-coated glass 
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capillary nanoflow needles were obtained from Protana (Type Medium NanoES 
spray capillaries for the Micromass Q-Tof, Odense, Denmark). Database searches 
(NCBInr, non-redundant protein database) were done using the MASCOT 
software from Matrix Science [3]. 
 
2.10.3 Results 
We observed, that 80% of the mouse TRAV gene segments contain a palindrome 
sequence (CTGCAG) or its related variant CTGTAG in their 23 bp spacer. Using 
gel shift assays we could show that these sequences are specifically recognized 
by some nuclear proteins. Point mutations in but not outside the CTGPyAG 
sequence abrogated its recognition by nuclear factors. Two distinct complexes 
recognized this conserved sequence: one was specific for palindrome structures 
and one was specific for the CTGPyAG sequence. The CTGPyAG binding 
complex was present in all four thymocyte sub-populations. Using a plasmid 
substrate and the RAG1, RAG2 expressing transformed pre-B cell 18.8, we could 
show that RSS containing the CTGCAG sequence are less efficiently used for 
recombination than RSS having no such sequence in their 23 bp spacer (data for 
all the findings up to this point are not shown in this thesis). We made attempts to 
identify the proteins contained in the two CTGPyAG-binding complexes seen on 
gel shift assays. Using a two step approach where nuclear extracts were first 
enriched with CTGCAG-binding activity through the utilization of immobilized 
double stranded oligonucleotides containing this sequence and a subsequent 
FPLC separation of the oligo-attached proteins, we could unambiguously identify 
at least three proteins contained in the non-palindrome-specific complex (the 
lower band on the gel shifts). Figure  2.10.1 details the two steps of this purification 
process: the upper panel shows the profile of elution of proteins associated to 
streptavidin-agarose via biotinylated double stranded TRAV7D-3 oligonucleotides 
(in the presence of an excess of free double stranded oligonuleotide not 
containing the CTGCAG sequence: the TRAV7D-3 Mut 2 double stranded 
oligonucleotide). Each fraction from this chromatography was tested in EMSA 
where the radioactive TRAV7D-3 23 bp spacer was used as a probe and 
incubated with the FPLC fractions in the presence of an excess of an 
oligonucleotide containing a CTGCAG sequence (marked A on Figure  2.10.1 A) or 
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an excess of a TRD-V-derived RSS 23 bp spacer that does not contain a 
CTGCAG sequence (double stranded oligonucleotide representing the 23bp 
spacer from TRDV6-2 marked D on Figure  2.10.1 A). In fractions C9 to C14 the 
binding to TRAV7D-3 is competed away with a CTGCAG-containing 
oligonucleotide pair but not with an irrelevant oligonucleotide pair. This shows that 
in these fractions we detected the CTGCAG-specific complex. All fractions 
containing the protein from the lower complex were pooled (pool 1) and all 
fractions containing the palindrome-specific complex were mixed in pool 2. Each 
pool contains many different proteins (data not shown) and was consequently 
further fractionated by an FPLC system using a monoQ column. The fractions 
eluted from this column were tested again in EMSA using a radioactive TRAV7D-3 
23bp spacer double stranded oligonucleotide. All the palindrome specific activity 
from pool 2 was lost after FPLC (data not shown). On the contrary, two FPLC 
fractions from pool 1 contain the CTGCAG-binding activity. These two fractions 
were separated on a acrylamide gel (Figure  2.10.1 C) together with flanking 
fractions and we could clearly visualize four proteins on the gel especially in the 
fraction C1 which shows the strongest CTGCAG-binding activity in EMSA (Figure 
 2.10.1 B). Mass spectrometry analysis of these 4 bands showed that they 
correspond to three proteins: G3BP1 (Ras-GTPase-activating protein SH3-
domain-binding protein) present as full length (protein P1 on Figure  2.10.1 C) and 
as a sub-fragment (protein P2 on Figure  2.10.1 C) has nucleic acid-binding activity 
and a proposed helicase function, High Mobility Group protein 2 (HMGB2 
previously called HMG2, protein P4 on Figure  2.10.1 C) already known to 
participate in RAG-mediated recombination and HMGB3 (previously called 
HMG2a or HMG4, protein P3 on Figure  2.10.1 C) . While G3BP1 and HMGB2 are 
ubiquitously expressed, HMGB3 is supposed to be expressed mainly in the 
embryo but still, ESTs corresponding to HMGB3 can be found in cDNA libraries 
from adult tissues like skeletal muscle, thymus, testis and liver [4]. 
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Figure  2.10.1 Identification of the CTGPyAG-specific nuclear proteins. 
To identify the proteins that bind specifically to the CTGPyAG sequence contained in the TRAV 
RSS 23 bp spacer, a 18.8 nuclear extract was mixed with a biotinylated double stranded 
oligonucleotide that contains a CTGCAG sequence in the presence of an excess of non-specific 
competitors: double stranded oligonucleotide that is mutated for the palindrome (TRAV7D-3 Mut 2) 
and poly dI:dC DNA. Biotinylated oligonucleotides were immobilized on a streptavidin column and 
co-precipitated proteins were eluted from the column usin increasing salt concentration. Fractions 
eluted from the column were tested by EMSA for the presence of the CTGCAG-binding complex 
(upper panel) when an excess of CTGCAG containing (A) or non-containing (D) non-labelled 
oligonucleotide was added. Two pools were made by mixing together consecutive fractions which 
showed a similar profile in EMSA. Pool 2 was further fractionated using anion exchange and again 
each fraction was tested for the presence of CTGCAG-binding proteins by EMSA. The fractions that 
show binding as well as the immediate neighboring fractions were concentrated and run on a 
preparative SDS PAGE. The 4 dominant bands visualized after staining were cut out and analyzed 
by mass spectrometry. 
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2.10.4 Discussion 
From all the results in the present work, only the identified proteins are discussed 
here in this thesis. The larger (68 kDa) of the three proteins involved in CTGPyAG 
recognition, G3BP1 was first identified in human cells as a protein interacting with 
GAP (ras-GTPase-Activating Protein) which is a negative regulator of Ras[5]. 
Although no spliced variant was found for G3BP1, the related G3BP2 gene can be 
alternatively spliced in mouse cells [6]. Such a yet un-identified splicing event in 
G3BP1 pre-mRNA might generate the two G3BP1 proteins that we observed with 
an apparent mass of 68 kDa for the full length protein and of 34 kDa for the 
protein potentially encoded by the uncharacterized short splice variant. As it is the 
case for the CTGPyAG-binding complex, G3BP1 is found to be ubiquitously 
expressed but a closer analysis of mouse spleens indicated a cell specific staining 
[7]. The identity of the cells expressing or not G3BP1 in lymphoid tissues has not 
yet been determined. The two known roles of G3BP1 are its RNase activity 
(cleavage in-between C and A residues in AU rich regions at the 3’ UTR of 
unstable RNA like the c-myc RNA [8]) and its helicase capacity [9]. Besides, 
G3BP1 contains an RNA recognition motif (RRM) that also exists in other proteins 
like SSAP (Stage-Specific Activator Protein). SSAP is a sequence-specific DNA-
binding protein that recognizes DNA through its RRM domain. Interestingly, the 
DNA sequence recognized by SSAP is a specific palindrome: TTTAAA. Since 
G3BP1 contains a RRM domain, it can also be expected to bind DNA in a 
sequence specific manner. The localization and the activity of G3BP1 are 
regulated by phosphorylation of serine residues [10]: hypophosphorylated in 
dividing cells, it localizes mainly in the cytosol and interacts with GAP, 
hyperphosphorylated in quiescent cells, it is translocated in the nucleus due to its 
nuclear transport 2 (NTF2)-like domain [11] and is active as an RNA-specific 
endonuclease [10, 8]. Nevertheless, G3BP1 can be detected and purified from the 
nuclei of dividing HeLa cells [9] in which it was shown to have a helicase activity. 
The ubiquitous expression of G3BP1, its regulated localization and activity, its 
homology to the sequence specific DNA-binding SSAP as well as its DNA helicase 
activity fit with the experimental and expected characteristics of the proteins 
contained in the CTGPyAG-binding complex. Further experiments will be required 
to precisely characterize the role of G3BP1 in TCR-alpha recombination and the 
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engineering of G3BP1 knock out mice might allow us to get more insights into the 
role of the CTGPyAG sequence in TCR recombination. The two proteins that are 
found in the CTGPyAG-binding complex on top of G3BP1 are from the High 
mobililty group proteins B (HMGB): HMGB2 and HMGB3. Proteins of the HMGB 
family [12] have acidic tails that allow them to bind DNA in the minor groove and in 
a structure- rather than sequence-dependent manner [13]. In humans, HMGB3 
(previously called HMG4 or HMG2a) is expressed during embryonic development 
and is found to be expressed in adult placenta and skeletal muscles [14] (thymus 
was not examined in that study). Since ESTs coding for HMGB3 are found in a 
library made from adult thymus (as well as from cDNA libraries made from adult 
testis and liver), the protein must be expressed also in this organ [4]. The fine 
tuning of the HMGB3 protein expression suggests that it may be a key player in 
the regulatory role of the CTGPyAG-binding complex on TRAV gene segments 
recombination. The smallest identified band corresponds to HMGB2 (previously 
called HMG2). Numerous evidences have indicated that this abundant and 
ubiquitous protein participates in RAG-mediated recombination together with 
HMGB1 (previously called HMG1). These two proteins improve RAG-mediated 
cleavages of DNA especially at a 23bp RSS through both enhancement of the 
bending of the DNA and stabilization of the RAG1-RAG2-RSS complex [15, 16, 
17]. HMGB2-deficient mice are viable but have a defect in sperm development 
[18]. They have a normal thymus and normal numbers of T and B cells. A detailed 
study of the TRAV genes expressed by peripheral T cells would have to be done 
in order to eventually identify deregulation in the identity of TRAV, TRDV or 
TRADV gene segments that would fit with our identification of HMG2B as part of 
the CTGPyAG-binding complex. As hypothesized for the RAG machinery, HMG 
proteins might stabilize the DNA-specific recognition of the CTGPyAG sequence 
by G3BP1. Besides, as suggested above, the regulation of HMG2B expression 
may account for stage specific activity of the CTGPyAG-binding complex. A fine 
study of G3BP1 and HMG2B gene expression in purified thymocytes 
subpopulations using real time quantitative PCR should also help in the 
characterization of the involvement of these proteins in the TRAV genes 
rearrangement.  
Besides G3BP1, HMGB2 and HMGB3 that are contained in the CTGPyAG-
specific binding complex, some other proteins contained in the palindrome specific 
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complex (pool 2 in Figure  2.10.1) might be involved in the regulation of TRAV 
recombination through recognition of the 23bp spacer. Using one step purification 
of the CTGCAG-binding protein by fishing with oligonucleotides, many proteins 
could be identified on a SDS PAGE gel (not shown). Some might be non-specific 
DNA binding proteins (although we used an excess of non specific DNA 
oligonucleotide that does not contain the CTGCAG sequence during the 
purification) but some might be part of the palindrome-specific complex that is lost 
during anion exchange HPLC. Interestingly, with such one step preparation we 
could visualize on a preparative SDS PAGE a strong band at a size of 95 kDa 
which contained both NP95, a potential DNA binding protein, and nucleolin which 
is a DNA Helicase [9]. More investigations are necessary to confirm the presence 
of these proteins in the palindrome-specific complex. 
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2.10.6 Abbreviations 
TCR  T cell receptor 
RSS  recombination signal sequences 
TRAV variable gene segments coding for the TCR α and δ chains which 
are rearranged only with TCR Jα gene segments 
TRDV  variable gene segments coding for the TCR α and δ chains which 
are rearranged only with TCR Dδ gene segments 
TRADV variable gene segments coding for the TCR α and δ chains which 
are rearranged with both, TCR Jα and TCR Dδ gene segments 
FPLC fast performance liquid chromatography 
EMSA  electrophoretic mobility shift assay 
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2.11 Systematic evolution of a DNA aptamer binding to 
rat brain tumor microvessels: selective targeting of 
endothelial regulatory protein pigpen 
The author of this dissertation contributed to this work by identifying the protein 
binding to the aptamer. 
 
2.11.1 Summary 
Tumor microvessels differ in structure and metabolic function from normal 
vasculature, and neoangiogenesis is associated with quantitative and qualitative 
changes in expression of endothelial proteins. Such molecules could serve as 
molecular addresses differentiating the tumor vasculature from those of the 
normal brain. We have applied Systematic Evolution of Ligands by EXponential 
enrichment (SELEX) against transformed endothelial cells as a complex target to 
select single-stranded DNA-ligands (aptamers) that function as histological 
markers to detect microvessels of rat experimental glioma, a fatal brain tumor that 
is highly vascularized. Both the SELEX selection procedure as well as subsequent 
deconvolution-SELEX were analyzed by fluorescence based methods (flow 
cytometry and fluorescence microscopy). Of 25 aptamers analyzed, one aptamer 
was selected that selectively bound microvessels of rat brain glioblastoma but not 
the vasculature of the normal rat brain including peritumoral areas. The molecular 
target protein of aptamer III.1 was isolated from endothelial cells by ligand-
mediated magnetic DNA affinity purification. This protein was identified by mass 
spectrometry as rat homologue of mouse pigpen, a not widely known endothelial 
protein the expression of which parallels the transition from quiescent to 
angiogenic phenotypes in vitro. Because neoangiogenesis, the formation of new 
blood vessels, is a key feature of tumor development, the presented aptamer can 
be used as a probe to analyze pathological angiogenesis of glioblastoma. The 
presented data show that pigpen is highly expressed in tumor microvessels of 
experimental rat brain glioblastoma and may play an important role in warranting 
blood supply, thus growth of brain tumors.  
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2.11.2 Introduction 
Systematic Evolution of Ligands by EXponential enrichment (SELEX) is a nucleic 
acid based combinatorial chemistry procedure that has been used to isolate 
relatively short high affinity ssDNA or RNA ligands, termed aptamers, to a wide 
variety of protein or low molecular weight compounds [14, 15]. Single-stranded 
nucleic acids, which can fold into very small and complex three-dimensional 
shapes with a great diversity of binding specificities, are isolated from a large pool 
of random sequence molecules (1014-1015 sequences) by reiterative rounds of 
selection and amplification [reviewed in 16]. Here we describe a fluorescence-
based SELEX procedure. Using transformed EC as a complex target allowed 
systematic evolution of fluorescence-labeled oligonucleotides and subsequent in 
situ deconvolution-SELEX by flow cytometry and fluorescence microscopy on 
cryostat tissue sections (Figure  2.11.1). Finally aptamers were generated that 
function as a histological marker to selectively stain microvessels of experimental 
rat glioblastoma, a brain tumor that is highly vascularized [17]. We present 
aptamer III.1, a ssDNA-ligand binding to pigpen, a not widely known endothelial 
protein of the Ewing’s sarcoma family that parallels the transition from quiescent to 
angiogenic phenotypes in vitro [18]. 
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Figure  2.11.1 Selection procedure for the generation of DNA aptamers binding to angiogenic 
microvessels of rat experimental glioma. 
(i), counterselection against N9 microglial cells (to reduce co-selection of aptamers binding to other 
cell types). (ii), incubation of successive SELEX pools with YPEN-1 endothelial cells. (iii), removal 
of unbound sequences. (iv), PCR amplification of cell-bound aptamers using modified primers. (v), 
FITC-ssDNA generation. (vi), PCR amplification using unmodified primers for (vii) sorting round 8 
pool aptamers into individual clones. (viii), deconvolution-SELEX (step 1) of cloned aptamers as a 
preselection to evaluate aptamers binding to endothelial cells. (ix), deconvolution-SELEX (step 2) to 
evaluate preselected aptamers selectivity against tumor microvessels embedded in their natural 
surrounding on tissue sections of rat brain glioblastoma.  
 
2.11.3 Materials and Methods 
2.11.3.1 Ligand Mediated Protein Purification 
1 mg (100 ml) of magnetic streptavidin beads were coated with 200 pmol of trB 
aptamer III.1 (MWG-Biotech AG) by incubation in 1 ml selection buffer (30 min, 
room temperature). As a control, 100 ml of magnetic beads were coated with 200 
pmol of unselected FITC-ssDNA (trB-96-nt). 1.5 x 108 Ypen-1 endothelial cells 
were lysed in the presence of protease inhibitors as described [27]. After 
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centrifugation, the protein pellet was resuspended in 400 ml of selection buffer, 
treated by ultra-sonication (0°C, 20 s), and incubated with aptamer III.1-coated 
magnetic beads in the presence of a 100-fold excess of tRNA (20 nmol) as an 
unspecific competitor in selection buffer (total volume 1.5 ml, 0°C, 15 min). The 
protein-aptamer-magnetic bead-complex was removed in a magnet stand and 
washed four times (first wash: 1 ml of selection buffer with 150 mM NaCl; second 
through fifth wash: 200 ml of selection buffer with 100 mM NaCl with 2 nmol 
tRNA). Protein is removed from aptamer-coated beads by incubation in 30 ml of 1 
M NaCl (0°C, 30 min) and analyzed by polyacrylamide gel electrophoresis after 
staining with Coomassie Blue. 
 
2.11.3.2 Protein Identification 
In gel tryptic digestion was performed as described [28] and modified as outlined 
below. Briefly, the protein band was excised from the gel, fully destained, and 
digested for 3 h with porcine trypsin (sequencing grade, modified; Promega) at a 
concentration of 67 ng/ml in 25 mM ammonium bicarbonate, pH 8.1, at 37°C. Prior 
to peptide mass mapping and sequencing of tryptic fragments by tandem mass 
spectrometry, the peptide mixture was extracted from the gel by two changes of 
50% trifluoroacetic acid/50% water followed by two changes of 50% trifluoroacetic 
acid/50% acetonitrile. The combined extracts were vacuum-dried. The dried 
peptides were redissolved in 0.1% trifluoroacetic acid and purified using a ready-
to-go pipette tip filled with C18 spherical silica reverse phase material 
(ZipTipC18™, Millipore). Peptides were eluted with 10 ml of 50% methanol/1% 
formic acid, and sequencing was performed by nanoelectrospray tandem mass 
spectrometry on a hybrid quadrupole orthogonal acceleration time of flight tandem 
mass spectrometer (Q-Tof, Micromass, Manchester, England) equipped with a 
nanoflow electrospray ionization source. Gold-coated glass capillary nanoflow 
needles were obtained from Protana (Type Medium NanoES spray capillaries for 
the Micromass Q-Tof, Odense, Denmark). The needle was filled with 3 µl of the 
sample and subsequently opened by breaking the tapered end of the tip under a 
microscope. A stable spray was observed applying a needle voltage of 1200-1400 
V, a back pressure of 2 p.s.i., and a source temperature of 40°C. The estimated 
flow rate was 20-50 nl/min. For nanoflow electrospray ionization tandem mass 
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spectrometry experiments, fragmentation was achieved by collision with argon 
atoms. Q1 was set to the mass of interest, and an optimized collision energy was 
applied. The integration time for the time of flight analyzer was 1 s with an 
interscan delay of 0.1 s. Database searches (NCBInr, non-redundant protein 
database) were done using the MASCOT software from Matrix Science [29]. 
 
2.11.4 Results 
2.11.4.1 Selection of ssDNA Aptamers that Bind Transformed 
Endothelial Cells 
SELEX was used essentially as described [30] to generate ssDNA aptamers 
against Adenovirus-12 SV40-transformed YPEN-1 rat endothelial cells. The 
selection was started with a SELEX library of ~1 x 1015 sequences, each 
containing a central randomized region of 60 nt flanked by two primer 
hybridization sites [22].  
Aptamers cloned from the eighth round of selection were evaluated by a two step 
deconvolution-SELEX procedure: (i) each sequence affinity against the 
transformed YPEN-1 EC cell line was preevaluated by flow cytometry, and (ii) the 
selective binding of aptamers to microvessels of C6 brain tumor was analyzed by 
fluorescence microscopy on cryostat tissue sections of rat brain glioblastoma. Of 
25 sequences (FITC-18C-96-nt) tested by flow cytometry, by comparison of 
endothelial cells stained with unselected ssDNA (FITC-18C-96-nt), 23 showed 
binding to YPEN-1 endothelial cells. Of these, 16 bound to the pathological 
microvasculature of C6 glioblastoma, and 7 showed no binding. Aptamer III.1 
displayed the most intensive staining of the vasculature exclusively in areas of 
solid tumor growth and was therefore chosen as the candidate to be further 
characterized as outlined below. 
Fluorescence-labeled aptamer III.1-staining showed increased fluorescence 
intensity of YPEN-1 EC by comparison with unselected ssDNA (FITC-18C-96-nt) 
as a negative control in fluorescence-activated cell sorter histograms (not shown). 
EC-specific binding was confirmed by staining against N9 microglial cells, which 
was negative (not shown). Histological analyses of aptamer III.1. revealed staining 
of the complex architecture of the pathological microvasculature within the cell-rich 
210   2.11. PROTEIN IDENTIFICATION 
 
 
tumor region but not of vasculature in peritumoral areas. Thus, our histological 
data gave strong indication that aptamer III.1 binds an endothelial molecular target 
that is involved in the process of EC proliferation, a key step of angiogenesis. 
 
2.11.4.2 Aptamer III.1-Mediated Target Identification 
The molecular target has been isolated by magnetic DNA affinity purification. 
Solubilized EC proteins were incubated with trB aptamer III.1 beforehand coupled 
to magnetic streptavidin beads. After thorough washing and subsequent release of 
aptamer-bound protein in high salt solution, proteins were analyzed by 
SDS/polyacrylamide gel electrophoresis (Figure  2.11.2). Polyacrylamide gel 
analyses revealed a distinct band migrating at ~70 kDa in the lane of aptamer 
III.1, which is absent in the lane containing a product of the control reaction 
(performed with unselected ssDNA) which revealed one single band of ~50 kDa. 
Peptide mass fingerprinting and sequencing of three of the tryptic peptide 
fragments of the protein by mass spectrometry and tandem mass spectrometry, 
respectively, were used to identify the aptamer-specific protein as the rat 
homologue of mouse pigpen protein (67 kDa), a so far, widely unknown 
endothelial protein that has been considered to parallel the transition from 
quiescent to angiogenic phenotypes in vitro [31] (Figure  2.11.3). 
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Figure  2.11.2 Coomassie Blue-stained polyacrylamide gel used to analyze the ligand-
mediated target purification. 
Lane A, molecular marker. Lane B, purification with aptamer III.1. Lane C, purification with 
unselected ssDNA (trB-96-nt). Lane D, untreated endothelial cells. The target band isolated in the 
reaction containing the aptamer III.1 is indicated by an asterisk and was identified as the 67-kDa 
protein pigpen. 
 
Figure  2.11.3 Sequence of murine pigpen and identified tryptic fragments (highlighted in 
grey). 
 
MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYGQSADTSGYGQSSYGSSYGQTQNTGYGTQSAP
QGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGGSSQSSSYGQPQSGGYGQQSGYGGQQQSYG
QQQSSYNPPQGYGQQNQYNSSSGGGGGGGGGNYGQDQSSMSGGGGGGGYGNQDQSGGGGGGYGGGQQDR
GGRGRGGGGGYNRSSGGYEPRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLG
ENVTIESVADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFSGNPIKVSFATRR
ADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPNPTCENMNFSWRN
ECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSR
GEHRQDRRERPY 
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2.11.6 Abbreviations 
EC  endothelial cell(s) 
SsDNA singlestranded DNA 
SELEX Systematic Evolution of Ligands by Exponential enrichment 
nt(s)  nucleotide(s) 
FITC  fluorescein isothiocyanate 
18C  18-carbon ethylene glycol spacer 
trB  triple biotin 
PCR  polymerase chain reaction 
BSA  bovine serum albumin 
DAPI  49,6 diamidino-2-phenylindole 
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2.12 Broadband detection electrospray ionization 
Fourier transform ion cyclotron resonance mass 
spectrometry to reveal enzymatically and 
chemically induced deamidation reactions within 
peptides 
These results are part of a publication. Only data from the author of this 
dissertation are shown in the following chapters. 
 
2.12.1 Introduction 
Coeliac disease is a complex inflammatory disorder, influenced by both, 
environmental factors and genetic disposition. Main characteristics are intolerance 
to ingested wheat gluten, leading to chronic inflammation in the small intestine. 
Coeliac disease can be efficiently treated by gluten-free diet. Gluten consists of a 
complex mixture of many gliadin and glutenin polypeptides. They are rich in 
proline and glutamine residues and poor in glutamic acid and aspartic acid. Serum 
antibodies specific for gluten and the autoantigen tissue transglutaminase are 
found in celiac disease patients. Primary HLA association in most celiac-disease 
patients is with HLA-DQ2, and in a minority of patients with DQ8. There is strong 
evidence that these MHC molecules present disease-related peptides derived 
from gluten to CD4+ T cells in the small intestine. Due to the preference of DQ2 
and DQ8 for negatively charged residues at the anchor amino acids and the low 
frequency of glutamic and aspartic acid in gluten proteins, it was found that lesion-
derived T cells predominantly recognize deamidated gluten peptides and that this 
deamidation can be mediated in situ by tissue transglutaminase. Current data 
suggest, that during an inflammation tissue transglutaminase is upregulated in the 
small intestine. In the presence of gluten from the diet, this leads to production of 
deamidated peptides, which can bind to DQ2 or DQ8 and which are recognized by 
CD4+ T cells. Tolerance might only exist towards unmodified peptides [1]. 
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Because enzymatic specificity of tissue transglutaminase is probably involved in 
selection of gluten T cell epitopes [2], it was analyzed which glutamine residue in 
the peptide LPFPQQPQQPFPQPQQ derived from γ-gliadin (85-100) is 
deamidated by tissue transglutaminase. The results of the following chapter 
support the observations described in the publication of Fleckenstein et al. [2] but 
are not shown therein. 
 
2.12.2 Results 
The peptide LPFPQQPQQPFPQPQQ derived from γ-gliadin (85-100), which was 
identified as a B-cell epitope in patients with coeliac disease [3], is enzymatically 
deamidated by tissue transglutaminase (tTGase), the autoantigen in celiac 
disease. It has a molecular mass of 1903.96 Da. The peptide was incubated with 
the commercial enzyme guinea pig (gp) tTGase for 4 h. After enzymatic treatment 
(done by Florian von der Mülbe), the sample was measured by nanoESI-MS and 
sequence analysis was done by CID. The overview spectra of the incubated 
peptide obtained after 0 h and 4 h is shown in Figure  2.12.1. After 4 h the 
molecular mass was increased by 1 Da due to the deamidation of Q (128 Da) to E 
(129 Da). Only small amounts were left unchanged (see small peak at 1904.3 Da 
after 4 h).  
 
 
Figure  2.12.1 Overview spectra of peptide LPFPQQPQQPFPQPQQ before and after 4 h 
treatment with tTGase. 
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To figure out which of the 7 glutamine residues has been converted to E, 
fragmentation was done by CID. Figure  2.12.2 shows masses of b- and y”-series 
fragments resulting from selected possible Q→E conversions. 
 
b
y''
583.3
711.3
1097.5
969.4
L P F P Q Q P Q Q P F P Q P Q Q
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
b
y''
584.3
712.3
1097.5
969.4
L P F P E Q P Q Q P F P Q P Q Q
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
b
y''
583.3
712.3
1097.5
969.4
L P F P Q E P Q Q P F P Q P Q Q
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1
A
B
C
 
Figure  2.12.2 Possible deamidation products of peptide LPFPQQPQQPFPQPQQ and masses 
of corresponding b- (above) and y”-(below) series ions. A original sequence, B Q5→E5 
deamidation, C Q6→E6 deamidation. 
 
A peak at m/z = 969.4 could still be detected after 4 h incubation, suggesting that 
Q9, Q13, Q15 and Q16 of this peptide were unchanged (not shown). After 4 h 
incubation with tTGase, the peak of 711.55 Da was almost completely shifted by 1 
Da to 712.56 Da. This indicated that mainly Q5 or Q6 was deamidated, and that 
alternatively, to a smaller extent, Q8 was deamidated. 
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Figure  2.12.3 Fragment spectra of peptide LPFPQQPQQPFPQPQQ before and after 4 h 
treatment with tTGase. Significant but not complete shift of 711.55 Da towards 712.56 Da 
indicates, that mainly Q5 or Q6 was deamidated. 
 
The b5-ion allows to distinguish between deamidation Q5 or Q6. Because 
additional signals of other fragments (not b-series ions) were detected in the 
region of interest (583.5 Da or 584.5 Da, not shown), acetylation was done to 
increase all fragments containing the N-terminus by 42 Da. After this, a peak of 
626.56 Da (584.5 Da + 42 Da) was seen, which has not been present before in 
the non-acetylated samples, showing that it was Q5 being deamidated to E after 
incubation with tTGase. 
 
 
Figure  2.12.4 Glutamine at position 5 is deamidated to glutamic acid. The peak of 626.56 Da 
corresponds to acetylated b-series fragment Ac-LPFPE. 
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Thus, it was shown that the peptide LPFPQQPQQPFPQPQQ from γ-gliadin (85-
100) was mainly deamidated to LPFPEQPQQPFPQPQQ and to a lower extent to 
LPFPQQPEQPFPQPQQ by tTGase. This was in accordance to the results shown 
by Fleckenstein et al. and others [4]: human tissue transglutaminase preferred 
mostly Q in the motif QxP but not in QP or QxxP. 
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2.12.4 Abbreviations 
TTGase tissue transglutaminase 
Ac-  acetyl- 
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2.13 Release of regulators of angiogenesis following 
Hypocrellin-A and -B photodynamic therapy of 
human brain tumor cells 
The author of this dissertation contributed the mass spectrometrical protein 
identification shown in Figure  2.13.3 to this work.  
 
2.13.1 Summary 
Photodynamic therapy (PDT) is an innovative strategy for the treatment of solid 
neoplasms of the brain. Aside from inducing cell death in tumor cells, PDT 
induces endothelial cell death and promotes formation of blood clots, however, 
exact mechanisms that trigger these phenomena remain largely unknown. We 
now used Western Blotting to analyze secretion of regulators of angiogenesis to 
the supernatants of one glioma, one macrophage and one endothelial cell line 
following Hypocrellin-A and -B photodynamic therapy. We observed induction of 
proangiogenic VEGF (vascular endothelial growth factor), and of antiangiogenic 
sFlt-1, angiostatin, p43, allograft inflammatory factor-1 and connective tissue 
growth factor. Release of thrombospondin-1 was diminished. Endostatin release 
was induced in glioma cells and reduced in macrophages and endothelial cells. 
These data show that a wide range of antiangiogenic factors is secreted by brain 
tumor cells following Hypocrellin photochemotherapy. However, VEGF release is 
also induced thus suggesting both favorable and deleterious effects on tumor 
outgrowth. 
 
2.13.2 Introduction 
During the course of maturation, brain tumor cells activate and recruit endothelial 
cells, thereby starting the fatal process of tumor tissue expansion that can only 
rarely be intercepted by conventional therapy strategies. Photodynamic therapy 
(PDT) has been extensively investigated in vitro and in clinical trials for the 
treatment of a variety of brain tumors, particularly gliomas [1]. The main 
advantage of PDT is considered to selectively target infiltrating tumor cells that are 
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predominantly responsible for local tumor recurrence and rapid formation of 
intracranial metastases remote from the primary tumor [2]. Subsequent light 
activation induces photooxidation, followed by selective tumor destruction via 
vascular and direct cellular mechanisms [3,4]. Aside from inducing cell death in 
tumor cells, PDT induces endothelial cell death and promotes formation of blood 
clots. Following sensitizer accumulation and irradiation, damage to sensitive sites 
within the microvasculature, namely to endothelial cells and the vascular 
basement membrane, is induced and leads to the establishment of thrombogenic 
sites within the vessel lumen. This initiates a physiological cascade of responses 
including platelet aggregation, the release of vasoactive molecules, leukocyte 
adhesion, increases in vascular permeability and vessel constriction. This results 
in tumor destruction by vascular collapse, blood flow stasis and tissue 
hemorrhages. However, exact mechanisms that trigger these phenomena remain 
largely unknown. Malignant brain tumors carry a lethal prognosis with a median 
survival of 15 months despite surgery, radiotherapy and chemotherapy [5,6]. PDT 
is, therefore, a logical therapeutic concept for brain tumors infiltrating into normal 
brain. However, no information is available about release of regulators of 
angiogenesis following PDT.  
 Angiogenesis plays an essential role not only in the physiological formation 
and maintenance of vessels, but also in pathological conditions that range from 
tumor growth to wound healing [7]. Several steps are involved in the successful 
formation of new blood vessels including the stimulation of endothelial cells by 
growth factors, subsequent degradation of the extracellular matrix by proteolytic 
enzymes followed by invasion of the extracellular matrix, migration and 
proliferation of endothelial cells and, finally, the formation of new capillary tubes 
[8]. The initiation of angiogenesis, the angiogenic switch, is dependent on a 
dynamic regulation between proangiogenic and antiangiogenic factors in the 
immediate environment of endothelial cells [9]. A positive balance in favor of 
angiogenic factors leads to new vessel formation, whereas the prevalence of 
antiangiogenic factors shifts the equilibrium to vessel quiescence or, even to 
vessel regression [10].  
In order to give a comprehensive overview of the release of angiogenic factors in 
brain tumor cells after photodynamic therapy, we now used Western Blotting to 
analyze proangiogenic VEGF (vascular endothelial growth factor), its receptor 
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VEGFR-1 (vascular endothelial growth factor receptor-1, Flt-1), and antiangiogenic 
thrombospondin-1, angiostatin, AIF-1 (allograft inflammatory factor-1), connective 
tissue growth factor (CTGF), endothelial-monocyte-activating polypeptide II/p43 
and endostatin/Collagen XVIII in the supernatants of LN229 glioma, U937 
macrophage and SVHCEC brain endothelial cell lines following Hypocrellin-A and 
-B photodynamic therapy. 
 
2.13.3 Materials and Methods 
2.13.3.1 Cell culture 
U937 macrophages were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA). The SVHCEC endothelial cell line was derived of 
brain endothelial cells and was a kind gift from Professor A. Muruganandam and 
has been described before [11]. The LN229 glioma cell line was a kind gift of 
Professor Michael Weller, Department of Neurology, Tübingen and has been 
described before [12]. Cells were raised in RPMI 1640 medium with Glutamax II 
(Gibco BRL, Paisley, Great Britain) containing 10% fetal calf serum (FCS, Gibco) 
and 100 units/ml penicillin and 100 µg/ml streptomycin (Fluka, Buchs, Switzerland) 
at 37°C and 5% CO2.  
 
2.13.3.2 Photodynamic therapy 
Hypocrellin-A and -B were used as photosensitizers because they both share a 
broad absorption spectrum in the visible light range (not shown). Preliminary 
experiments were used to determine illumination times and Hypocrellin 
concentrations. Normal growth media were supplemented with a concentration of 
5 µmol Hypocrellin A or Hypocrellin B (both Molecular Probes Europe BV, Leiden, 
The Netherlands) for 24 h in the dark. Cells were then irradiated using a 11-W 
Dulux lamp (Osram, Germany, not shown) placed 1 inch above the cell surface for 
15 min at a light dose of approximately 4 mW/cm2 as assessed using a luxmeter. 
All irradiations were performed at room temperature. Controls included cell 
preparations without illumination and Hypocrellin A- and -B supplementation. 
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2.13.3.3 Protein preparation and Western Blotting 
Following stimulation, cell lines were washed twice with phosphate buffered saline, 
pH 7.5 and then resubstituted with serum-free medium. After 24 h incubation time, 
supernatants were collected by centrifugation and proteins were precipitated by 
acetone incubation for 15 min at -20°C. Cells were collected following 
trypsinization. The resulting pellet was washed twice with PBS, resuspended in 
running buffer containing 125 mM Tris base, 20 % glycerol, 2 % SDS, 1 % 
bromophenol blue and 2 % 2-ME, sonicated for 1 min and boiled for 10 min in a 
water bath. Protein concentration was determined using a Bradford assay with 
albumin as a standard. 50 µg of total protein was loaded, electrophoresed on a 10 
% SDS-polyacrylamide gel and transferred to PVDF membranes (Biorad, Munich, 
Germany) by semi-dry blotting. Membranes were blocked with FCS and the 
primary monoclonal antibodies directed against vascular endothelial growth factor 
(VEGF, rabbit polyclonal, Ab-2, Oncogene Research Products, San Diego, CA, 
USA, PC37), vascular endothelial growth factor recepor-1 (Flt-1, rabbit polyclonal, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-9029), thrombospondin-1 
(goat polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-12312), 
angiostatin (rabbit polyclonal, AB-1, Oncogene Research Products, San Diego, 
CA, USA, PC371), allograft inflammatory factor-1 (AIF-1) [13], endothelial 
monocyte activating polypeptide (EMAP II/p43) [14], connective tissue growth 
factor (CTGF) [15] and endostatin/Collagen XVIII [16] (all BMA Biomedicals, 
Augst, Switzerland) were visualized using HRP conjugated anti-rabbit, anti-goat 
and anti-mouse secondary antibodies and consecutive ECL visualization.  
 
2.13.3.4 AIF-1 protein confirmation 
In one experiment that was conducted to analyze the nature of the 50 kDa bands, 
we added 8 M urea, a chaotropic agent that is well known to disrupt oligomer 
formation of proteins [17] and/or ß-mercaptoethanol to the sample buffer, 
incubated the samples for the indicated time spans and consequently performed 
either 12% SDS-PAGE or 12% SDS 6M urea PAGE followed by Western 
analyses. Protein concentration was determined using the Bradford technique with 
bovine albumin as a standard. Indicated amounts of total protein were loaded per 
lane, electrophoresed and transferred to PVDF membranes (Biorad, Munich, 
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Germany) by semi-dry blotting. Then, membranes were blocked with FCS and 
primary monoclonal antibodies directed against AIF-1 were visualized using HRP 
conjugated avidin-biotin complex and ECL visualization.  
In gel tryptic digestion was performed as described [18] and modified as outlined 
below. Briefly, the protein band was excised from the gel, fully destained, and 
digested for 3 h with porcine trypsin (sequencing grade, modified; Promega) at a 
concentration of 67 ng/µl in 25 mM ammonium bicarbonate, pH 8.1, at 37°C. Prior 
to peptide mass mapping and sequencing of tryptic fragments by tandem mass 
spectrometry, the peptide mixture was extracted from the gel by 1% formic acid 
followed by two changes of 50% methanol. The combined extracts were vacuum-
dried until only 1-2 µl were left and the peptides were purified by ZipTip according 
to the manufacturers’ instructions (Millipore, Bedford, MA, USA). MALDI-TOF 
analysis from the matrix α-cyano-4-hydroxycinnamic acid/nitrocellulose prepared 
on the target using the fast evaporation method [19] was performed on a Bruker 
Reflex III (Bruker Daltonik, Bremen, Germany) equipped with a N2 337 nm laser, 
gridless pulsed ion extraction and externally calibrated using synthetic peptides 
with known masses. The spectra were obtained in positive ionisation mode at 23 
kV.  
Sequence verification of some fragments were performed by nanoelectrospray 
tandem mass spectrometry on a hybrid quadrupole orthogonal acceleration time 
of flight tandem mass spectrometer (Q-Tof, Micromass, Manchester, England) 
equipped with a nanoflow electrospray ionisation source. Gold-coated glass 
capillary nanoflow needles were obtained from Protana (Type Medium NanoES 
spray capillaries for the Micromass Q-Tof, Odense, Denmark). Database searches 
(NCBInr, non-redundant protein database) were done using the MASCOT 
software from Matrix Science [20]. 
 
2.13.4 Results 
For photodynamic therapy, we chose Hypocrellin-A and -B because of their broad 
absorption spectrum in the visible light range (not shown). For illumination, a 
common table top fluorescent tube with an emission spectrum that matches the 
absorption spectra of Hypocrellin-A and -B was chosen. Another advantage is its 
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shape that exactly matches the shape of the cell culture flasks thus allowing an 
even illumination of the cells.  
Hypocrellin A and -B photodynamic therapy induced visible morphological 
changes in LN229 glioma, U937 macrophage and SVHCEC endothelial cells. 
After 6 hours, LN229 glioma cells showed multiple intracellular bodies (not 
shown). In addition, the cells showed a rounder morphology. Occasionally, 
protrusions of the cellular membrane were observed. However, no clear signs of 
cell death could be detected. U937 cells also showed multiple inclusion bodies 
and occasionally protrusions of the cellular membrane (not shown). SVHCEC cells 
were characterized by the formation of inclusion bodies. However, their shape 
mainly remained unaltered (not shown). 24 hours after illumination (not shown), all 
cells analyzed were characterized by morphological alterations that did not differ 
from the ones at 6 hours post illumination. No further deterioration was detected. 
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Figure  2.13.1 Western Blotting of SVHCEC, LN229 and U937 cells demonstrates accentuated 
release of VEGF (A) and VEGFR-1/Flt-1 (B). 
A singular thrombospondin-1 band was observed in unstimulated LN229 supernatants that 
disappeared after Hypocrellin A and -B PDT (C). Induction of different molecular weight angiostatin 
proteins was detected in all cells analyzed (D). A 43 kDa EMAP II band was induced in LN229 and 
U937 supernatants after Hypocrellin A and -B PDT (E). A 51 kDa AIF-1 band was induced in 
SVHCEC and LN229 cells by Hypocrellin A and -B (F). CTGF was released to the supernatants of 
all analyzed cells after PDT (G). Endostatin release to the supernatants (H). 
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Western Blotting revealed increased induction of proangiogenic VEGF in all 
analyzed cell lines following both Hypocrellin A and -B stimulation (Figure  2.13.1 
A). Surprisingly, we observed induction of an approximately 30 kDa Flt-1 
immunoreactive band that most likely represents the soluble form of Flt-1 (Figure 
 2.13.1 B). Thrombospondin-1 was detected only in unstimulated LN229 cells but 
neither in unstimulated SVHCEC or U937 cells nor in PDT stimulated LN229 cells 
suggesting diminution by Hypocrellin A and -B photochemotherapy (Figure  2.13.1 
C). The 38 kDa angiostatin was only detected in supernatants of unstimulated 
LN229 but not in SVHCEC or U937 cells (Figure  2.13.1 D). After PDT, we 
observed induction of approximately 90 kDa bands in SVHCEC and U937 cells 
and of approximately 20 kDa bands in Hypocrellin A stimulated LN229 and U937 
cells. No EMAP II/p43 immunoreactive bands were detected in unstimulated and 
Hypocrellin A and -B stimulated SVHCEC supernatants. In LN229 and U937 cells, 
we observed the induction of an approximately 43 kDa band following both 
Hypocrellin A and -B stimulation (Figure  2.13.1 E). No AIF-1 was observed in the 
supernatants of unstimulated cells (Figure  2.13.1 F). In contrast, we observed 
release of an approximately 51 kDa band to Hypocrellin A and -B stimulated 
SVHCEC and LN229 but not U937 cell supernatants (Figure  2.13.1 F). No CTGF 
was detected in unstimulated SVHCEC, LN229 and U937 cells (Figure  2.13.1 G). 
After Hypocrellin A and -B photodynamic therapy, prominent induction of CTGF 
was readily observed in all analyzed supernatants (Figure  2.13.1 G). Endostatin 
was observed in all analyzed unstimulated cell supernatants (Figure  2.13.1 H). 
After Hypocrellin A and -B PDT, more prominent bands were observed in the 
supernatants of LN229 cells and weaker bands in SVHCEC and U937 
supernatants (Figure  2.13.1 H).  
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Figure  2.13.2 Western Blot analyses of recombinant AIF-1. Western Blot analyses of 5 µg of the 
recombinant AIF-1 protein per lane using 12 % SDS-PAGE shows reduction of the observed 50 
kDa bands predominantly following incubation of the recombinant protein for 1 h in 8 M urea under 
reducing conditions (ß-ME = ß-mercaptoethanol) (A). After a 20 h incubation period at 25°C of the 
recombinant AIF-1 in the 8 M urea ß-ME buffer, the otherwise observed 50 kDa bands were further 
reduced (B). Using the same samples, 6M urea SDS-PAGE resulted in the complete diminution of 
the 50 kDa bands in the ß-ME 8 M urea sample (C). 
 
In order to determine the origin of the observed aproximately 50 kDa AIF-1 bands, 
we performed 12% SDS PAGE with preincubation of the recombinant AIF-1 
protein with either non-reducting sample buffer (SB), reducing sample buffer (ß-
ME) or chaotropic 8 M urea for 1 h at 25°C (Figure  2.13.2 A). The 50 kDa bands in 
the reducing sample were slightly weaker than the ones in the non-reducing 
sample, while non-reducing 8 M urea preincubation resulted in no alteration. After 
preincubation of the sample under chaotropic (urea) and reducing (ß-ME) 
conditions, we observed a strong diminution of the 50 kDa bands. These results 
were confirmed following preincubation of the same samples for 20 h at 25°C 
(Figure  2.13.2 B). To further increase stringency, we used the same samples and 
performed 6 M urea SDS PAGE followed by Western Blotting (Figure  2.13.2 C). 
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Here, the bands generally appeared much weaker and the reduced and urea-
incubated sample completely lost the 50 kDa bands. 
To provide more evidence for these data, we performed in gel tryptic digestion of 
the three observed AIF-1 bands. The tryptic digest of the 17 kDa-band of 
recombinant AIF-1 revealed 4 tryptic fragments (AIF-189-108 MH+: 2161.00, AIF-154-
71 oxidized MH+: 2106.91, AIF-1120-127 oxidized MH+: 1088.50, and AIF-182-87 MH+: 
740.41) as determined by MALDI MS, signal m/z = 2161.00 being the highest one 
(Figure  2.13.3 A). Most likely because of the weak intensity of the highest band, in 
this digest only the previously highest signal with m/z = 2161.00 again could be 
detected (Figure  2.13.3 B). Sequencing of the peptide with the mass 2160.00 Da 
by tandem ESI MS confirmed identity to AIF-189-108 in the digest of the 17 kDa 
band as well as in the highest band (Figure  2.13.3 C). From these results, 
together with the above named data, we conclude that AIF-1 forms trimers in vivo, 
and in part, in vitro. 
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Figure  2.13.3 Peptide mass fingerprint of the tryptic digest of the recombinant 17 kDa AIF-1 
band. Four tryptic fragments of AIF-1 were detected, the peak of AIF-189-108 being the most 
dominant (A). AIF-189-108 was detected in tryptic digests of all three bands of recombinant AIF-1 (B). 
Fragment spectra of the peptide with the mass 2160.00 confirmed that the peptide was indeed AIF-
189-108. Upper spectrum shows fragmentation of doubly charged parent ion ((M+2H)2+: 1081.04) in 
the digest of the 17 kDa band, lower spectrum was recorded from digest of the upper 50 kDa band 
(C). 
 
2.13.5 Discussion 
Approximately 17 000 glioblastoma brain tumors are diagnosed and 12000 deaths 
from glioblastoma occur within the European Community annually. Despite 
surgery, radiotherapy and chemotherapy, the 5 year survival rate in patients with 
glioblastoma is below 1 %. Radical resection is oftentimes not possible because of 
infiltrating tumor growth to the normal brain parenchyma. Photosensitizers are 
known to accumulate in tumor cells to a greater extent than in normal glial or 
232   2.13. PROTEIN IDENTIFICATION 
 
 
neuronal cells and have therefore become an alternative to battle solid neoplasms 
of the brain [21,22]. Interestingly, photodynamic therapy has profound effects on 
the vasculature of solid neoplasms [23]. PDT induces hypoxia by reducing tumor 
perfusion [24], a concept that recently gave rise to specific PDT protocols to 
selectively target the tumor vasculature [25]. A staged process is thought to 
account for the overall observed reduction of blood flow following PDT, with 
endothelial cell death being the final consequence [26]. However, increased 
permeability in endothelial cells that results in the release of clotting factors and in 
turn vessel constriction and occlusion, vascular collapse and disruption, blood flow 
stasis and tissue hemorrhage are consequences prior to endothelial cell death 
[27,28,29]. Only few individual factors that mediate this process have been 
identified including thromboxane and prostacyclin [30].  
Using hypocrellin A and -B photodynamic therapy, we now observed release of 
both pro- and antiangiogenic factors not only from brain tumor cells but also 
macrophages and endothelial cells. This is the first description of hypocrellin 
function on brain tumor cells and of the cell-type specific induction of release of 
regulators of angiogenesis following photodynamic therapy in general. 
VEGF is probably the most prominent inducer of vessel formation. VEGF was 
initially defined to induce vascular leak and promote vascular endothelial cell 
proliferation [31,32]. It is required for both vasculogenesis, where mesoderm-
derived angioblasts form tubes, and for angiogenesis, where capillaries form by 
sprouting or intussusception from existing vessels [7]. Other members of the 
VEGF family were identified on their homology to VEGF [33] with overlapping 
abilities to interact with a set of cell-surface receptors that trigger response to 
these factors, VEGF-B/VRF [34,35], VEGF-C/VRP [36,37] and VEGF-D/FlGF 
[38,39]. VEGF-C and VEGF-D bind both VEGFR-3/Flt-4 and VEGFR-2 [36,40]. 
The corresponding receptor(s) for VEGF-B has not been reported. VEGF-B exists 
as two alternatively spliced forms, VEGF-B167 and VEGF-B186, which differ in 
their affinity for heparin and thus release and bioavailability, and it forms 
heterodimers with VEGF [34,41], a property likely to alter its receptor specificity, 
biological effects and appearance in Western Blotting experiments.  
VEGF exerts its functions through binding to two receptor tyrosine kinases, 
VEGFR-1/Flt-1 and VEGFR-2/KDR [8]. These receptors are expressed almost 
exclusively on endothelial cells, although VEGFR-1 is also found in monocytes, 
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where it mediates migration [42,43]. Interestingly, a mRNA for a soluble truncated 
form of Flt-1 (sFlt-1) was generated by alternative splicing in endothelial cells that 
functions as a competitive inhibitor of VEGF [44]. Accordingly, transfection 
experiments revealed prominent antitumor activity of sFlt-1 [45]. Recombinant 
sFlt-1 revealed that this antitumor activity is due to dominant-negative inhibition of 
VEGF-induced angiogenesis [46]. 
CTGF is a 349 amino-acid protein that has been originally described as a mitogen 
produced by human umbilical cord endothelial cells [47]. Until recently, CTGF has 
been thought to mediate predominantly fibrotic diseases [48] by modulating 
fibroblast reactivity [49]. However, CTGF has been recently identified as a 
regulator of angiogenesis [50] by binding to integrins alphavß3 that has been 
implicated in tumor neoangiogenesis and metastasis [51]. Thus, CTGF functions, 
at least in part, through integrin-dependent pathways with a direct role in the 
adhesion, migration and survival of endothelial cells during blood vessel growth. 
Close interactions between VEGF, Flt-1 and CTGF have been described. VEGF 
induces expression of CTGF via KDR, Flt-1, and phosphatidylinositol 3-kinase-akt-
dependent pathways in vascular cells [52]. VEGF then is capable to bind CTGF to 
inhibit its proangiogenic function [53], a process that can be reversed by matrix 
metalloproteinases [54]. In this context, it is of note that we observed release of 
VEGF, sFLT-1 and CTGF after Hypocrellin A and -B stimulation in a similar 
fashion in all cells analyzed. In addition, we observed a reduction of 
thrombospondin-1 release by LN229 cells. Thrombospondin-1 is a potent natural 
inhibitor of angiogenesis that induces endothelial cell apoptosis in vitro and 
downregulates neovascularization in vivo [55]. Interestingly, thrombospondin-1 
attenuates VEGF-mediated Bcl-2 expression in endothelial cells in vitro [56], 
suppresses VEGF mobilization [57] and therefore acts, at least in part, as VEGF 
counterpart. These data are supported by opposing up- or downregulation of 
VEGF and Thrombospondin by p73 [58] and Smad4/DPC4 [59].  
 Endostatin is a 20 kDa C-terminal fragment of collagen XVIII, and 
extracellular administration inhibits endothelial proliferation and migration in vitro 
and angiogenesis and tumor growth in vivo by inducing apoptosis in endothelial 
cells [60,61]. Endostatin inhibits VEGF-induced endothelial cell migration and 
tumor growth [62] by inhibiting the binding of VEGF to endothelial cells and the 
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extracellular domain of KDR/Flk-1 [63] and has therefore become a promising 
inhibitor of neovascularization in solid neoplasms. 
 In addition, we analyzed three angiogenic molecules that have yet not been 
described to interact with VEGF: angiostatin, p43/EMAP II and AIF-1. Angiostatin, 
a proteolytic fragment of plasminogen, contains either the first three or first four 
kringle domains of plasminogen and is a potent inhibitor of tumor-induced 
angiogenesis in animal models [64,65]. Angiostatin has been reported to increase 
endothelial cell apoptosis and the activity of focal adhesion kinase [66] and block 
the migration of endothelial cells [67]. Smaller fragments of angiostatin have been 
described that display differential effects on the suppression of endothelial cell 
growth [68].  
 EMAP II is a 23 kDa protein that is proteolytically cleaved from the C-
terminal region of the p43 protein, which in turn constitutes a noncatalytic subunit 
of the aminoacyl tRNA synthetase complex. p43 is one of the three auxiliary 
components invariably associated with nine aminoacyl-tRNA synthetases as a 
multienzyme complex ubiquitous to all eukaryotic cells from flies to humans [69]. 
In vivo, EMAP II induces hemorrhage of blood vessels of certain experimental 
tumors, like fibrosarcoma, melanoma and adenocarcinoma and EMAP II 
administration has therefore become a novel and promising antiangiogenic 
strategy to battle neoplasia [70-72]. Release of the 43 kDa antiangiogenic 
endothelial-monocyte-activating polypeptide II/p43 (EMAP II/p43) band from the 
glioma and the macrophage cell line is of note, because EMAP II can be derived 
by proteolytical cleavage from the C-terminal region of the p43 precursor 
molecule, which in turn constitutes a noncatalytic subunit of the aminoacyl tRNA 
synthetase complex. Interestingly, a recent publication showed evidence that p43 
itself is specifically secreted from intact mammalian cells while EMAP II is 
released only when the cells were disrupted. Secretion of p43 was also observed 
when its expression was increased. These results suggest that p43 itself should 
be a real cytokine secreted by an active mechanism. THP-1 macrophages treated 
with the full-length p43 protein showed higher cytokine activity than EMAP II, 
further supporting p43 as an active cytokine. p43 was also shown to activate 
MAPKs and NFkB, and to induce cytokines and chemokines such as TNF, IL-8, 
MCP-1, MIP-1a, MIP-1b, MIP-2a, IL-1b, and RANTES [73].  
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 AIF-1 is a 17 kd IFN-γ inducible Ca2+- binding EF-hand protein that is 
encoded within the HLA class III genomic region [74] and has originally been 
cloned from activated macrophages in human and rat atherosclerotic allogenic 
heart grafts undergoing chronic transplant rejection [75]. It was initially 
demonstrated that AIF-1 is a modulator of the immune response during 
macrophage activation [74-75]. Three proteins are probably identical with AIF-1 
termed Iba1 (ionized Ca2+-binding adaptor), MRF-1 (microglia response factor) 
and daintain. Considerable but not complete sequence identity with AIF-1 has 
been described for IRT-1 (interferon responsive transcript), BART-1 (balloon 
angioplasty responsive transcript), and other, yet unassigned alternatively spliced 
variants [76]. Some evidence points to a proangiogenic function of AIF-1. 
Transfection and constitutive expression of AIF-1 in a primary and a rat vascular 
smooth muscle cell line resulted in enhanced growth proportional to the amount of 
AIF-1 expressed. Constitutive expression of AIF-1 results in a shorter cell cycle 
and AIF-1 overexpression also permits growth in serum-reduced media [77,78]. 
Other data show evidence that AIF-1 has antiangiogenic function by augmenting 
the production of interleukin-6, -10 and -12 by a mouse macrophage line [79], 
cytokines that differentially inhibit angiogenesis [80-83]. 
 In conclusion, Hypocrellin A and B photodynamic therapy of cells of human 
gliomas not only induce apoptosis but moreover elicits the release of distinct 
angiogenic proteins that are capable to crucially determine neoplastic outgrowth 
and vascularization, a fact that needs to be taken into account during 
photodynamic therapy. 
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3 Summary 
Genomics (oligonucleotide microarray based expression profiling) and MHC class 
I-ligandome analysis (mass spectrometry) were combined to analyse tumors of 
renal cell carcinoma patients. This can be performed in an appropriate timeframe 
after surgical intervention to allow rapid subsequent vaccination. Thus, it was 
demonstrated in seven cases that it is possible to extract information from a single 
excised tumor specimen that leads to an optimized design of a multi-epitope, 
peptide-based vaccine directed against the tumor of an individual patient and 
considering all expressed HLA-alleles. 
 
New tumor associated antigens together with MHC class I-ligands encoded by 
them can be identified using this approach. In vitro T cell analyses carried out for 
two of the newly discovered ligands have proven that, first, they were T cell 
epitopes, and, second, T cells specific for these epitopes mediated lysis of tumor 
cells but not control cells. 
 
As part of the complete approach, a database based on oligonucleotide 
microarrays was built covering 22.000 gene expression values of twenty one 
human healthy tissues and organs. 
 
Finally, a clinical study using this approach was started and four RCC patients 
were already analyzed and three patients vaccinated. 
 
The results of this thesis presented in part two provided new insights into the 
antigen processing mechanisms. First, there was evidence for a novel luminal 
endoplasmic reticulum aminopeptidase involved in epitope trimming events, which 
in the meantime has been identified as being ERAP1. 
Second, it could be shown that tripeptidyl peptidase plays an essential role in the 
generation of an MHC class I epitope. 
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Small projects, mainly performed to improve technical skills in protein and peptide 
analysis, were related to protein identification, another dealt with detection of 
glutamine deamidations. 
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5 Abbreviations 
APC Antigen presenting cell  SDS Sodium Dodecyl Sulfate 
AA Amino acid  TAP Transporter Associated with  
BCR B cell receptor   Antigen Processing 
BPI Base peak ion  TFA Trifluoro Acetic Acid 
CD Cluster of differentiation  TIC Total Ion Current 
CID Collision induced decay  TIL Tumor Infiltrating Lymphocyte 
CTL Cytotoxic T lymphocyte  TOF Time of Flight 
ER Endoplasmic reticulum    
ESI Electrospray ionization    
EST Expressed sequence tag  One letter code for amino acids 
FACS Fluorescence activated cell     
 sorter  A Alanine 
HLA Human leucocyte antigen  C Cysteine 
HSP Heat shock protein  D Aspartic acid 
IFN Interferon  E Glutamic acid 
Ig Immunoglobulin  F Phenylalanine 
IL Interleukin  G Glycine 
LCM Laser capture microdissection  H Histidine 
LMP Low molecular weight  I Isoleucine 
 polypeptide  K Lysine 
MALDI Matrix assisted laser desorption  L Leucine 
 ionization  M Methionine 
MHC Major histocompatibility complex  N Asparagine 
MS Mass spectrometry  P Proline 
MS/MS Tandem mass spectrometry  Q Glutamine 
MW Molecular weight  R Arginine 
NK-cell Natural killer cell  S Serine 
PAGE Polyacrylamide gel   T Threonine 
 electrophoresis  V Valine 
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PH Potentia hydrogenii  Y Tyrosine 
RP-HPLC Reversed Phase-High     
 Performance Liquid    
 Chromatography    
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